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Abstract 
In this work, characterization of Marinesco-Sjögren Syndrome (MSS) was performed for the first 
time on the proteome level using mass spectrometry (MS)-based quantitative proteomics strategies. 
MSS is a neuromuscular and neurodegenerative disorder and it is caused due to the mutational 
inactivation of SIL1 protein, which results in malfunctioning of protein folding machinery mediated 
by the chaperone BiP that can lead to the ER stress-induced cell death via apoptotic signaling. The 
major goals were (i) to understand the rescue mechanisms in SIL1-deficient non-vulnerable tissues 
from human and (ii) to verify the cellular perturbations caused due to the loss of functional SIL1 in 
woozy mouse (i.e. mouse model of MSS). To achieve these aims, samples derived from five different 
MSS cases and two different tissues from woozy along with their respective healthy controls were 
studied. 
For this, comparative LC-MS proteomics approaches such as chemical labeling (i.e. iTRAQ) and label-
free quantification (precursor ion intensity based and NSAF) were employed. During which, sample 
preparation workflows were optimized that enabled to process clinical samples related to MSS that 
included primary cell lines and mammalian tissues for the subsequent quantitative LC-MS analyses. 
This also included an investigation of occurrence of artificial protein carbamylation, which is a well-
known unwanted artefact in quantitative proteomics. 
By employing these workflows, abundances of thousands of proteins in both MSS patients and 
woozy were relatively quantified. Among these, the number of differentially regulated proteins 
varied depending on the cell/tissue type and the clinical state i.e. SIL1-affected or unaffected. 
However, in both conditions, the absence of functional SIL1 showed disturbed cellular activities 
suggesting its important role in BiP-mediated protein folding process. In MSS SIL1 non-vulnerable 
tissues data, the processes which might mitigate the ER-stress induced due to SIL1 loss were 
identified. Next, proteome analysis of SIL1 depleted HEK293 cell line was performed to study the 
pathophysiology of SIL1 loss in more detail. Additionally, a targeted-MS based method was 
developed to assay proteins that are involved in the unfolded protein response pathway, which is 
triggered under the ER-stress conditions. Lastly, proteomic profiling of a human myoblastic RCMH 
cell line was carried out that can serve as an in vitro model to investigate muscle and neuromuscular 
disorders. 
Abstract (in German)   
 
Abstract (in German) 
In dieser Arbeit wurde eine Charakterisierung des Marinesco-Sjörgen Syndroms (MSS) zum ersten 
Mal auf Proteom-Ebene mittels Massenspektrometrie-basierten, quantitativen Methoden 
durchgeführt. MSS ist eine neuromuskuläre und neurodegenerative Erkrankung und wird verursacht 
durch mutations-bedingte Inaktivierung des SIL1 Proteins. Diese führt zu einer Störung der 
Proteinfaltung durch das Chaperonprotein BiP und somit zu einer ER-Stresssituation mit möglichem 
folgendem Zelltod durch Apoptose. Das Hauptziel bestand darin, die Rettungsmechanismen in SIL1 
unabhängigen Geweben (human) zu verstehen, sowie bei fehlendem funktionellen SIL1 in woozy 
Mäusen (MSS-Mausmodell) die verursachten Störungen auf zellulärer Ebene zu bestimmen. 
Hierzu wurden vergleichende, proteomische Strategien, wie chemische Isotopenmarkierung und 
Label-freie Quantifizierung angewandt. Innerhalb der Durchführung wurden Methoden der 
Probenvorbereitung weiter optimiert, um eine effektive Aufbereitung von klinischen Proben im 
Zusammenhang mit MSS und auch von Primärzelllinien sowie Säugerzellgeweben für anschließende, 
quantitative LC-MS Analytik zu ermöglichen. 
Durch Nutzung dieser erstellten Arbeitsanweisungen, konnten tausende von Proteinen in MSS-
Patienten und woozy relativ quantifiziert werden. Unter diesen Proteinen variierte die Menge von 
differenziell regulierten Proteinen abhängig von Zell- und Gewebstyp und vom klinischen Zustand, 
insbesondere durch deren Abhängigkeit von SIL1 oder Unabhängigkeit davon. Dennoch zeigte sich 
bei Abwesenheit von funktionellem SIL1 eine Störung der zellulären Aktivität in beiden Zuständen 
(SIL1 abhängig oder unabhängig). Dies deutet auf eine wichtige Funktion von SIL1 in der BiP-
vermittelten Proteinfaltung hin. In MSS SIL1 unabhängigem Gewebe wurden die Prozesse, welche 
womöglich die Reduktion des ER-Stresszustandes herbeiführen und durch SIL1-Verlust induziert ist, 
identifiziert. Anschließend wurde eine Proteomanalyse von SIL1 knock-down HEK293 Zelllinien 
durchgeführt, um die Pathophysiologie im Falle von SIL1-Verlust im Detail zu untersuchen. 
Weiterhin wurde eine targeted-MS basierte Strategie entwickelt, um Proteine zu studieren, welche 
involviert sind in Signalwegen der Antwort auf ungefaltete Proteine und im Fall von ER-
Stresssituation hervorgerufen wird. Letztlich wurde eine proteomische Analyse einer humanen 
RCMH Zelllinie durchgeführt. Diese Zelllinie kann womöglich als ein in vitro Modell zur Untersuchung 
von muskulären und neuromuskulären Fehlsteuerungen dienen. 
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Abbreviations 
2-DE   two-dimensional gel electrophoresis 
Å  angstrom  
ACN  acetonitrile 
ANOVA analysis of variance 
BCA  bicinchoninic acid 
CID   collision-induced dissociation 
Da  Dalton 
DDA  data dependent acquisition 
DTT  dithiothreitol 
EBV  Epstein-Barr virus 
e.g.  for example 
EtOH  ethanol 
FA  formic acid 
FDR  false discovery rate 
HCD  higher energy collisional dissociation 
HEK293 human embryonic kidney cell line 
HPLC high performance liquid chromatography 
HR/AM high-resolution accurate mass 
IAA  iodoacetamide 
i.e.  that is 
IPG  immobilized pH-gradient 
IEF  isoelectric focusing 
iTRAQ  isobaric tags for relative and absolute quantification 
MS  mass spectrometry 
MS/MS tandem mass spectrometry  
MSS  Marinesco-Sjögren Syndrome  
MW  molecular weight 
m/z  mass-to-charge 
PRM  parallel reaction monitoring 
PSM  peptide-spectrum match 
ppm  parts per million 
rcf  relative centrifugal force 
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SPEC  solid phase extraction cartridge 
SRM  selected reaction monitoring  
TFA  trifluoroacetic acid 
TIC  total ion chromatogram 
u   atomic mass unit 
 
Note: Throughout the text, the symbols for human genes are italicized characters that are all in upper-case e.g. SIL1 
and the respective proteins are non-italicized characters e.g. SIL1. In case of mouse, only the first letter is in upper-
case e.g. Sil1 and Sil1 - gene and protein symbols, respectively. 
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Chemical structures of amino acids 
Name, three and single letter codes; monoisotopic residue mass 
 
Notes: 
- Trypsin cleaves at the carboxyl (C)-terminus of K and R unless followed by P. 
- iTRAQ labels covalently react with the primary amines on N-terminus of protein/peptide and K side chains. 
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1 Introduction 
 Endoplasmic reticulum and protein folding process 1.1
The endoplasmic reticulum (ER) also known as the sarcoplasmic reticulum (in skeletal muscle 
fibers) is the largest subcellular organelle in eukaryotic cells. Being a single membrane system, 
the ER is located closely to the nucleus and connected to it by the outer nuclear membrane of 
the nuclear envelope. Based on morphology and function, there are two types of ER i.e. smooth 
ER (sER) and rough ER (rER). The sER has a smooth outer surface and it is mostly involved in the 
synthesis and metabolism of phospholipids and steroids. In contrast, the outer membrane of 
the rER is constellated with the ribosomes, which harbor translational elongation factors that 
are regarded as the workhorses of protein biosynthesis 1. Evidently, the rER (hereafter referred 
as only ER) is the site of production, folding and translocation of nearly one-third of all proteins 
in an eukaryotic cell 2. It is estimated that the protein concentration in the ER lumen can reach 
up to 100 mg/mL 3. Most importantly, the maturation of newly synthesized secretory and 
membrane proteins starts in the ER lumen. Properly folded proteins travel from the ER through 
the ER-Golgi-intermediate compartment (ERGIC) and the Golgi apparatus to their final 
destinations (e.g. cell surface or the extracellular space) 4. The entry of incipient proteins into 
the ER for their maturation can be either by post- or co-translational transport 5. During the co-
translational protein translocation (Fig. 1.1), the nascent polypeptide chains are imported into 
the ER through the signal-gated SEC61 pore complex 6. The signal peptide sequences are then 
cleaved off by the signal peptidase (Spase) and the residual polypeptide sequences are 
subjected to the protein-folding machinery, which mainly comprises ER-resident molecular 
chaperones and other folding enzymes. Chaperones are a group of proteins that assist folding 
and interactions between the polypeptide chains and thus gives rise to functional proteins 7. 
The newly synthesized proteins are further stabilized by covalent post-translational 
modifications (PTMs) such as N-glycosylation and formation of the disulfide bonds, which are 
catalyzed by oligosaccharyltransferase and protein disulfide isomerases (PDI), respectively. 
Moreover, the ER compartment is a store house of cellular calcium (Ca2+) and thus the ER plays 
a major role in maintaining Ca2+ dependent homeostasis 8. Notably, the estimated available 
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(unbound) Ca2+ concentration in the ER can reach up to 1 mM 9. Due to the presence of such 
diverse group of biomolecules including a large dynamic range of unfolded/folded proteins in a 
high oxidizing environment (crucial for the formation of disulfide bonds mediated by PDI) and 
high Ca2+ concentration; a strict ER-quality control (ERQC) mechanism has evolved and 
conserved in eukaryotes that determines the fate of newly synthesized polypeptide chains 10. In 
summary, different components of the ER-protein folding machinery orchestrate 
folding/unfolding of the nascent polypeptides and thus prevent their aggregation and 
assembled macromolecular subunits 7 (Table 1.1). 
Table 1.1: The main components (families) of the ER protein folding machinery 11. 
 
1.1.1 SIL1-BiP chaperone system 
Among the multitude of proteins involved in the ERQC, the lumenal chaperone BiP - a member 
of the HSP70 family, plays a key role 12. BiP, also called glucose related protein 78 (GRP78), is 
one of the most abundant ER-resident chaperones that is involved in various important 
regulatory processes. These include (i) folding/unfolding of nascent polypeptide chains and 
mature proteins, (ii) maintaining the ER-Ca2+ homeostasis, (iii) protein translocation across the 
ER-membrane, (iv) involvement in the ER-associated degradation (ERAD) and initiation of the 
unfolded protein response (UPR) pathway 13. Like other HSP70 chaperones, BiP has an N-
terminal nucleotide binding domain, which interacts with ATP/ADP and a C-terminal substrate 
binding domain that interacts with un-/misfolded proteins, respectively. Usually, the substrates 
bound by BiP are shielded from non-specific interactions with other unfolded proteins by their 
aggregation prone exposed hydrophobic regions, which are typically buried in the native state, 
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and act as BiP binding targets. In the ER lumen, BiP shuttles between ATP and ADP-bound 
states. The ATP-bound BiP has low-affinity but faster exchange rate of substrates, whereas the 
ADP-bound state has high-affinity and slow exchange rate of substrates. This BiP-ATP/-ADP 
interchange process is known as the ATPase cycle, which is controlled by the ER-resident co-
chaperones (HSP40 proteins) and nucleotide exchange/releasing factors (NEFs) 14. On one hand, 
HSP40s function in promoting the hydrolysis of ATP, which causes a conformational change that 
induces tight binding of BiP to substrates. The NEFs, on the other hand, catalyze the removal of 
ADP that allows BiP to release the substrates, which subsequently proceed towards the ERGIC 
and the Golgi apparatus to attain their final native states.  
 
Figure 1.1: The co-translational protein transport pathway targets nascent polypeptides to the ER membrane via 
the signal recognition particle (SRP). In the ER lumen, BiP shuttles between ATP and ADP-bound states. This BiP 
ATP-ADP interchange process is known as the J ATPase cycle, which is regulated by the ER-resident co-chaperones 
and NEFs i.e. SIL1 and GRP170. Both NEFs displace ADP and subsequently release of the substrate (properly folded 
protein) from BiP to complete the protein folding process. The unbound BiP binds with the free ATP molecules in 
the ER lumen and the complete process is repeated. Figure adapted from 5. 
There are two known NEFs for BiP i.e. (i) N-linked glycoprotein SIL1 (suppressor of ∆ire1 ∆lhs1 
double mutant number 1) and (ii) GRP170 (glucose related protein 170) also known as hypoxia 
up-regulated 1 15. Additionally, GRP170 has a cytoprotective function (under hypoxic conditions) 
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and can act as a chaperone 10, whereas no such chaperone activity has been reported for SIL1 so 
far. Notably, the analysis of the canine pancreatic rough microsomes revealed molar ratios of: 
2.358 for BiP, 0.283 for GRP170 and 0.002 for SIL1 with respect to the alpha-subunit of SEC61 
complex 16.Both SIL1 and GRP170 interact with the nucleotide binding domain of the ADP-
bound BiP-substrate complex and displace ADP to subsequently release substrates from BiP 10, 
17. However, SIL1 preferentially binds to BiP and catalyzes the release of ADP that eventually 
completes the protein folding process 18 (Fig. 1.1). Structural analysis studies that were 
performed on SIL1-BiP complexes in yeast (Saccharomyces cerevisiae) have shown that the SIL1 
ATPase domain interacts directly with the nucleotide binding domain of BiP with an equilibrium 
dissociation constant (Kd) of 13 nM 19. Therefore, the SIL1-BiP interaction complex plays an 
essential role in the protein folding process and in maintaining cellular homeostasis. Evidently, 
the absence of SIL1 can cause decreased activity or loss of functional BiP and consequently the 
newly synthesized proteins might not be translocated into the ER leading to their accumulation 
in the cytosol, whereas the proteins that have entered the ER lumen remain in a un-/misfolded 
state and tend to aggregate. Furthermore, some of the important secretory and membrane 
proteins might fail to reach their final destinations and can cause secondary loss-of-functions 20. 
 ER stress, homeostasis and apoptosis 1.2
Many physiological and pathophysiological conditions such as altered protein folding capacity, 
disturbed N-glycosylation or disulfide bond formation, hypoxia, bacterial/viral infections or 
alterations of the ER-Ca2+ homeostasis can promote ER stress 21. This term describes an 
imbalance between the cellular demand for ER function/homeostasis and capacity 22. 
Regardless of the above mentioned causes, the protein folding machinery is often compromised 
under ER stress situation resulting in an increasing amount of un-/misfolded proteins in the ER 
lumen that tend to form insoluble aggregates (e.g. inclusion bodies) 23. The underlying 
mechanism of aggregate formation is the interaction between hydrophobic regions of the 
partially folded intermediates, especially β sheets 24 leading to a non-native protein 
conformation that becomes devoid of its molecular function 23. 
To alleviate the ER stress, two main stress response pathways are triggered to restore normal 
physiological functions in the eukaryotic cells i.e. (i) adaptive and (ii) apoptotic mechanisms 25. 
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The adaptive (or protective) response attempts to establish cellular homeostasis by three ways, 
which are regulated by the unfolded protein response (UPR) 26. There are three ER-resident 
transmembrane proteins (known as UPR stress sensors) that transduce the unfolded protein 
signal across the ER membrane (i) double-stranded RNA-activated protein kinase (PKR)-like 
endoplasmic reticulum kinase (PERK), (ii) activating  transcription factor 6 (ATF6) and (iii) 
inositol-requiring protein 1α (IRE1α), respectively 27 (Fig. 1.2).  
 
Figure 1.2: ER stress and activation of the UPR pathway. Under normal conditions, the ER folding machinery 
ensures proper maturation of proteins, which are further stabilized and targeted to their respective destinations by 
the secretory pathway. However, under the ER-stress conditions, aggregation of misfolded proteins occurs and the 
cell initially tries to restore homeostasis by triggering the UPR pathway (adaptive phase). The transmembrane BiP-
bound UPR transducers (PERK, ATF6 and IRE1) modulate cellular homeostasis by downstream signaling pathways; 
however, under persistent stress conditions, the cell undergoes the apoptotic (or programmed cell death) phase 28. 
These three signaling sensors of the UPR pathway operate in parallel and they are supposed to 
sense the ER-stress through BiP binding/release by their respective lumenal domains 25. The first 
protective mechanism is mediated by PERK, which is activated by dimerization and 
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phosphorylation. Once activated, PERK phosphorylates initiation factor eIF2, resulting in 
translation attenuation to prevent further synthesis of nascent proteins. The second mechanism 
involves ATF6, which is sequentially cleaved into two subunits: ATF6α and ATF6β by two distinct 
proteases i.e. site-1 protease and site-2 protease, respectively that are located in the Golgi 
complex. Both subunits then translocate into the nucleus and positively promote transcription 
of the ER stress target genes including the ER-resident molecular chaperones and the folding 
enzymes 29. The last adaptive mechanism is mediated by IRE1, which is activated by 
oligomerization and autophosphorylation. Upon activation, it regulates (i) chaperone induction, 
(ii) the ERAD and (iii) enlargement of the ER surface area to accommodate the bulk of unfolded 
proteins 11b. The ERAD machinery specializes in recognizing the misfolded proteins and 
(retro)translocates them to the cytoplasm for their degradation by the ubiquitin-proteasome 
pathway 30. This pathway involves two steps: First, proteins destined for degradation are 
subjected to ubiquitination, a PTM in which a single or multiple ubiquitin protein molecules are 
attached to the Lys residues of the substrate proteins. Second, ubiquitin-tagged proteins are 
proteolytically degraded in the 26S proteasome complex 31 or occasionally, by the 
lysosomes/vacuole 32. However, under prolonged and persistent ER-stress conditions; the 
adaptive response pathway ceases and usually gives way to the apoptotic pathway, which is 
mediated by C/EBP homologous protein (CHOP) or c-Jun N-Terminal kinase (JNK) leading to 
programmed cell death 33. 
 Protein aggregation related mammalian disorders 1.3
Accumulation and aggregation of un-/misfolded proteins is cytotoxic and causes tissue and 
organ damage that can lead to progressive development of various neurodegenerative 23, 34 
neuromuscular and muscle disorders in mammals 35. A collective term known as 
"conformational" or "folding" diseases describes the pathological conditions caused by 
abnormally folded cellular proteins and their aggregation 34b, 36. Some of the well-known 
examples include Alzheimer’s disease, Huntington’s disease and Parkinson’s disease 34a. Over 
the years, clinical evidences accumulated from many patients’ biopsy who suffered from these 
diseases have revealed the presence of intra-/extracellular aggregates of un-/misfolded proteins 
or mutated gene products (non-functional proteins) 37. Besides, studies conducted on human 
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and mouse models of neurodegeneration and neuromuscular degeneration showed altered 
levels of chaperones, UPR sensors and apoptotic mediators, which indicate the ER stress related 
activation of the ERAD and UPR pathways and disturbed protein clearance processes. Notably, 
these mechanisms were found to be critical for the survival of cells especially in 
neurodegenerative disorders in man and mouse models 37-38. 
1.3.1 Marinesco-Sjögren Syndrome 
Marinesco-Sjögren Syndrome (MSS, OMIM: 248800) is a progressive multi-systemic 
neuromuscular disorder first described in 1931 by Gheorge Marinesco 39. It is a rare genetic 
autosomal recessive condition with phenotypic variability 40 and so far 200 cases of MSS were 
reported according to the Orphanet Reports Series 2015 (http://www.orpha.net/consor/cgi-
bin/Education_Home.php). In the past decade, genetic studies have identified mutations in SIL1 
(chromosome 5q31) as the main cause of MSS in nearly 60% of the examined cases 41. The 
clinical symptoms of MSS patients are: mental impairment, bilateral congenital or infantile 
cataracts, marked vacuolar myopathy and cerebellar ataxia 42. However, ataxia, cataracts and 
myopathy represent the characteristic "clinical triad" or "classical MSS-phenotype" 41a (Fig. 1.3 
A-C).  
 
Figure 1.3: Clinical and electron microscopy findings in MSS patients - the characteristic "clinical triad". (A) Marked 
cerebellar atrophy in patient MSS33 at age 24 years (T1-weighted magnetic resonance imaging, MRI). (B) Cataract 
in a 7-year old patient 41a. (C) Dense membranous structures surrounding the myonucleus (red arrows; biopsy of a 
15-year old patient) scale 1 µm, respectively  41a, 41b. 
Mental retardation can be of varying degree or maybe absent 41a. Additional clinical symptoms 
in some MSS cases are short stature, hypogonadism, scoliosis, nystagmus and strabism ("non-
A 
B
 
C
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classical MSS-phenotype") 41a. However, a small proportion of cases with the "classical" and a 
high proportion of cases with "non-classical" MSS-phenotypes do not have SIL1 mutations 
thereby indicating a heterogeneity of this phenotype. Notably, mutations within the functional 
candidate genes HSPA5 (BiP) and HYOU1 (GRP170) were already excluded by molecular genetic 
studies of SIL1 mutation-negative MSS patients. Besides these phenotypic alterations, 
morphological studies on the muscle specimens of most MSS patients showed severe 
mitochondrial alterations and myonuclear irregularities. The presence of irregular electron-
dense membranes surrounding a part of the diseased myonuclei is a striking feature of MSS-
related myopathy 35, 43 (Fig. 1.3 C). Recently Krieger et al., 41a confirmed the presence of 46 
different types of mutations on SIL1, further consolidating the wide mutational spectrum. 
Depending on the type of mutation, the functional SIL1 can be (i) completely absent, (ii) 
truncated (loss of critical functional domains) or (iii) destabilized and thus leading to an 
impaired BiP-associated protein folding process 41a, 44. Importantly, in man, mutations in SIL1 
show selective vulnerability affecting only certain tissues/organs, which include the brain, the 
eyes and skeletal muscles 45. Notably, the muscular and central nervous vulnerability can be 
confirmed in mice 34c, 35 whereas the eyes do not seem to be affected by SIL1-deficiency 46. The 
plausible speculation for this behavior could be that certain cell types and organs are fully 
dependent on the functional SIL1 in the BiP-mediated protein folding process 5, 18. 
Proteomic analyses of the MSS patients and an index patient 
Proteomic studies of two different cell types that were derived from clinically unaffected tissues 
of five different MSS families were performed in this work (Table 1.2). Genetic analysis of the 
fibroblasts cultures from the skin biopsies and lymphoblastoid cells taken from these MSS 
patients have revealed the presence of following SIL1 mutations: exon skipping (MSS2), small in-
frame exon deletions (MSS24), missense mutation (MSS32), frameshift mutation in the last exon 
(MSS64), and nonsense mutation (MSS33) 41a, 41b. These mutations result in the expression of 
SIL1 protein, albeit in low levels and mostly in the non-functional form as the domains 
responsible for SIL1-BiP interaction are either absent in the expressed protein or the 
residual/truncated SIL1 exhibits weak binding with BiP 41a, 41b. 
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In addition to these five MSS cases, proteome analysis of the muscle lysate derived from an 
index patient (female, Caucasian) who presented phenotypic manifestations similar to MSS, but 
not related to SIL1 mutations was also performed in this work. Apart from SIL1, mutations of all 
limb girdle muscular dystrophy related genes were excluded as to be the disease causative 
factor of the patients’ phenotype. Moreover, these symptoms were also identical to a distal 
myopathy 1 disorder (OMIM: 160500), which is caused due the mutations in MYH7 that encodes 
for the cardiac β-myosin heavy chain or myosin-7 protein mostly found in the cardiac (heart) 
and skeletal muscles. Genetic analysis of the index patient DNA revealed a single nucleotide 
polymorphism in MYH7. However, this variant is considered as clinically non-relevant 
(http://www.ncbi.nlm.nih.gov/clinvar/variation/43056/#supporting-observations) and does not 
correlate with the severe phenotypic abnormalities showed by the index patient. In spite of the 
non-similar genetic defect, overlapping clinical symptoms with MSS, such as prominent 
myopathic changes including the considerable presence of protein aggregates, led to perform a 
comparative proteomics investigation by making use of skeletal muscle protein extract to gain 
preliminary insights into the myopathic changes of the index patient with respect to healthy 
controls. 
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Table 1.2: Ethnic details and clinical features of MSS patients with SIL1 mutations 41a, 41b. Table legend: del = deletion; het = heterozygous; hom = homozygous; mat 
= maternal; pat = paternal; + = present; - = absent; n.a = not available; P = proximal limbs; D = distal limbs. 
Family MSS2 MSS24 MSS32 MSS33 MSS94 
Sex male female male male male 
Age 5 years 4 years 6 years 26 years 28 years 
Ethnic origin Turkey Turkey United States Italy Pakistan 
SIL1 mutation(s) 645+1G-A, skipping, exon 6 (hom) p.V231_l232del (hom) p.G312R (mat); p.F345fs (pat) p.S256fs (hom) p.E101fs (hom) 
            
Cataracts (age at diagnosis) + 4.5 years - + 4 years + 3 years + 
Ataxia + + + + + 
Cerebellar atrophy + + + + + 
Muscle weakness n. a. + - P=D - 
Muscle atrophy n. a. + P=D P=D - 
Muscle biopsy findings myopathic myopathic myopathic myopathic myopathic 
Membranous structure associated with myonuclei + n. a. n. a. + + 
Cell type used for proteomics analysis fibroblasts lymphoblastoid cells 
Clinical state unaffected 
 
Non-SIL1 related index patient: The clinical symptoms were: progressive microcephaly at 4 months; moderate gait ataxia with weak tendon reflexes and 
moderately elevated creatinine kinase level (365 U/L) at 2 y indicative of neuromuscular disorder; progressive generalized muscle weakness and myopathic facies 
between 3 to 5 years of age; from the age above 5, she was completely wheelchair-bound. The muscle biopsy for morphological and proteomics analyses was 
taken at 5 years of age. 
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1.3.2 Animal model of MSS 
In 2005, Zhao and colleagues 34c described a murine phenotype caused by mutant transcripts of 
Sil1 (located on murine chromosome 18). These transcripts demonstrate splicing between exon 
7 of Sil1 and an ETn retrotransposon inserted between nucleotides 4,799 and 4,800. The 
chimeric transcript includes an in-frame stop codon after 96 nucleotides of ETn sequence. These 
homozygous mutant animals (commonly referred as woozy mice) suffer from cerebellar atrophy 
due to loss of the Purkinje cells from ages 3 to 4 months 34c, 35, 47 (Fig. 1.4 A, B) and develop 
advancing myopathy 35.  
 
Figure 1.4: Immunohistochemistry (IHC) findings show (A) Purkinje cell loss and proliferation of glial cells in the 
cerebellum of Sil1-deficient woozy mouse (black arrows: proliferated Bergmann-glia; white arrow: a single survived 
Purkinje cell). (B) Regular density and arrangement of Purkinje cells in the cerebellum of wild type littermate 35 
(white arrows). Scale 1 µm. 
SIL1 is widely expressed in the brain, but its loss evidently affects the cerebellar Purkinje cells 
causing fatal consequences including autophagy and apoptosis 34c leading to gait ataxia. 
Interestingly, it was shown that in woozy mice, concomitant overexpression of GRP170 rescues 
the Purkinje cell loss 47. However, the exact role of the increased levels of GRP170 in Purkinje 
cells is still uncertain owing to the fact that GRP170 has a dual function i.e. chaperone activity as 
well as NEF for BiP 10. Recently, Inaguma et al., 48 examined the pathophysiological significance 
of SIL1 mutations in corticogenesis of MSS by conditional RNAi-based Sil1-silencing in mice.  
Depletion of murine SIL1 caused neuronal migration delay during corticogenesis, which could be 
rescued by concomitant expression RNAi-resistant Sil1, but not by three MSS-causing Sil1 
mutants. Moreover, SIL1-BiP interaction as well as BiP function was found to be crucial for 
neuronal migration ex vivo. Besides, time-lapse imaging revealed morphological disorganization 
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associated with abnormal migration of SIL1-deficient neurons in mice. Based on their findings, 
the authors concluded that abnormal neuronal migration and interhemispheric axon 
development may contribute to mental impairment in the pathophysiology MSS. 
Therefore, due to the genetic background similarity and phenotypic resemblances, the woozy 
mouse serves as a suitable in vivo model to study the functional role of SIL1 in MSS 10. 
 Proteome analysis - in general 1.4
Unlike the genetic material (deoxyribonucleic acid or DNA), which is predominantly static and 
stable; the protein composition of a cell is highly dynamic and complex 49. Slightly over two 
decades ago, Marc Wilkins coined the word "proteome" to describe the total protein population 
of a cell at a given point of time 50. Recently, the human genome project provided a wealth of 
information about the human genetic code and revealed the number of protein-coding genes 
i.e. ~25,000 51. However, the exact number of genes is still under debate and it is believed to 
fluctuate in the future 52. Interestingly, it has been suggested that these genes code for up to an 
estimated 1,000,000 distinct proteins. This disagreement between gene expression and the 
actual form of biologically active protein cannot be explained by transcriptomics, which is the 
study of the complete set of messenger ribonucleic acid or mRNA transcripts ("transcriptome") 
expressed by an organism’s genome at a particular point in time. However, the large 
discrepancy between genes and proteins is attributed to factors such as alternative splicing and 
PTMs of proteins 53. Therefore, it could be argued that studying proteins in living organisms 
provides more biological information with respect to gene expression because most of the 
metabolic and cellular processes are carried out by proteins. In contrast, the mRNA most often 
serves as an intermediate between genetic information and the functional proteins. 
Following the footsteps of the human genome project, the human proteome project (HPP) was 
initiated in the year 2010, which aimed to identify all the proteins encoded by 20,300 genes. The 
key objectives of the HPP are (i) identification of protein isoforms as well as PTMs, (ii) 
quantification of differentially regulated proteins in control/disease states and (iii) annotation of 
the proteins to their biological function. Notably, one of the three main driving forces of the 
HPP apart from protein capture (antibody-based) profiling and protein information databases is 
mass spectrometry (MS) based proteomics 54. Owing to the rapid technological developments in 
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instrumentation, the current MS-based proteomics workflows are capable of identifying several 
thousands of proteins in a span of few days 55 to just an hour 56 under ideal conditions. On the 
one hand, fast MS-based proteomics analysis is providing substantial amount of qualitative 
(identification) information using minute (µg) sample amounts and better analysis than two 
dimensional gel-based (i.e. 2-DE) approaches of complex samples such as cell lysates and PTMs 
(e.g. phosphorylation). On the other hand, quantitative proteomics techniques have gradually 
matured and their application to study human disorders has gained momentum 57 in the past 15 
years. Moreover, cancer and clinical biomarker research areas have also been consistently 
utilizing quantitative proteomics approaches for understanding the molecular basis of disease 
mechanisms and to identify novel disease markers, respectively 58 (Fig. 1.5). 
 
Figure 1.5: Number of accumulated research articles containing words "quantitative proteomics" only or in 
combination with human diseases/cancers/biomarkers in their abstracts. Overall, there has been a steady increase 
in all aspects since January-2001 till December-2015 (http://www.ncbi.nlm.nih.gov/pubmed). 
1.4.1 Mass spectrometry - based proteomics 
Characterization of proteins and peptides by mass spectrometry was boosted with the invention 
of two soft ionization procedures namely, matrix-assisted laser desorption ionization (MALDI) 59 
and electrospray ionization (ESI) 60. Both techniques can transform biomolecules (e.g. proteins 
and peptides) into gas phase ions in a non-destructive way to allow subsequent analysis by a 
mass spectrometer (MS). However, in recent years, ESI has become the method of choice in the 
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field of MS-based proteomics mainly because of its ease to couple high-performance liquid 
chromatography (HPLC) separations with a MS 61. 
1.4.1.1 Electrospray ionization 
The process of generating ions by ESI is carried out under atmospheric pressure and the 
molecules to be ionized are in a liquid state (Fig. 1.6).  
 
Figure 1.6: Schematic representation of ESI process. Gas-phase ions are produced by a repeated process of solvent 
evaporation and Coulombic explosions of multiply-charged droplets. The ions are subsequently transferred into MS 
which is usually operated under high vacuum (10-3 - 10-10 Torr) for two reasons: (i) to avoid collisions with neutral 
gas molecules and (ii) to increase the mean free path of ions. A feature of ESI is that highly multiply charged ions 
can be produced from these droplets, thereby allowing the analysis of biomolecules such as proteins and peptides 
by mass spectrometers with limited m/z range (e.g. 2,000). Figure adapted from: 
http://www.bris.ac.uk/nerclsmsf/techniques/hplcms.html. 
The analyte solution is passed through a capillary (an ESI emitter), which is usually connected to 
an HPLC (LC-MS). A potential difference of usually ± 1.5 - 4.5 kV is applied between the emitter 
and the counter electrode. This strong electric field induces charge accumulation at the liquid 
surface located at the tip of the emitter (inner diameter ~10 µm). In positive ESI mode, the 
accumulated charges (positive) are attracted towards the counter electrode (negative) due to 
the electrostatic repulsion from the emitter (same polarity). When the voltage reaches a 
threshold value, known as the Taylor voltage, the liquid surface changes rapidly its shape to 
become a rounded cone - the "Taylor cone" and from the tip of this cone the liquid is sprayed 
(liquid filament). This process produces charged droplets and as the solvent evaporation occurs, 
the droplet shrinks until it reaches a point such that the surface tension can no longer sustain 
the charge repulsions ("Rayleigh limit"). At this point a "Coulombic explosion" of the multiply 
charged droplet occurs and a series of smaller (secondary) droplets are ejected. These droplets 
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again shrink due to evaporation and emit even smaller droplets. Furthermore, formation and 
desolvation of the droplets is aided by a heated capillary and in some cases by nebulizing gas 
(Nitrogen) flow at the MS inlet. This process of solvent evaporation and Coulombic explosion 
occurs repeatedly to generate smaller and secondary droplets until peptide ions are transferred 
to the gas phase - the mechanism of which is not completely revealed to date 62. ESI has proven 
effective in producing gas phase ions of proteins and peptides. Notably, multiple charge states 
are often observed and the number of charges per biomolecule analyte typically depends on (i) 
the length of amino acid chain, (ii) the number of ionizable functional groups and (iii) the pH of 
HPLC solvents. Furthermore, a technical improvement of ESI known as the nano-electrospray 
ionization (nano-ESI) works with small analyte volume i.e. microliter (µL) range and at 
nanoliter/min flow rate has shown to increase the sensitivity of the analysis 63. 
1.4.1.2 Reversed-phase chromatography 
In so-called bottom-up proteomics, MS analysis is performed on the peptide level typically after 
proteolytic digestion of proteins using suitable proteases (e.g. trypsin). However, for highly 
complex proteomes e.g. human, a fractionation step prior to MS analysis is necessary. LC-MS 
mostly done with reversed-phase (RP) chromatography and MS - is a powerful combination to 
reduce the sample complexity of peptide mixtures 61 (Fig. 1.7).  
 
Figure 1.6: Block diagram of a HPLC system with a reversed-phase column (for peptide separations) and a UV 
detection system.  
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In RP, the peptide solutions are separated based on their varying degree of reversible 
hydrophobic interactions with a non-polar stationary phase in a polar mobile phase. The RP 
stationary phase column normally consists of uniform porous silica particles that are bonded 
with long chain alkyl groups (e.g. octadecyl/C18) whereas, the mobile phase include polar 
solvents such as water, methanol or acetonitrile. Peptide sequences that are mainly composed 
of hydrophilic amino acids preferably interact with the polar phase and hydrophobic amino acid 
containing peptides will adsorb strongly to the RP. The elution of peptides from the stationary 
phase is usually done by changing the composition of the mobile phase. Because of their diverse 
binding affinities, the preferred elution method of peptides from the RP stationary phase is 
performed by gradually increasing the organic concentration of the mobile phase over time (i.e. 
"gradient elution"). Often, the peptides eluting from the RP column pass through a detection 
system that monitors the separation usually a UV-wavelength detector, which measures the 
absorbance of the peptide bond at a wavelength of ~214 nm. In case of an LC-MS setup, the 
effluent from the column (through the UV detector) is coupled directly to a MS using an ESI 
interface. 
1.4.1.3 Off-line fractionation strategies 
In spite of its routine application, one-dimensional RP is still not sufficiently efficient to separate 
complex peptide mixtures. For this reason, multi-dimensional separation techniques that can 
exploit the physicochemical properties (e.g. charge, isoelectric point, hydrophobicity, molecular 
weight) of proteins/peptides have been developed 64. Usually, the first dimension separation is 
carried out by gel-based or chromatography-based techniques followed by second dimension 
LC-MS analysis. In the present work, a modified version of isoelectric focusing known as the 
OFFGEL fractionator (Agilent) was used, which enables to recover the separated 
proteins/peptides fractions (24) in the liquid phase 65. These individual fractions can be 
subsequently analyzed by LC-MS (Fig. 1.8 A). 
Alternatively, two dimensional liquid chromatography (2D-LC) methods have been developed to 
improve the proteome coverage 66. The effectiveness of any chromatographic method depends 
on its "separation power", which is described by the peak capacity i.e. the total number of peaks 
that can be fit into a chromatogram when every peak is separated from adjacent peaks. In order 
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to maximize the peak capacity, 2D-LC techniques often employ two chromatographic methods 
that have dissimilar (i.e. orthogonal) separation mechanisms or selectivities. For instance, the 
multi-dimensional protein identification technology (MudPIT) introduced by Yates and co-
workers involves strong cation exchange (SCX) chromatography in the first dimension and RP in 
the second dimension prior to MS analysis 67. Another 2D-LC strategy employs RP-HPLC 
separations in both dimensions, which are operated at two different pH values 68 (Fig. 1.8 B). 
First, the peptide mixtures are fractionated off-line by RP at basic pH (~10.0) and afterwards 
each fraction is subjected to LC-MS analysis, which is usually done at a low pH (~2.0). Although 
the chromatographic properties of peptides differ substantially between pH 2.0 and 10.0, this 
approach is considered as semi-orthogonal since it uses RP-RP chromatography in both 
dimensions. Nevertheless, Gilar and co-workers could demonstrate the dramatic change of 
charge distribution within the peptide chain due to the high-/low- pH values of RP-HPLC mobile 
phase 69. Furthermore, concatenating several early, middle, and late fractions of high-pH RPC 
could minimize the overlap between the first and second dimensions and should improve 
overall proteome coverage. Recent studies have demonstrated that the orthogonality of 
concatenated high-/low- pH RP-RP fractionation is not only comparable to SCX-RP-HPLC, but 
also yielded slightly higher protein sequence coverages 70. 
 
Figure 1.8: Examples of off-line fractionation strategies. (A) Protein or peptide separations are performed in a multi-
compartment device called OFFGEL fractionator. In a pH gradient (3 - 10) the sample components migrate towards the anode or 
the cathode until they reach the pH values, where their net charge is zero: their isoelectric points (pI). The resulting fractions are 
in solution, which are recovered for subsequent LC-MS analysis. (B) UV chromatogram depicting the separation of a peptide 
mixture on a RP column using a linear organic gradient and operated at a high pH (6.0) HPLC. Each fraction is collected at regular 
retention time intervals, typically 60 s and to improve the separation orthogonality, several fractions from different elution time 
points are concatenated prior to LC-MS analysis. 
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1.4.1.4 Mass analyzers 
MS usually consist of the following parts: (i) ion source (e.g. ESI) and optics, (ii) mass analyzer, 
(iii) detector and (iv) data processing electronics. Mass analyzers are an integral part of each 
instrument because they separate gas phase ions according to their mass-to-charge (m/z) ratios. 
Almost all mass analyzers use electric or electromagnetic fields to separate ions and the 
difference between the devices lies in the manner in which these fields are applied. Mass 
spectra are constructed by plotting ion intensity as a function of m/z ratio. A great variety of 
mass analyzers have been developed in the past century and each mass analyzer has unique 
performance characteristics. Some of these parameters have direct implications in the 
proteomics field 71 and they are briefly described below. 
The resolution (R) of a mass analyzer is its ability to distinguish between two neighboring 
ions/peaks that differ only slightly in their mass (i.e. Δ m or Δ m/z). Mathematically, it is the 
inverse of resolving power given as m/Δ m. The most commonly used method to measure the 
resolution of a mass analyzer follows the full-width, half-maximum (FWHM) definition, which 
uses the width of a single peak at 50% of its height to determine Δ m (Fig. 1.9 A). In LC-MS based 
proteomics, high resolution mass analysis enables (i) to distinguish co-eluting or overlapping 
peptides, (ii) to accurately determine the charge states of the peptide ions and (iii) to determine 
their molecular masses (or m/z values) (Fig. 1.9 B).  
 
Figure 1.9: (A) FWHM method for determining resolution for a mass spectrometer measured at a given ion. (B) 
Comparison of two resolution values. High R not only enables to resolve the isotopic peaks but also for charge state 
determination and accurate mass determination. 
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High resolution MS usually refers to R values > 10,000 however, the resolution varies with the 
m/z value and it is instrument dependent. Mass accuracy is defined as the difference between 
the measured (experimental) mass and its calculated (theoretical) value, which is usually 
described in a relative manner e.g. part per million (ppm). Accurate mass measurement (1 - 2 
ppm) allows a more confident identification of analytes. Although there is no direct correlation 
between mass accuracy and resolution, a correctly calibrated instrument with high resolution 
(e.g. R ≥ 60,000) can provide ≤ 1 ppm mass accuracy. Sensitivity and dynamic range are closely 
related terms associated with a MS, which give an indication of the maximum range of analyte 
concentrations that can be detected in a given sample. These are important parameters for 
proteomics analysis as biological samples have large differences in analyte concentrations. 
Analysis speed or scan rate of a mass analyzer refers to how fast it scans a mass spectrum. This 
is important for LC-MS applications where the chromatographic peak widths are typically 
between 5 - 10 s FWHM. 
Commonly used instruments in proteomics are quadrupole (Fig. 1.10 A) and linear ion trap (Fig. 
1.10 B) mass spectrometers that offer high sensitivity and fast scan rates depending on their 
mode of operation. The downside however, is both analyzers generate low resolution (R usually 
2,000 and 4,000, respectively) and low mass accuracy (~100 ppm) data. Nearly a decade ago, a 
new device called the Orbitrap mass analyzer 72 (Fig. 1.10 C) provided features of both high -
resolution and high mass accuracy 73. The latest generation of Orbitrap mass analyzer offers 
maximum resolution of up to 450,000 (FWHM at 200 m/z) and mass accuracy between 1 - 3 
ppm (Orbitrap Fusion tribrid MS, Thermo Scientific). 
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Figure 1.10: The working principles of the three commonly used MS in the field of proteomics. (A) 
Quadrupole mass analyzer consists of four precisely parallel metal rods. Opposite electrodes are 
connected and one pair receives a positive, the other pair a negative direct current (DC) potential that is 
superimposed by a time-dependent radio frequency (RF) potential. When ions are injected into the 
quadrupole in the direction of the rods, the oscillating electric field in the center of the quadrupole can 
be set to allow only a narrow mass-to-charge (m/z) range to pass on a stable trajectory. Stable 
oscillations are only achieved by ions of given m/z values for a given rod assembly, oscillation frequency, 
RF voltages, and DC voltage. The remaining ions will strike the rods. Thus, a quadrupole rather acts as a 
mass filter than as a conventional MS. Ramping the amplitude of the DC and RF potentials enables 
different narrow m/z ranges to pass the quadrupole and thereby generates a mass spectrum. (B) The 
design of the quadrupole linear ion trap (2D trap) by Jae Schwartz et al. 74 resembles a quadrupole that is 
split into three sections. The central section of the three parts is the largest and is intended to store the 
ions, whereas the front and back sections can be used for ion manipulation and for applying an axial 
trapping potential. Ions are trapped by DC potentials applied to ends of the four hyperbolic rods, X and Y 
(on all three segments of each rod) and RF applied to all rods. The behavior of the ions and their 
movement is explained by the Mathieu’s differential equations and stability diagram (for a detailed 
explanation please refer to 75). Ramping the amplitude of the main RF, ions leave the trap - low m/z to 
high m/z. An ejection slit in one of the central rods that allows ion ejection and detection by an electron 
multiplier. Besides storing ions, 2D traps can be combined with other mass analyzers in hybrid 
instruments and used to isolate ions of selected m/z ratios, to perform tandem mass spectrometry 
(MS/MS) experiments. (C) The Orbitrap mass analyzer is based on an earlier ion storage device, the 
Kingdon trap 76, which uses electrostatic fields to trap and analyze ions and consists of one central 
spindle and one outer barrel-like electrode that are connected by a ceramic ring. Ions injected into the 
Orbitrap are electrostatically trapped while rotating and oscillating along the central electrode. The axial 
oscillating frequency is dependent on the m/z of the ion. Oscillating ions induce an image current signal 
on the outer electrodes. Image current signals are converted into frequencies by Fourier transformation. 
The frequencies, which are characteristic of each ion m/z value, are finally converted into a mass 
spectrum 72. 
To meet the requirements of the proteomics research area, which typically demands rapid and 
accurate analysis of biomolecules; hybrid MS were developed recently which combine two or 
more different types of mass analyzers. For example in the LTQ Orbitrap XL (Thermo Scientific), 
throughput and sensitivity are maximized by acquiring MS data at high resolution and accuracy 
with the Orbitrap, whereas MS/MS (see next chapter) data is recorded (in parallel or alternating 
fashion) at high speed with low resolution in a linear ion trap mass analyzer (Fig. 1.11). A brief 
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description of the three different hybrid mass spectrometers that were employed in this work is 
given below (Figs. 1.11 - 1.13). 
 
Figure 1.11: Schematic of a LTQ Orbitrap XL MS (Thermo Scientific, http://planetorbitrap.com/). The linear trap 
quadrupole (LTQ, known as linear ion trap) is used at the front end for ion trapping, ion selection, fragmentation 
reactions and low resolution ion detection, whereas the Orbitrap is used for high resolution (R > 100,000), high 
mass accuracy (< 3 ppm) ion detection 73. 
 
 
Figure 1.12: Schematic of an Orbitrap Elite MS (Thermo Scientific, http://planetorbitrap.com/). Key differences 
from LTQ Orbitrap XL are: the single linear ion trap was replaced by two identical linear ion traps that are operated 
at different gas pressure regimes. The first trap is held at higher pressure for improved trapping and fragmentation 
whereas the second trap is kept at lower pressure for enhanced scanning capabilities. Furthermore, the HCD 
collision cell was modified for faster extraction and more efficient transmission of all ions. Key improvements 
compared to the LTQ Orbitrap Velos (which has an identical instrument design) are: faster scan speed and better 
dynamic range of the linear ion trap and the novel "high-field" Orbitrap, which offers a resolution of 240,000 at m/z 
400 at one scan/second (1 Hz) 77. 
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Figure 1.13: Schematic of a Q Exactive MS (Thermo Scientific, http://planetorbitrap.com/) with the Orbitrap for 
high resolution and high mass accuracy analysis of both precursor and product ions. Peptide ions are isolated for 
MS/MS by the quadrupole and are subjected to HCD fragmentation and stored in the C-trap, which allows for ion 
accumulation and Orbitrap mass analysis of ions from the preceding event in parallel, resulting in fast duty cycle. 
Furthermore, implementation of the enhanced Fourier Transform (eFT) algorithm to process the image current 
from the detector results in a twofold increase in resolution in comparision to the standalone Orbitrap analyzer 
called Exactive 78. 
1.4.1.5 Tandem mass spectrometry 
In bottom-up proteomics, tandem mass spectrometry (or MS/MS) analysis is performed to 
obtain amino acid sequence information of the peptide ions 79. Peptide sequencing by MS/MS 
method involves at least two stages of mass analysis. In the first stage MS analysis, a peptide (or 
precursor) ions of a specific m/z window (e.g. 500.0 - 502.0 m/z) are selected and subsequently 
dissociated. Among different types of fragmentation procedures, collision induced dissociation 
(CID) is the most frequently employed peptide dissociation technique 80. In CID, the selected 
precursor ion (m/z value) is activated by collisions with inert gas atoms (e.g. Argon, Helium or 
Nitrogen) 81. With each collision, a part of the kinetic energy is converted into internal 
(vibrational/rotational) energy of the precursor ion. If the gained internal energy is high enough 
the precursor ion will dissociate resulting in the cleavage of the weakest bond first, which is 
usually the CO-NH amide bond in peptides thus generating predominantly the so-called b- and 
y-type fragment (product) ions 82 (Fig. 1.14). Fragmentation is a statistical process where certain 
amino acid (combinations) dissociate more easily than others, but owing to the huge numbers 
of peptide ions that are fragmented, many different types of b- and y-ions are generated that 
help to sequence a peptide. In the second stage of MS, the resulting m/z values of these 
fragment (or product) ions are analyzed. 
Bent flatapole 
Electrospray 
ion source 
S-lens 
Quadrupole C-trap 
HCD collision cell 
Orbitrap  
mass analyzer 
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Figure 1.14: There are mainly three different types of bonds that can dissociate along the peptide backbone i.e. CH-CO, CO-NH 
and NH-CH bonds upon chemical reactions with inert gases. The nomenclature for the product ions as per the fragmentation 
rules is "a, b, c" ions containing the N-terminus and the "x, y, z" ions containing the C-terminus of the peptide, respectively 82-83. 
Collisional-induced dissociation such as CID and HCD predominantly cleave the peptide bond (CO-NH) and generate b-type or y-
type ions. In the figure, b2 and y2 ions are shown as representative structures of charged product ions. As many different types 
of b- and y-ions are generated during fragmentation, these ions can be used to sequence a peptide in an MS/MS scan. 
The instruments that are capable of performing MS/MS experiments can be classified into two 
groups: tandem-in-space and tandem-in-time instruments 84. Tandem-in-space instruments 
require separate mass analyzers to be utilized for each MS stage e.g. triple quadrupole mass 
spectrometer, wherein the first and last quadrupoles act as the actual mass filters with the 
middle quadrupole acting as a CID cell. The type of CID process performed by such instruments 
is referred to as beam-type CID. In contrast, tandem-in-time instruments separate the different 
MS stages by time with the various stages of MS/MS being performed in one mass analyzer e.g. 
linear ion trap. This type of CID process is known as resonant-excitation collision induced 
dissociation or ion trap CID. Here, fragmentation is achieved through hundreds of weak 
collisions, and ion trap CID has a certain limitation i.e. ions below 30% of the precursor m/z are 
lost during trapping making it unsuitable for the isobaric-tagging based quantitative techniques 
that rely on low m/z values. Nevertheless, linear ion trap - Orbitrap hybrid instruments e.g. 
Orbitrap XL, Velos or Elite, Q Exactive (Figs. 1.11 - 1.13) are equipped with a collision cell that 
can perform higher-energy collision induced dissociation (HCD), which is similar to the 
fragmentation achieved in linear quadrupole mass spectrometers  i.e. beam-type CID 85. In 
beam-type CID, fragmentation is achieved by single higher energy collisions and no low m/z 
value cutoff limitation is given, therefore it is well-suited for experiments e.g. isobaric tags for 
relative and absolute quantitation (iTRAQ) 86. 
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1.4.1.6 MS data acquisition strategies 
Depending on the configuration and performance characteristics, the MS data can be acquired 
in several ways. There are two different approaches that are commonly used in the MS-based 
proteomics namely: (i) data dependent acquisition (DDA) and (ii) data independent acquisition 
(DIA), the latter will not be further explained since it was not applied in this work. In DDA mode, 
a full MS scan over a set m/z range (e.g. 300 - 1,500 m/z) is acquired at first. This represents the 
m/z of all ions (peptide) present at that time point. Next, typically the N most abundant 
precursor ions (Top N) present in that MS scan are selected, separately isolated and subjected 
to fragmentation and MS/MS analysis. After acquiring the N MS/MS spectra to complete the 
"cycle", the instrument repeats this procedure. For instance, in a Q Exactive MS, one cycle 
comprising a single full MS scan in the Orbitrap at a resolution of 70,000 (FWHM at 200 m/z) 
and ten (Top 10) DDA HCD MS/MS scans (Orbitrap at R = 17,500) takes around 1.1 s. To avoid 
redundant acquisition of MS/MS from the most abundant peptide ions in typical LC elution 
windows of ~5-20 s, the so-called dynamic exclusion is used, which usually puts the m/z value of 
a precursor ion into an exclusion list for a set duration of time after its MS/MS spectrum has 
been acquired once. Despite being a highly sensitive approach, it has been observed that the 
DDA is biased toward the most abundant peptides mainly due to (i) stochastic nature of the 
precursor ion selection and (ii) the extreme complexity of the sample (e.g. human cell lysate), 
which overwhelms the performance of LC separation and the scan speed of the instrument thus 
leading to undersampling of the low abundant species 87. This consequently hampers the overall 
dynamic range of the analysis 88. 
1.4.1.7 Database dependent protein identification 
In this approach, peptide identification is performed by correlating experimental tandem MS 
spectra with theoretical spectra predicted for each peptide contained in a protein sequence 
database. The search database is simply a FASTA text file, where individual protein sequence 
entries are concatenated with the protein identifier as a delimiter, with alternative protein 
isoforms being handled as an individual protein entry. Many different algorithms have been 
developed for identifying tandem MS data using database search engines, which operate in a 
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similar manner and follow the same general 
workflow. The acquired MS/MS spectra are 
compared and correlated against 
theoretical spectra constructed for each 
database entry that satisfies a certain set of 
database search parameters i.e. mass 
tolerance (which depends on the MS 
system that was used), enzyme constraint, 
and types of PTMs specified by the user. A 
scoring scheme is then used to measure the 
degree of similarity between the 
experimental MS/MS spectra and 
theoretical fragmentation patterns. Next, 
the candidate peptides are ranked 
according to the computed score and the 
highest scoring peptide sequence (peptide 
to spectrum match or PSM) is selected for 
further analysis (Fig. 1.15). The identified 
peptide sequences are then mapped to 
their corresponding proteins followed by 
statistical evaluation and validation 61. The 
main difference between different search 
algorithms is the scoring function used to 
quantify the degree of similarity between 
the acquired tandem mass spectrum and the candidate peptides retrieved from the database. 
For instance Sequest 89 scores peptide sequences by the cross-correlation between the 
intensities of peaks on the observed and the theoretical spectra whereas, Mascot 90 scoring is 
based on the absolute probability that the observed match is a random event. An ion score is 
reported as -10*log10 (p), where p is the absolute probability. A higher score indicates a more 
confident match. Furthermore, to assess the reliability and validate the reported PSMs, a 
Figure 1.15: Peptide identification by correlating acquired MS/MS 
spectrum with theoretical spectra predicted for each peptide 
contained in a protein database. Most search algorithms mainly 
use m/z information (e.g. all the y ions are given equal relative 
abundance in the theoretical spectra) and not intensity 
information.  In the figure, the best PSM is D (in red color). 
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target/decoy search strategy was introduced 91. In this approach, the MS/MS spectra are 
searched by algorithms not only against the standard sequence database (target), but also 
against a database containing usually reversed protein sequences (decoy). The idea is that PSMs 
obtained from the decoy database are random hits and therefore can be used to estimate the 
number of incorrect (random) target PSMs for any given criteria such as score thresholds or 
heuristic methods. This enables the calculation of the false discovery rate (FDR) by simply 
counting the number of decoy and target PSMs that meet the chosen acceptance criteria 92. 
Usually, a 1% FDR is used on PSM, peptide or protein level as a threshold for high confident 
protein identifications. 
1.4.2 Quantitative proteomics to study human diseases 
Quantitative proteomics is a prerequisite to investigate the highly dynamic proteome of living 
organisms as it describes the differences in expression of proteins among different biological 
states (e.g. healthy vs. disease, wild type vs. specific mutation) 93. However, MS is not per se 
"inherently quantitative" 57a since peptides generated from intact proteins, each of which has 
unique physical (e.g. MW, amino acid composition) and chemical (e.g. hydrophobicity, pI) 
properties will influence the overall LC-MS performance characteristics that might complicate 
peptide/protein quantification 57a, 94. For this reason, stable (i.e. non-radioactive) isotope 
based strategies have been introduced that take the advantage of a MS ability to quantitatively 
distinguish the relative abundances of these heavy isotopes in otherwise identical chemical 
species, regardless of competing ion concentrations 95. The basic assumption of stable isotope 
labeling for peptide and protein quantification is that the physicochemical properties of the 
differentially labeled peptides are nearly identical 96. This includes sample preparation 
procedures, LC-separation performance, ionization efficiency and MS/MS fragmentation 
behavior 97. The most commonly used stable isotopes are: 13C, 15N, 2H, 18O and they can be 
introduced by (i) chemical reactions of a labeling reagent with a distinct functional group (e.g. 
iTRAQ) 98, (ii) metabolic processes (e.g. stable isotope labeling by amino acids in cell culture, 
SILAC) 57b or (iii) enzyme (e.g. trypsin)-facilitated 18O labeling (e.g. H218O) 99. Depending on the 
type of label, differentially labeled samples can be combined at different steps of the sample 
preparation workflow assuming an overall near-complete labeling efficiency. Peptide 
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quantification is performed either on MS or MS/MS level. The basis of quantification is the shift 
in absolute mass corresponding to the stable isotope incorporated into the peptide or 
protein. Thus in case two samples were labeled either "light" or "heavy", pooled and analyzed 
together, typically each peptide will appear in both, the light and the heavy form in the final LC-
MS analysis. For each of these two forms of the peptide the area under the curve of the isotopic 
envelope is integrated over the LC elution time. Finally, as the units obtained in MS are rather 
arbitrary and do not directly allow deducing peptide concentrations/amounts - a relative 
quantification, i.e. determining the relative change across samples, is performed by calculating 
the ratio of the peak areas of the differentially labeled peptides. In so-called label-free precursor 
ion intensity-based quantification works with the same principle however, peptide abundances 
are retrieved from consecutive LC-MS analyses since owing to the lack of stable heavy isotopes, 
each sample has to be analyzed individually. Moreover, targeted MS methods such as selected 
reaction monitoring (SRM) and parallel reaction monitoring (PRM), which offer the specific 
analysis of dedicated proteins - comparable to immunoblot assays (e.g. WB) may be used for 
protein quantitation 100. In the present work, chemical labeling (by iTRAQ reagents), label-free 
approaches and PRM were employed for relative protein quantification and their principles and 
applications are given below. 
1.4.2.1 Protein quantification with labeling reagents 
The use of isobaric mass tags to monitor relative changes in protein abundances across altered 
biological systems have been part of LC-MS-based proteomics for more than a decade. iTRAQ 98 
is one of the most popular technologies and it enables relative protein quantification of up to 8 
distinct biological samples in a single LC-MS/MS analysis. An iTRAQ label consists of a primary 
amine reactive group, a balancer group, and a reporter group. The amine-reactive, (N-
hydroxysuccinimide ester) group reacts mainly with the unblocked (e.g. acetylated) primary 
amines present at the N-termini of proteins/peptides and the epsilon side chain of Lys residues 
to attach the tags to the respective biomolecules. The mass normalization group (carbonyl 
moiety) compensates for the mass difference among the different reporter ion (N-
methylpiperazine) groups such that different isotopic variants of the tag are isobaric. The overall 
mass of reporter and balance groups of the reagent are kept constant using differential isotopic 
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enrichment with 13C, 15N, and 18O atoms. In an iTRAQ 4-plex set, the reporter group ranges in 
nominal mass from m/z 114 - 117, whereas the balance group ranges in mass from 28 to 31 Da, 
so that the combined mass remains constant (145 Da) for each of the four reagents (Fig. 1.16 A).  
 
Figure 1.16: (A) Chemical structure of an iTRAQ 4-plex reagent. (B) Representative MS and MS/MS spectra of an 
iTRAQ labeled peptide (4-plex) which was subjected to HCD fragmentation. The full MS scan shows a single 
precursor ion peak isolated for HCD. The MS/MS spectrum depicts a series of product ions (b- and y- type) which 
are used for peptide identification, whereas the reporter ion signals in the low m/z region are used for relative 
quantification. 
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To increase the multiplexing capacity, iTRAQ 8-plex version was introduced with reporter ion 
masses at m/z 113 - 118, 119 and 121 (and balance groups ranging from 24 to 31 Da). Typically, 
iTRAQ labeling is performed on the peptide level after proteolytic digestion. Each peptide 
mixture is labeled with a different channel of iTRAQ reagents. The differentially labeled samples 
are then combined and subjected to LC-MS/MS analysis. Due to the isobaric nature of the tags, 
the differentially labeled peptides are indistinguishable during the full MS scan and are 
consequently jointly selected for MS/MS. Upon fragmentation, each tag releases its individual 
reporter ion and the signal intensities of these ions then reflect the peptide abundances 
between differently labeled samples. In parallel, the sequence of the peptide is determined 
from the product ions (b- and y-type ions) that are generated by the cleavage of peptide bond in 
the same MS/MS spectrum (Fig. 1.16 B). 
There are several advantages of iTRAQ compared to other strategies. Firstly, multiplexing, which 
is the ability to combine and analyze several samples (up to 8) within one experiment eliminates 
the need to compare multiple LC-MS/MS datasets and can reduce run-to-run variation. 
Secondly, as the chemical derivatization process is performed on the peptide level, iTRAQ allows 
labeling of virtually any samples, including mammalian tissues and body fluids such as blood 
serum/plasma samples, which is not feasible with metabolic labeling (e.g. SILAC). Thirdly, due to 
the isobaric nature of the tags, multiplexing does not increase sample complexity which is the 
case for SILAC and the signal intensity of the same peptide from all samples is summed up 
during the full MS scan. This increases the sensitivity of the analysis and allows identification 
and quantification of low-abundant proteins in complex samples 101. However, similar to other 
reporter ion based quantification strategies, iTRAQ is prone to the so-called "ratio compression" 
issue, which occurs due to the interference from interfering peptide ions that are within the 
isolation window (typically 2 - 3 m/z) 102. As all peptides release the same reporter ions such co-
isolation interfering peptides results in distortion of the reporter ion intensities of the peptide of 
interest. Furthermore, reporter ion interference by co-isolated contaminating peptides can 
incline the observed ratios towards unity as the expression of majority of the proteins remains 
unchanged in most experiments. This leads to an underestimation or compression of actual 
protein abundance differences in the analyzed samples and consequently affects overall 
quantification accuracy 103. To address this interference issue, several solutions have been 
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proposed. By employing a robust fractionation step prior to LC-MS analysis could solve the co-
eluting peptides problem by reducing the sample complexity 104 and narrowing the precursor 
ion isolation window during MS analysis might reduce the amount of undesired interference 105. 
Recently, Ting et al. proposed triple-stage mass spectrometry (MS3) approach to overcome the 
reporter ion interference problem more efficiently. In this method isolated peptide ion is 
initially subjected to ion trap-CID fragmentation. Subsequently, one of the most intense 
fragment ions is isolated for HCD fragmentation to generate the reporter ion intensities 106. 
1.4.2.2 Label-free protein quantification  
Label-free MS methods for relative protein quantification of different biological states or to 
estimate the absolute protein abundances in a given cell type are a promising alternative over 
labeling based strategies 107. This is mainly because (i) it requires less sample preparation steps, 
(ii) they can be applied to any biological material, (iii) the complexity of the sample is not 
increased since mixing of different proteomes is not required, and therefore (iv) no ratio 
compression can occur. MS-based label-free protein quantification can be performed in two 
ways i.e. using precursor ion areas/intensities or by spectral counting 108 (Fig. 1.17). 
 
Figure 1.17: Proteins extracted from either cell culture/tissues that belong to two different conditions (in the figure 
red and blue colors represent disease and healthy states, respectively) are enzymatically digested and analyzed 
directly by LC-MS. Label-free relative protein quantification can be done by using precursor ion intensities (top) or 
spectral counting (bottom). In the above hypothetical example, the same peptide in blue (or healthy) sample is 
more abundant relative to the red (or disease) sample. 
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Precursor ion intensity-based quantification relies on the principle that the area of a peak in the 
full MS scan is a measure of the abundance of the corresponding peptide in the sample i.e. a 
twofold increase in this signal should reflect a twofold increase of this peptide. Peptides are 
identified based on their MS/MS spectra and then the corresponding precursor peaks are 
identified in each LC-MS run. Depending on the used software, the areas under these peaks are 
calculated and the areas of different peptides that belong to same protein are summed. By 
comparing these summed peak areas across different samples, relative protein quantification is 
achieved. For instance, all the steps that are involved in this type of label-free quantification can 
be performed using dedicated software e.g. Progenesis (see Section 3.2.14.2.1). In contrast, the 
spectral counting approach relies on the MS/MS data acquired from the DDA experiments. 
Relative quantification is done by comparing the sum of PSM for a given protein across multiple 
samples 107. The rationale is that increasing amounts of protein/peptide will lead to higher 
numbers of PSMs. Furthermore, the spectral counting approach can also be extended for the 
rough estimation of protein abundances in a given sample. The frequently used methods for this 
purpose in bottom-up proteomics experiments are: exponentially modified protein abundance 
index (emPAI) 109, absolute protein expression index (APEX) 110 and normalized spectral 
abundance factor (NSAF) 111. Recently, McIlwain and co-workers performed a comparative 
analysis between different spectral counting methods which are currently used for estimating 
relative protein abundances in complex proteomes. Their study concluded that NSAF performs 
better in terms of linear response to protein abundance and gives more reproducible results 
when compared to other methods e.g. emPAI 112. In this work, the NSAF approach was used to 
estimate the protein abundances in human RCMH cell line and to perform relative protein 
quantification of human skeletal muscles (see Section 3.2.14.2.2). Despite being a 
straightforward approach, the major drawback of all label-free quantification methods is the 
massive increase in total analysis time as each sample is measured individually. Consequently, 
the probability of variation between the LC-MS runs of different samples might increase leading 
to decrease in precision and accuracy. Thus, label-free quantification approaches require 
extremely robust instrumentation that is capable of providing reproducible LC separation and 
subsequent MS detection 57a. However, in DDA-based label-free experiments, the overall 
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protein quantification is hampered due to its inherent drawbacks i.e. stochastic nature of 
precursor ion selection and bias towards high abundant peptides. 
1.4.2.3 Protein quantification with targeted MS 
Selection reaction monitoring (SRM) and the recently introduced parallel reaction monitoring 
(PRM) 113 are the commonly used MS-based technologies in the field of targeted quantitative 
proteomics 114. Owing to their non-scanning nature (i.e. no full MS is recorded), both sensitivity 
and linear response over a wide dynamic range are increased when compared with other MS 
data acquisition techniques such as DDA and DIA. This enables the detection of low-abundance 
proteins in highly complex mixtures, which is crucial for systematic quantitative studies 115. 
SRM is usually performed on a triple quadrupole instrument wherein the first and the third 
quadrupoles act as filters to specifically select predefined m/z values corresponding to the 
precursor ion (Q1) and a specific product ion of the peptide (Q3), respectively. The second 
quadrupole (Q3) serves as a collision cell for fragmentation (beam type CID). Only if the correct 
pair of precursor and product ion m/z values, referred to as a "transition" is present, a signal is 
detected. In SRM, several such transitions per peptide are monitored and their peak areas are 
integrated, similar to label-free quantification described above. The difference is, that here not 
the entire sample is quantified, but pre-defined, selected peptides, thus allowing a highly 
sensitive, specific and fast analysis with highest precision 100 (Fig. 1.18 A). Whereas, in the PRM 
approach, the last quadrupole (Q3) is replaced with a high resolution mass analyzer (e.g. the 
Orbitrap) to acquire a full MS/MS. Quantification in PRM is carried out by extracting several 
fragment ions of the targeted peptide post-acquisition on the software level as "pseudo-
transitions", which are integrated to generate corresponding peak areas 100, 113 (Fig. 1.18 B). 
However, PRM-based targeted analysis is emerging as a highly selective and sensitive approach 
for protein quantification since the full MS/MS spectra of the targeted peptide ions are acquired 
with high resolution e.g. 70,000 (FWHM at m/z 200) and high mass accuracy (< 1 ppm) when 
compared to SRM that offers both low resolution and mass accuracy data generated by the 
quadrupole (R = 2,000 and ~100 ppm, respectively). Additionally, as all the product ions of a 
targeted peptide are detected during PRM analysis, there is no essential requirement for the 
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product ion m/z values information (which is a prerequisite for SRM), which saves time in the 
assay method development 113, 116. 
 
Figure 1.18: (A) Schematic of SRM performed on a triple quadrupole mass spectrometer. In SRM, the first 
quadrupole (Q1) is used for isolation and the second (Q2) as a collision chamber for fragmentation and the third 
quadrupole for mass selective transfer of fragment ion peaks, to generate so-called precursor-fragment transitions. 
(B) Schematic of PRM performed on a Q Exactive mass spectrometer (figure adapted from Thermo Scientific). In 
PRM, a target precursor ion is isolated by the quadrupole analyzer with a narrow m/z window (up to ±0.2 m/z) and 
fragmented in the HCD cell. The resulting fragment ions are then co-detected in the Orbitrap mass analyzer to 
generate high resolution and high mass accuracy MS/MS data. Peak areas of fragment ions are extracted using 
narrow mass (≤ 10 ppm) windows and integrated across the chromatographic elution profile. During the data 
processing, subsets of fragment ions with highest intensities in the MS/MS spectrum are used for both peptide 
identification and quantification using dedicated software e.g. Skyline 117. 
In this work, PRM was used to establish an assay for quantifying UPR-related proteins (see 
Section 1.2). As some of the UPR-related proteins/factors are usually present in low abundance 
in a complex cell lysate, a PRM-based targeted assay is an ideal method for the precise 
identification and quantification of these proteins. The details of the assay method 
development are given in the sections 3.2.13 and 3.2.15.3. 
 
  
2 Aim 
The goal of this work was to study pathological implications caused due to altered protein 
folding mechanisms in the endoplasmic reticulum (ER). For this, quantitative proteomics was 
used to study Marinesco-Sjögren Syndrome (MSS; OMIM 248800) as a model. MSS is a rare, 
genetically inherited multi-systemic disorder and the patients mainly suffer from the eyes, the 
brain and skeletal muscle abnormalities. Genetic studies have revealed mutations in SIL1/Sil1 as 
the main cause of MSS in man and mouse, respectively. SIL1 is a nucleotide exchange factor 
(NEF) for the ER-resident chaperone BiP, which controls a plethora of essential processes and 
most importantly assists in (un)folding of proteins in the ER. Loss of functional SIL1 
compromises the folding capacity of BiP leading to the aggregation of misfolded proteins and 
eventually failure of cellular functions. Despite being ubiquitously expressed, loss of SIL1 affects 
only certain tissues/organs and several questions remained unsolved pertaining to the selective 
vulnerability of SIL1 loss. The existence of other rescue mechanisms besides the presumed 
overexpression of GRP170 - an alternate NEF for BiP, is speculated in the SIL1 non-vulnerable 
cells/tissues, albeit these processes have not been identified so far. The function of SIL1 as a key 
player in the protein folding process in the ER and consequently its impact on cellular 
homeostasis renders quantitative proteomics as promising tool to understand dysfunctional 
mechanisms and compensatory mechanisms associated with SIL1. 
Therefore, the main aims of this dissertation were (i) to identify possible alternate mechanisms 
that compensate for the loss of functional SIL1 and thus maintain homeostasis in SIL1-deficient 
unaffected tissues and (ii) to see the global impact of SIL1 loss on the proteome level in SIL1-
deficient affected tissues using MS-based proteomics. Moreover, to establish quantitative 
workflows to study genetic defects e.g. MSS on the level of primary cell cultures, tissue biopsy 
and in vitro models (e.g. HEK293). Additionally, the role of the unfolded protein response (UPR) 
pathway in maintaining cellular homeostasis due to the impaired SIL1-BiP protein folding 
machinery was briefly addressed. 
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3 Materials and methods 
 Materials 3.1
3.1.1 Chemicals 
Table 3.1: Used chemicals and reagents. 
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3.1.2 Instruments and disposable consumables 
Table 3.2: Used laboratory equipment and instruments. 
 
3.1.3 LC-columns, HPLCs and mass spectrometers 
Table 3.3: Used columns, HPLC systems and mass spectrometers. 
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3.1.4 Data analysis software 
Table 3.5: Used software for LC-MS data acquisition, control and analysis. 
 
 Methods 3.2
3.2.1 Cell and tissue samples for proteomics analyses 
All human cell culture i.e. primary dermal fibroblasts, Epstein Barr virus (EBV) - transformed 
lymphoblastoid cells (LCs), SIL1-depleted HEK293, RCMH and tissue i.e. human (index patient), 
mouse (cerebella and skeletal muscles) samples for various proteomics analyses were prepared 
and provided (as denatured cell lysates, dissected and frozen tissues) by Dr. Andreas Roos and 
his group members at the Institute of Neuropathology, RWTH Aachen University Hospital, 
Aachen, Germany (Dr. Roos present address: Institute of Genetic Medicine, Newcastle 
University, United Kingdom). Furthermore, all biochemical experiments including cell viability 
assays, immunohistochemistry (IHC), plasmid transfections, tandem affinity purification (TAP) 
assay, Western Blotting (WB) and transmission electron microscopy (TEM) were performed 
under the supervision of Dr. Roos in the Aachen University Hospital. All research activities were 
approved by the Ethical Committee of the University Hospital RWTH (ethics approval number: 
EK104/10), Aachen and they were conducted in accordance with the 1989 declaration of 
Helsinki. Moreover, all procedures involving mice were approved by the University Hospital 
Aachen Institutional Animal Care and Use Committee and conducted in compliance with the 
legal standards for the care and use of laboratory animals. Because the genetic diagnosis was 
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performed before the patients underwent a biopsy, skeletal muscle specimens (clinically 
affected due to SIL1 mutations) were not available for proteomics studies due to ethical 
reasons. Nevertheless, the MSS patients agreed to provide skin biopsies or peripheral blood for 
scientific purposes. Therefore, by making use of the skin biopsies and the blood withdrawals, 
fibroblast and immortalized lymphoblastoid cell lines (see below) were generated, respectively. 
3.2.1.1 Clinically unaffected cell types 
Five male MSS patients with genetically and biochemically proven SIL1 mutations were included 
in this work (i.e. MSS2, MSS24, MSS32, MSS33, MSS94) 41a along with respective healthy donors; 
matched for both age and sex. All patients presented with the major clinical hallmarks of SIL1-
related MSS. Skin biopsies of MSS2 patient and control were dissected under sterile conditions 
and isolated primary human dermal fibroblast cells were cultured in FibroGRO™ (Millipore) 
culture medium supplemented with 10% Penicillin-Streptomycin. Lymphoblastoid cells (LCs) of 
the remaining four MSS patients and the respective healthy controls were obtained by 
peripheral blood withdrawal and were subsequently immortalized using the EBV-producing 
marmoset B-cell line (B95-8) as a source of EBV for stimulation and transformation. Culturing of 
the immortalized LCs was maintained at 37°C in a 5% CO2 atmosphere. 
3.2.1.2 SIL1-depleted human embryonic kidney 293 cells 
Human embryonic kidney 293 (HEK293) cells were transfected with 20 µg of a mixture of human 
29mer SIL1 HuSH short hairpin -RNA-plasmids (OriGene) using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer´s protocol. 24 hours post-transfection, cells were split on three 
10 cm plates and selection for stable transfected cells was carried out using 7.5 µg/mL 
puromycin (Millipore) as a selection antibiotic. Stably transfected clones (cell colonies) were 
harvested, cultured and tested for remaining SIL1 levels using immunoblot technique. Two SIL1-
depleted cell clones (∆SIL1_1 and ∆SIL1_2) as well as one scrambled (Scr) transfected cell clone 
was selected for subsequent proteomics, biochemical and morphological studies. Culturing of 
the HEK293 cells was maintained at 37°C in a 5% CO2 atmosphere. 
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3.2.1.3 Human myoblastic RCMH cells 
After defrosting, RCMH cells 118 were cultured in Dulbecco's modiﬁed Eagle's medium F-12-Ham 
containing 0.1% sodium bicarbonate (Sigma-Aldrich, Taufkirchen, Germany) and 12.5% fetal calf 
serum (Biowest) at 37°C in a 5% CO2 atmosphere to a confluence of approximately 70% before 
subjecting to proteomics and morphological studies. 
3.2.1.4 Clinically affected tissues 
3.2.1.4.1 Mouse 
Sil1 (located on murine chromosome 18) mutants were obtained from the Jackson Laboratories 
(strain name: CXB5/By-Sil1wz/J; stock number 003777). Homozygous affected animals (woozy) 
as well as wildtype littermates were obtained by mating heterozygous males with heterozygous 
females. Only female mice were used and they were 26-weeks old at the time of sacrifice. Two 
tissues i.e. cerebellum and skeletal muscle that are phenotypically affected due to Sil1 
mutations were used for proteomics, biochemical and morphological analyses. 
3.2.1.4.2 Human 
A skeletal muscle biopsy (Musculus quadriceps femoris) derived from an index patient (female, 
Caucasian) suffering from a phenotype similar to MSS, but not related to SIL1 mutations was 
prepared for proteomics analysis at the Institute of Neuropathology, Aachen. For relative 
proteome comparison, the muscle lysates of two controls (matched for age, sex and muscle 
group) were also prepared at the same Institute. 
3.2.2 Cell lysis and benzonase treatment 
Human cells were lysed using 1% SDS buffer comprising 150 mM NaCl, 50 mM Tris-Cl, pH 7.8 
and complete Mini (protease inhibitor cocktail). This procedure was carried out on ice and 
under a laminar flow hood. The volume of the lysis buffer was based on the assumption that 
100 µL of buffer would be sufficient to solubilize e.g. one million cells. Typically, 200 - 300 µL of 
lysis buffer was used and cell homogenization was performed by pipetting the mixture up and 
down until the pellet was completely solubilized. In case of viscous cell lysates, benzonase (25 
Materials and methods  52 
 
U/µL) was added with 2 mM MgCl2 and the samples were incubated at 37°C for 30 min in order 
to degrade the nucleic acids (DNA and RNA) and reduce viscosity. Afterwards, the samples were 
clarified by centrifugation at 4°C and 18,000 rcf for 30 min. Finally, the clear supernatant was 
collected in a LoBind Eppendorf tube and stored at -80°C until further use. 
3.2.3 Tissue processing 
The brain section i.e. cerebellum and skeletal muscles derived from the same mouse i.e. either 
wild type or woozy (see Section 3.2.1.4.1) were processed/homogenized separately by 
mechanical grinding using mortar and pestle. In total, three biological replicates of each wild 
type and woozy were used in this work. Tissue dissection and grinding were performed on ice 
and under a laminar flow hood. After processing of each sample, all the equipment i.e. 
dissection platform, spatulas, mortar and pestle and ultrasonic probe were properly sterilized 
and dried completely before proceeding to the next sample. 
3.2.3.1 Brain section 
Approximately 1 mg of cerebellum obtained from six different mice was processed individually. 
The tissues were first snap frozen followed by mechanical grinding. Next, 600 µL of lysis buffer 
comprising 0.1% SDS, 1% sodium deoxychloate, 1% Triton X-100, 150 mM NaCl, 1mM 
Na2EDTA.2H2O, 50 mM Tris-Cl, pH 8.0 and complete Mini were added to the ground tissue and 
mixed to obtain a homogenous lysate. Next, the samples were treated with benzonase as 
described in section 3.2.2 and stored at -80°C until further use. 
3.2.3.2 Skeletal muscle 
The mammalian skeletal muscle fibers are extremely tough due to their inherent composition. 
Hence, a 2-step homogenization procedure was employed involving mechanical grinding and 
ultrasonication. First, ~1 mg of skeletal muscle was homogenized by grinding in a mortar using a 
pestle as described above. To the ground tissue, 600 µL of lysis buffer comprising 4% SDS, 10% 
2-mercaptoethanol, 10% glycerol, 125 mM Tris-Cl, pH 6.4 and complete Mini were added and 
the grinding process was continued. Lysates were transferred into a LoBind Eppendorf tube and 
subjected to ultrasonication for 30 seconds (amplitude: 30; pulse 1s/1s) in the second step. 
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Next, the tissue lysates were clarified by centrifugation at 10°C and 25,000 rcf for 10 min. The 
supernatant was collected in a LoBind Eppendorf tube. To remove the harsh buffer components 
and make the samples amenable to the downstream sample preparation procedures (on-filter 
proteolysis, see Section 3.2.6), organic solvent protein precipitation was performed. An aliquot 
of 200 µL of tissue lysate was diluted 10-fold with ice cold EtOH in 1:10 ratio, briefly vortexed 
and stored at -40°C for 60 min followed by centrifugation in a pre-cooled (4°C) centrifuge at 
18,000 rcf for 30 min. Next, the supernatant was discarded and the pellet was washed with 100 
µL of ice cold acetone, briefly vortexed and centrifuged as mentioned above for 15 min. Finally, 
the supernatant was discarded and the protein pellet was dried under a laminar flow hood. 
Protein pellets were resolubilized with 6 M GuHCl, 50 mM NH4HCO3, pH 7.8 and stored at -80°C 
until further use. 
3.2.4 Determination of protein concentration 
Estimation of protein concentration of cell and tissue lysates was performed by a calorimetric 
bicinchoninic acid assay according to the manufacturer’s instructions (Pierce BCA Protein Assay 
Kit). Briefly, three serial dilutions per sample were prepared with ultra-pure water and each 
dilution was aliquoted (25 µL) in triplicates into a 96-well plate. To each well, 200 µL of BCA 
solution (reagent A:B in 50:1 ratio) were added and the plate was incubated at 60°C for 30 min. 
Bovine serum albumin was used to determine the standard curve (5 - 250 µg/mL concentration 
range, five-point calibration, triplicate standards) and the absorbance was measured at a 
wavelength of 570 nm using a microtiterplate reader. 
3.2.5 Carbamidomethylation 
Cysteines were reduced with 10 mM DTT and incubation at 56°C for 30 min. The free thiol (-SH) 
groups were subsequently alkylated (carbamidomethylation) by the addition of 30 mM IAA and 
incubation at room temperature (RT) for 30 min in the dark. 
3.2.6 Spin filter assisted sample preparation 
Sample clean-up and proteolysis after carbamidomethylation were performed using molecular 
weight cut off (MWCO) membrane spin filters. This approach was first described by Manza et al. 
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119, which was later modified and introduced as filter aided sample preparation (FASP) by 
Wiśniewski et al. 120. This protocol was demonstrated to be effective in removing most of the 
lysis buffer components especially SDS, which is the major interfering contaminant in LC-MS 
analysis due to its strong ionization. The FASP protocol involves a centrifugal device consisting of 
a membrane filtration unit with nominal molecular weight cut-off (MWCO) of 10, 30 or 50 kDa. 
These MWCO sizes are based on an approximation for non-denatured proteins (mostly 
globular), but these spin filters are often used after (i) protein denaturation with SDS and urea 
as well as (ii) reduction and alkylation. Therefore, 30 kDa MWCO membrane spin filters were 
used in this work, which are also most commonly used by other groups in proteomics field 121. 
Briefly, proteins in the sample are trapped in a high-MWCO filter unit whereas salts, low-
molecular weight compounds and contaminants from samples flow through the spin filter and 
can be discarded. The use of urea buffer at high concentration (8.0 M) enables the removal of 
nearly all the surfactant (e.g. SDS) from the sample. Subsequent washes with an alkaline buffer 
e.g. 50 mM NH4HCO3, pH 7.8 eliminates urea from the spin filters. Finally, to the concentrated 
proteins, trypsin is added directly on to the spin filter for proteolytic digestion. After on-filter 
trypsin digestion, the tryptic peptides are eluted with the 50 mM NH4HCO3, pH 7.8 followed by 
a washing step with 0.5 M NaCl solution. The filter retains any high-molecular weight material 
such as partially digested or completely undigested proteins and debris. A description of FASP 
procedure performed in this work, albeit with slight changes using a 30 kDa MWCO filter is 
given below. 
The sample lysate (after carbamidomethylation, see Section 3.2.5) was diluted with freshly 
prepared 8.0 M urea/100 mM Tris-Cl, pH 8.5 buffer 122 such that the concentration of urea was 
around 7.0 M. The lysate was placed on the spin filter and the device was centrifuged at 13,500 
rcf at RT for 20 min. All the following centrifugation steps were performed at 13,500 rcf at RT for 
15 min. To eliminate residual SDS, three washing steps were carried out with 100 µL of 8 M 
urea/100 mM Tris-HCl, pH 8.5. For buffer exchange, the spin filter was washed thrice with 100 
µL of 50 mM NH4HCO3, pH 7.8.  Here, the FASP workflow was slightly modified for instance 50 
mM NH4HCO3, pH 7.8 was replaced with 50 mM triethylammonium bicarbonate (TEAB), pH 8.5 
buffer as it does not contain primary amines as opposed to the former buffer to avoid desalting 
step prior to iTRAQ labeling. At first, for MSS fibroblasts and LCs cell lysates and their respective 
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controls, 50 mM NH4HCO3, pH 7.8 buffer was used, but it was changed later (as part of 
workflow optimization) to 50 mM TEAB, pH 8.5 buffer for processing mice tissue lysates. After 
buffer exchange, 100 µL of proteolysis buffer comprising: trypsin (1:40 w/w of enzyme to 
substrate ratio), NH4HCO3, pH 7.8 or TEAB pH 8.5, a chaotrope (GuHCl) and calcium chloride (as 
a source of Ca2+) were added to the concentrated proteins and the spin filter was incubated at 
37°C overnight. The latter two components (i.e. GuHCl and Ca2+) were added to keep the 
proteins in a solubilized state and to stabilize trypsin 123, respectively. After incubation, the 
generated peptides were recovered by centrifugation followed by two consequent washing 
steps with 50 µL of 50 mM NH4HCO3, pH 7.8 (or 50 mM TEAB, pH 8.5). However, in the final 
step during peptides extraction, ultra-pure water was used instead of 0.5 M NaCl as mentioned 
in the original FASP protocol. The reason was to circumvent the desalting step in case 50 mM 
TEAB buffer, pH 8.5 was used. Test experiments that were conducted to compare the modified 
FASP protocol with the original one showed nearly identical results in terms of peptide recovery 
and subsequent protein identifications (Fig. 3.1 B). 
 
Figure 3.1: Human fibroblast cell lysates were processed with the FASP protocol and for peptides recovery (after overnight 
digestion with trypsin) in a second step, the spin filters were washed either with 0.5 M NaCl as in the original protocol or with 
ultra-pure water. LC-MS (see Section 3.2.13) and data analyses (see Section 3.2.14) were performed in the same manner for 
both conditions. (A) UV traces of the two conditions look nearly the same. (B) Database search results obtained from the raw 
MS data analysis of the two conditions show nearly same number of identifications in terms of proteins and peptides. However, 
the numbers of peptide spectrum matches (PSMs) were slightly higher (~13%) for ultra-pure water condition. 
In case of mice skeletal muscle samples, the proteins that were solubilized with 6 M GuHCl 
buffer (see Section 3.2.3.2) were diluted 2-fold with 50 mM TEAB, pH 8.5 and placed on 30 kDa 
MWCO filters. Next, the washing steps and proteolysis were carried as described above. Thus 
generated tryptic peptides were acidified to a final pH < 3.0 with 10% TFA and stored at -80°C 
until further use. 
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3.2.7 In solution digestion of muscle lysates - human 
The amount of protein in the skeletal muscle lysate obtained from an index patient and two 
controls was roughly estimated to be 5 µg per sample. Sample processing with FASP was not 
feasible since the components of the lysis buffer were not compatible with the MWCO 
membrane filters. For this reason, ethanol protein precipitation (see Section 3.2.3.2) followed 
by in solution digestion were performed. Next, protein pellets were resolubilized with 1 M 
GuHCl, 50 mM NH4HCO3, pH 7.8 and the samples were subjected to carbamidomethylation (see 
Section 3.2.5). Samples were then diluted with 50 mM NH4HCO3, pH 7.8 to a final GuHCl 
concentration of 0.2 M. Trypsin was added in 1:40 (w/w) of enzyme to substrate ratio and 
samples were incubated at 37°C overnight. After incubation, tryptic peptides were acidified to a 
final pH < 3.0 with 10% TFA and stored at -80°C until further use. 
3.2.8 Evaluation of the digestion efficiency 
Tryptic peptides were checked for digestion efficiency using a monolithic HPLC system as 
previously described 124. Monolithic columns are more robust and sensitive than other 
techniques that are used for digestion control e.g. SDS-PAGE followed by coomassie or silver 
staining. Approximately, 1 µg of peptides were loaded on to a 200 µm x 5 mm pre-column with 
0.1% TFA followed by separation on a 200 µm x 5 cm main column (both PepSwift, Thermo 
Scientific) with a 22 min LC gradient ranging from 10 - 50% of 84% ACN in 0.1% TFA at a flow 
rate of 2.2 µL/min using a UltiMate 3000 RSLC HPLC system. 
3.2.9 Chemical labeling using iTRAQ reagents 
In total four different iTRAQ-based experiments were performed in this work, which include one 
4-plex and three 8-plex versions of the reagents. Whereas the 4-plex iTRAQ was used in the 
beginning, an iTRAQ 8-plex labeling procedure was established in the course of this work. The 
sample details, labeling scheme and the peptide amounts used for each label/condition are 
summarized below (Tables 3.6 - 3.8). Before labeling with iTRAQ tags, each sample (~1 µg) was 
analyzed on a nano-LC-MS system (see Section 3.2.13). The sample amounts were corrected 
based on the alignment of total ion chromatograms (TICs) to compensate for systematic errors 
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derived e.g. from the protein concentration estimation, such that each sample had identical 
starting material before labeling. In case of mice tissues (skeletal muscle and brain), where only 
three biological replicates were available, two pooled samples were generated by mixing equal 
amounts of peptides of respective biological triplicates (wild type or woozy). 
Table 3.6: Labeling scheme of the human fibroblast cells with iTRAQ 4-plex. 
Passage Gender Sample name iTRAQ reagent Peptide amount per label  
9 Male 
Healthy.1 114 
100 µg 
Healthy.2 115 
MSS2.1 116 
MSS2.2 117 
Table 3.7: Labeling scheme of the human EBV-lymphoblastoid cells with iTRAQ 8-plex. 
Passage Gender Sample name iTRAQ reagent Peptide amount per label 
11 Male 
Healthy.1 113 
40 µg 
Healthy.2 114 
Healthy.3 115 
Healthy.4 116 
MSS24 117 
MSS32 118 
MSS33 119 
MSS94 121 
Table 3.8: Labeling scheme of mice cerebella and skeletal muscles with iTRAQ 8-plex. 
Age  Gender Sample name iTRAQ reagent Peptide amount per label  
26 weeks Female 
Wildtype.1 113 
30 µg 
Wildtype.2 114 
Wildtype.3 115 
Woozy.1 116 
Woozy.2 117 
Woozy.3 118 
Wildtype mix 119 
Woozy mix 121 
*numbers in the sample name column indicate biological replicate. 
The iTRAQ labeling procedure with 4- or 8-plex reagents was carried out according to the 
manufacturer’s instructions (AB SCIEX). The dried peptides were resolubilized with 0.5 M TEAB, 
pH 8.5, whereas the iTRAQ 4-plex reagents were diluted with ethanol and the 8-plex reagents 
with isopropanol (both LC-MS grade, 100%). In order to prevent rapid hydrolysis of the chemical 
tags, the organic concentration was kept ≥ 60% and 70% for 4 and 8-plex versions, respectively. 
Next, the individual label mixtures were added to the corresponding peptide sample solutions 
and were incubated at 25°C for 1 h (4-plex) or 2 h (8-plex). After incubation, the differentially 
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labeled samples were combined (multiplexing) and the reaction was quenched by adding 100 µL 
of ultra-pure water. The volume of the pooled peptide solution was reduced in a SpeedVac to 
~20 µL, subsequently acidified with 10% TFA to a final pH < 3.0 and stored at -80°C until further 
use. 
3.2.10 Desalting of proteolytic digests and iTRAQ labeled samples 
Depending on the amount of peptides, the acidified (pH < 3.0) tryptic digests were desalted 
either with C18 Pipette Tips (10 µL and 100 µL; OMIX) or C18 solid phase extraction cartridges 
(SPEC, 4 mg sorbent, Agilent) using a vacuum manifold system. All volumes were appropriately 
used according to the column specifications i.e. size/capacity of the used tip/SPEC. First, the C18 
material was activated with 100% ACN followed by equilibration with 0.1% TFA. Next, the 
peptide solutions were loaded on to the pre-equilibrated columns and the flow through was 
reloaded twice. The columns were then washed with 0.1% TFA and finally, the bound peptides 
were eluted with 60% ACN in 0.1% TFA. The eluates were completely dried in a SpeedVac and 
stored at -80°C until further use. 
3.2.11 Off-line peptide fractionation 
In this work, OFFGEL IEF and high-pH RP fractionation techniques were employed to reduce the 
sample complexity prior to LC-MS analysis. Both fractionation methods are powerful in terms of 
resolution, and a systematic comparative analysis between these two methods was performed 
together with BSc. Jennifer Baumann (Bachelor thesis under my supervision). This showed 
better orthogonality for the high-pH RP approach. Furthermore, the high-pH RP fractions could 
be directly subjected to LC-MS analysis after solvent evaporation thus avoiding the laborious 
desalting procedure required for OFFGEL fractions, which might also lead to sample losses. 
3.2.11.1 OFFGEL isoelectric focusing 
The dried iTRAQ 4-plex labeled and desalted peptides (human fibroblasts) were separated using 
an OFFGEL Fractionator with a 24-well set-up. The peptide samples were resolubilized to a final 
volume of 3.6 mL using the OFFGEL peptide stock solution (12% glycerol plus 1.2% carrier 
ampholytes). Prior focusing, the IPG gel strip with a linear pH range 3 - 10 was treated with the 
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peptide IPG strip rehydration solution (OFFGEL peptide stock plus 0.2% water) for 15 min. Next, 
150 μL of sample solution was loaded in each well. The IEF of the peptides was performed at 50 
μA starting current and a maximum power supply of 200 mW. The voltage was increased from 
300 to 8,000 V until 60 kVh were reached. After focusing, the separated peptide fractions were 
immediately transferred into LoBind Eppendorf tubes. Each individual fraction was acidified 
with 10% TFA to a final pH < 3.0 and desalted as described in section 3.2.10. The eluates were 
completely dried in a SpeedVac and resolubilized in 0.1% TFA prior to nano-LC-MS analysis. 
3.2.11.2 High-pH RP fractionation  
In general, the RP fractionations can be conducted at pH 10.0 125 albeit, high pH conditions can 
affect column and capillary stability due to the hydrolysis of siloxane groups 126. Therefore, in 
this work all RP fractionations were performed at pH 6.0 using an UltiMate 3000 HPLC system. 
The desalted and dried peptides were resolubilized in buffer A (10 mM ammonium acetate, 0.4 
mM FA, pH 6.0) and fractionated on a C18 RP column (Table 3.9) with a binary buffer system; 
buffer A: 10 mM ammonium acetate, 0.4 mM FA, pH 6.0 and buffer B:  84% ACN in 10 mM 
ammonium acetate, 0.4 mM FA, pH 6.0. Peptides were loaded onto the column with buffer A at 
a flow rate of 12.5 µL/min and separation was carried out using the following gradient: 3% B for 
10 min, 3-50% B in 65 min, 50-60% B in 5 min, 60-95% B in 5 min, 95% B hold for 5 min, 95%-3% 
B in 5 min and finally column re-equilibration with 3% B for 20 min. 
Table 3.9: Details of the offline RP fractionation carried out at pH 6.0 using an UltiMate 3000 HPLC. 
Sample details RP Column details Fraction collection details 
iTRAQ 8-plex labeled human EBV-LCs; 
50 µg multiplexed sample ZORBAX 300SB C18, 0.5 
mm ID, 15 cm length, 5 µm 
particle size, 300 Å pore 
size 
24 fractions were collected at 30 sec 
intervals from min 15 to 85 in 
concatenation mode iTRAQ 8-plex labeled mice cerebella;                
50 µg multiplexed sample 
iTRAQ 8-plex labeled mouse skeletal muscles;                              
25 µg multiplexed sample BioBasic C18, 0.5 mm ID, 
15 cm length, 5 µm particle 
size, 300 Å pore size 
24 fractions were collected at 60 sec 
intervals from min 15 to 75 in 
concatenation mode 
Unlabeled human RCMH (myoblastic cell line); 
25 µg tryptic digest 
16 fractions were collected at 60 sec 
intervals from min 15 to 75 in 
concatenation mode 
 
Each fraction was collected at 30s (or 60 s) time interval and in total 24 (or 16) fractions were 
collected in a LoBind Eppendorf tubes from 15 min to 75 min (or 85 min) retention time . After 
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collecting the first 24 (or 16) fractions, the collection process was repeated from the first 
collection tube i.e. in a concatenation mode to improve the orthogonality of the analysis. After 
fractionation, all peptide fractions were completely dried in a SpeedVac and resolubilized in 
0.1% TFA prior to nano-LC-MS analysis. 
3.2.12 In vitro carbamylation 
To optimize sample preparation methods for LC-MS analysis, the occurrence of protein 
carbamylation which can be artificially induced through urea was evaluated in this work. Due to 
its strong chaotropic nature, urea is the most commonly used denaturing agent in the 
proteomics workflows and is an essential part of the here used FASP protocol for sample 
preparation and digestion. However, a possible drawback of using urea is the potentially 
occurring in vitro carbamylation of primary amines (occurring due to decomposition of urea to 
isocyanate, over time and preferably upon heating), which results in an undesired artefact, 
especially hampering quantitative studies that are based on labeling of primary amines. 
3.2.12.1 Peptide stock mixture and in vitro carbamylation conditions 
Protein stock solutions of β-casein, β-lactoglobulin, hemoglobin, serum albumin (all bovine) and 
myoglobin (horse) were prepared in ultra-pure water at a concentration of 1 mg/mL. 100 µg of 
each protein solution was diluted 10-fold with 50 mM NH4HCO3, pH 7.8. All five proteins were 
processed independently. Carbamidomethylation was performed as described in section 3.2.5. 
Trypsin was added in 1:50 (w/w) of enzyme to substrate ratio and proteins were digested at 
37°C overnight. The generated tryptic peptides of each protein were acidified with 10% TFA to a 
final pH < 3.0 followed by SPE (see Section 3.2.10). To prepare the stock peptide mixture, the 
eluates corresponding to 800 pmol of each digested protein were pooled. This combined 
peptide mixture was then divided into 50 pmol aliquots, which were completely dried in a 
SpeedVac. Next, each dried peptide mixture aliquot was resolubilized in 50 µL [final 
concentration: 1 pmol/µL] of freshly prepared urea buffers (see below). The peptide mixture 
was then used to evaluate the extent of urea-induced carbamylation under below mentioned 
conditions typically used in bottom-up proteomics workflows and each experimental setup was 
performed in triplicate. Moreover, to find if degradation of urea into isocyanate occurs in solid 
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form over long term storage, each incubation condition was performed once with ~4 month old 
and once with ~8 year old urea. The conditions were: (1) control (in 0.1% TFA), (2) harsh 
treatment (8.0 M urea, 100 mM Tris-HCl, pH 8.5; 61°C, 15 h), (3) reduction of disulfide bonds 
(8.0 M urea, 100 mM Tris-HCl, pH 8.5; 56°C, 30 min) 127, different overnight digestion conditions 
with trypsin at 37°C for 15 h, i.e. (4) 2.0 M urea, 50 mM NH4HCO3, pH 7.8 128, (5) 2.0 M urea, 
100 mM Tris-HCl, pH 8.5 129, (6) 0.1 M urea, 50 mM NH4HCO3, pH 7.8, (7) overnight digestion in 
presence of GuHCl instead of urea (0.2 M GuHCl, 50 mM NH4HCO3, pH 7.8; 37°C, 15 h), (8) 
overnight digestion with Lys-C, a serine protease that cleaves at the C-terminus of Lys residues 
(8.0 M urea, 100 mM Tris-HCl, pH 8.5; 20°C, 18 h) 120. 
3.2.12.2 Two-step digest of fibroblast cells 
Next, the extent of urea-induced in vitro carbamylation occurring during preparation of complex 
samples e.g. as a total cell lysate was evaluated. Approximately, 250 µg of fibroblast cell pellets 
were lysed with 100 µL of RapiGest SF (surfactant) solution i.e. lyophilized RapiGest powder was 
reconstituted in 50 mM NH4HCO3, pH 7.8 to get a final concentration of 0.1% w/v. Benzonase 
and protein concentration determination steps were performed as described in sections 3.2.2 
and 3.2.4, respectively. 20 µg protein aliquots for each urea-based and urea-free (used as a 
positive control) processing were taken. In case of urea-based, samples were diluted 10-fold 
with 8.0 M urea/100 mM Tris-HCl, pH 8.5, whereas urea-free samples were diluted 10-fold with 
RapiGest solution. Carbamidomethylation was performed as previously described (see Section 
3.2.5), but with 5 mM DTT and 15 mM IAA, respectively. In the first step, Lys-C was added in 
1:100 (w/w) of enzyme to substrate ratio and the samples were incubated at 20°C for 18 h. For 
the second step, the urea concentration was lowered from 8.0 M to 2.0 M with 100 mM Tris-
HCl, pH 8.5 in both sample sets. Proteolysis was continued with trypsin (1:100 w/w) at 20°C for 
4 h. Next, the digests were acidified with 10% TFA to a final concentration of 0.4% and 
incubated at 37°C for 45 min for the hydrolysis of RapiGest. After incubation, the samples were 
centrifuged at 13,000 rcf for 10 min to pellet the hydrolytic byproducts of the surfactant and the 
clear supernatant was collected for nano-LC-MS analysis. 
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3.2.13 Nano-LC-ESI-MS analysis 
All peptide separations were carried out on C18 RP columns with a binary gradient (buffer A: 
0.1% FA; buffer B: 84% ACN in 0.1% FA, pH 2.7) using nano-flow U3000 HPLC or U3000 RSLC 
HPLC systems (Thermo Scientific). The C18 RP columns used were either commercial or self-
packed (in house). The dimensions of the commercial C18 Acclaim PepMap (Thermo Scientific) 
column were: trapping column 100 μm inner diameter x 2 cm length, 5 μm particle size, 100 Å 
pore size, and main column 75 µm inner diameter x 15 cm or 50 cm length, 2 μm particle size, 
100 Å pore size. The self-packed columns were filled with Kinetex C18 material (Phenomenex) 
having 2.6 µm particle size, 100 Å pore size and their dimensions were: trapping column 100 µm 
x 2 cm and main column 75 µm x 30 cm. All peptide solutions were prepared in 15 µL of loading 
buffer i.e. 0.1% TFA prior to LC-MS analysis. Peptides were first preconcentrated on the trapping 
column using 0.1% TFA followed by separation on the main column using the above mentioned 
binary gradient ranging from 3-42% B for 50 min, 120 min, 127 min, 200 min at a flowrate of 230 
nL/min, 250 nL/min. 
The following mass spectrometers were employed for performing MS and MS/MS analysis: LTQ 
Orbitrap XL, LTQ Orbitrap Velos, Orbitrap Elite and Q Exactive (all from Thermo Scientific). ESI 
was used as an interface between the HPLC and MS. All MS were operated in a DDA mode. The 
key DDA parameter settings, such as the number of MS/MS scan events (Top N), dynamic 
exclusion duration, automatic gain control (AGC) target values i.e. the number of charges to 
inject and analyze and maximum ion injection times (IT) i.e. the maximum time that ions are 
allowed to accumulate in the linear ion trap or the C-trap, before being transferred to the 
Orbitrap were selected according to the complexity of the sample and performance 
characteristics of the respective MS. The type of fragmentation for MS/MS was chosen 
depending on the purpose of the analysis e.g. HCD for iTRAQ labeled samples. Furthermore, 
internal calibration of the Orbitrap was done by using the polysiloxane ion at m/z 371.101236 as 
lock mass 130 on all MS instruments. During MS analysis of the iTRAQ-labeled samples, a 10% 
(v/v) NH4OH solution was placed in front of the ESI source for charge state reduction since 
isobaric tags increase the peptide charge states during ESI-MS consequently decreasing protein 
identification rates 131. As different LC-MS combinations have been used during this work, 
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instead of listing all the parameters for each sample set, some examples will be given for the 
respective sample type. An overview of the LC-MS instruments and the parameters used for 
data acquisition for individual experiments is given in the Appendices 10.1 and 10.2. The HPLC 
and MS instruments were controlled by Chromeleon and Xcalibur software (both Thermo 
Scientific), respectively. 
MSS fibroblasts - iTRAQ 4-plex 
Each OFFGEL fraction (total 24 samples) was analyzed using an Ultimate 3000 HPLC system 
coupled to an LTQ-Orbitrap Velos. Peptide solutions were preconcentrated on a trapping 
column for 20 min using 0.1% TFA at a flow rate of 5 µL/min followed by separation on a main 
column (both self-packed) with a 200 min LC gradient ranging from 3-45% B at a flow rate of 230 
nL/min. Full MS scans were acquired in the Orbitrap from m/z 300 to 2,000 at a resolution of 
60,000 (at m/z 400) after accumulation of 1 x 106 ions (AGC target value) with a maximum IT of 
50 ms. MS/MS events were triggered from the full survey scan and based on the minimum 
intensity threshold of 5,000. Dynamic exclusion duration for 12 s was applied (at a repeat count 
of 1, exclusion list size of 500) with a 5 ppm tolerance around the selected precursor and its 
isotopes. Monoisotopic precursor selection was turned on and only charge states from +2 to +4 
were selected for fragmentation. The five most intense precursor ions were subjected to 
MS/MS in a HCD collision cell with an AGC value of 5 x 103 ions and a maximum IT of 100 ms 
with an isolation window of ±1.5 m/z. Precursor ion activation was done with an activation time 
of 0.1 ms and a normalized collision energy (NCE) of 45% was used. Slightly higher collision 
energy is required for iTRAQ-labeled peptides owing to the presence of isobaric tags to increase 
the fragmentation efficiency. HCD is preferred over CID fragmentation (in the LTQ) as the 
former method has no low-mass cutoff and the iTRAQ reporter ions (typically observed from 
m/z 113) can be extracted and subsequently detected. The MS/MS scans were acquired in the 
Orbitrap at a resolution of 7,500 (at m/z 400) with a starting mass of 105 m/z. 
Mice skeletal muscles - iTRAQ 8-plex 
Each pH 6.0 fraction (total 24 samples) was analyzed using an Ultimate 3000 RSLC HPLC system 
coupled to a Q Exactive (see Fig. 1.13). Peptides were preconcentrated on a trapping column for 
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10 min using 0.1% TFA at a flow rate of 20 µL/min followed by separation on a 50 cm main 
column (both Acclaim PepMap) with a 127 min LC gradient ranging from 3-42% B at a flow rate 
of 250 nL/min. The full MS scans were acquired from m/z 200 to 2,000 at a resolution of 70,000 
(at m/z 200) with an AGC target value of 1 × 106 ions and maximum IT of 120 ms. Isolation of 
precursors was performed by the quadrupole with a window of 2.0 m/z. The fifteen most 
intense ions were fragmented in the HCD cell with an AGC target value of 2 × 105 ions and 
maximum IT of 120 ms with a NCE of 30%. MS/MS scans were acquired at a resolution of 17,500 
with a starting mass of 105 m/z taking into account a dynamic exclusion of 20 s. Precursor ions 
with charge states of +1, > +5 or unassigned were excluded from MS/MS analysis. The 
"underfill" ratio, which specifies the minimum percentage of the target value likely to be 
reached at maximum fill time, was defined as 10%, which corresponds to a minimum precursor 
intensity of 1.7 x 105 to trigger a MS/MS scan. 
SIL1-depleted HEK293 cells - Label-free analysis 
In total two sample sets, each comprising one control (Scr) and two SIL1-depleted cell lines 
(∆SIL1_1 and ∆SIL1_2) were processed and each condition was measured in triplicate, resulting 
in a total of 18 LC-MS runs. Each condition (1 µg each) was analyzed using an Ultimate 3000 
RSLC coupled to an Orbitrap Elite (see Fig. 1.12). Peptides were separated as described above 
using a 187 min LC gradient ranging from 3-42% B at a flow rate of 250 nL/min. Full MS survey 
scans were acquired in the Orbitrap from m/z 300 to 1,500 at a resolution of 60,000 with an 
AGC target value of 1 x 106 ions and maximum IT of 100 ms. MS/MS events were triggered from 
the full scan and with a minimum intensity threshold of 2,000. A dynamic exclusion of 30 s was 
used (at a repeat count of 1, exclusion list size of 500) with 10 ppm tolerance around the 
selected precursor and its isotopes. Monoisotopic precursor selection was turned on and only 
charge states from +2 to +4 were selected for fragmentation. Fragmentation of the 15 most 
intense signals were subjected to ion trap CID with an AGC value of 1 x 104 ions and a maximum 
IT of 100 ms at an isolation window of ±2.0 m/z. CID spectra were generated with a NCE of 35% 
and an activation time of 10 ms. 
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SIL1-depleted HEK293 cells - Targeted-MS analysis 
For targeted MS analysis, 27 proteins that are known to be involved in the ER stress and the UPR 
pathway 22b, 132 were selected and relatively quantified between control and SIL1-depleted 
HEK293 cells using an in house developed PRM-based assay on Q Exactive instrument (see 
Section 1.4.2.3). The assay method development was done using Skyline software 117 as follows. 
At first, the peptides were selected from in silico digested FASTA sequences of the respective 
proteins using the human UniProt database (see Table 3.11) as a background proteome. Next, 
these peptides were filtered according to the following criteria for ensuring reliable protein 
quantitation: (i) uniqueness, (ii) fully tryptic with no missed cleavage sites, (iii) a length of 8-25 
amino acid residues and (iv) no Met residues. After filtering, a total of 76 precursors with charge 
states +2 or +3 were exported as inclusion list from Skyline for an unscheduled (i.e. no retention 
time boundaries for the precursor m/z were specified) targeted PRM analysis. Simultaneously, a 
Q Exactive spectral library was generated using the identified peptide MS/MS data of all these 
proteins obtained from conducted label-free DDA analyses to manually validate the peak 
assignments of the acquired PRM data. 
Each condition was analyzed in triplicate (9 samples, 1 µg each) and peptides were separated 
using an Ultimate 3000 RSLC system as described above with a 127 min LC gradient ranging 
from 3-42% B at a flow rate of 250 nL/min. The Q Exactive was operated in a PRM mode and 
precursor isolation was performed by the quadrupole in the front end with an isolation width of 
2.0 m/z. Fragmentation was performed in the HCD cell with a NCE of 27% and up to 18 PRM 
scans were acquired at a resolution of 70,000 with an AGC target value of 1 x 106 ions and a 
maximum injection time of 150 ms as triggered by the scheduled inclusion list. Thus generated 
raw MS/MS data were imported into Skyline for visualization, manual validation and assignment 
of retention time boundaries (predicted by Skyline). Next, the analysis of all 9 samples (1 µg 
each) was repeated with same LC-MS setup as described above, but with defined retention time 
windows information for each individual precursor m/z (in total 76) was added in the inclusion 
list. To avoid the loss of precursor peptides (most likely due to unpredicted retention time shifts 
during LC separation), the retention time boundaries were increased by ±3.5 min around the 
predicted value from the Skyline (i.e. 2 min). 
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3.2.14 Database searches 
Database searches and data analysis of iTRAQ samples were performed using Proteome 
Discoverer or PD (Thermo Scientific). Whereas, Progenesis from Nonlinear Dynamics (Newcastle 
upon Tyne, U.K.), searchGUI 133 and PeptideShaker software 134 were used to process label-free 
data. To maximize the number of PSMs, a multiple-search engine strategy was applied using the 
same set of search parameters. In PD, the raw MS data can be directly imported and all steps in 
the protein identification/quantification pipeline can be performed in an automated fashion 
based on a user-defined workflow. PD can generate peak lists from the raw data files, perform 
sequence database searches with single or multiple algorithms, combines the output in case a 
multiple-engine search strategy is applied, validates protein identifications using a FDR on the 
PSM level (typically 1% using Peptide Validator or Percolator settings) and finally, combines this 
information with quantitative information per peptide and protein (e.g. iTRAQ). SearchGUI, 
however, only supports mascot generic format (mgf) files as the input format for the MS/MS 
searches and ProteoWizard 135 was used to convert raw data to mgf. Similar to PD, searchGUI 
also facilitates multiple-search engine strategy, albeit requires a platform to combine, visualize 
and analyze the identification results. Here, PeptideShaker software, which is a search engine 
independent platform, was used for the interpretation of search results from multiple engines 
and also for validating the data using a FDR (1%) on the PSM, peptide and protein level. 
In both PD and searchGUI, the following parameters were selected for the database searches of 
all experiments. Trypsin was selected as protease allowing a maximum of two missed cleavages 
and the searches were performed using Mascot 90, Sequest 89, X! Tandem 136, MS-GF+ 137 
algorithms in a target/decoy mode against either a human or a mouse UniProt database (both 
downloaded on 11th of December 2013, containing 20,273 and 16,649 target entries, 
respectively. see Table 3.10). Whereas, the database searches of the peptide mixtures from the 
carbamylation experiment were performed against a merged database containing the amino 
acid sequences of the five model proteins taken from UniProt, in a yeast background taken from 
Saccharomyces genome database summing up to a total 6,723 target sequences to facilitate 
FDR calculation. Carbamidomethylation of Cys and oxidation of Met were set as fixed and 
variable modifications, respectively. Precursor ion mass tolerance was set to 10 ppm (MS scans 
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acquired in the Orbitrap), whereas product ion tolerances were set to 0.5 Da and 0.02 Da for 
MS/MS data acquired in the linear ion trap and in the Orbitrap, respectively. In case of iTRAQ 
experiments, iTRAQ-related modifications i.e. 4 and 8-plex versions were set on N-terminus and 
Lys as fixed modifications and the vendor (AB SCIEX) provided isotope purity correction factors 
were implied in the reporter ions quantifier node of PD software for the iTRAQ data analysis 
(Table 3.11). 
Table 3.10: Details of the protein sequence databases. The decoys were generated by reversing the forward target sequences. 
 
Table 3.11: Used algorithms and software for database searches. Cys carbamidomethylation and Met oxidation were used as 
fixed and variable modifications, respectively for all the datasets.  
 
3.2.15 Data analysis and statistical evaluation 
Data analyses including statistical evaluation were carried out as described below using 
Microsoft Excel 2010. 
3.2.15.1 iTRAQ data 
The results from PD were exported with the following data filtering criteria: PSMs with FDR < 
1%, search engine rank 1 and proteins that were quantified with ≥ 2 unique peptides. 
MSS fibroblasts: iTRAQ 4-plex data 
To normalize the iTRAQ ratio data, which is inherently asymmetrical (i.e. skewed), the ratio data 
was transformed into log values to a base of 2. Values with a log2-ratio of zero represent equal 
expression; values of -1 and 1 represent twofold down- and twofold upregulation, respectively. 
As a general assumption, in most cases, only a relatively low subset of proteins is expected to be 
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differentially regulated and therefore the majority of the log-ratios are expected to be centered 
around zero. However, due to the experimental bias e.g. pipetting errors or deviating BCA assay 
results, the median of the log-transformed ratios might differ from zero (Fig. 3.2 MD1). In such 
cases, the individual channel log2-transformed ratios of each protein were zero-centered by 
subtracting the protein specific medians taken across all the samples to compensate for the 
systematic errors. In PD, four different ratios were generated by using two replicates of MSS2 
patient and healthy controls i.e. MSS2.1/Healthy.1, MSS2.1/Healthy.2, MSS2.2/Healthy.1 and 
MSS2.2/Healthy.2. Firstly, the individual channel ratios of each protein were log2-transformed 
and for each channel an overall median (MD1) of all proteins was calculated (Fig. 3.2). 
 
Figure 3.2: Four ratios were obtained from PD (columns D - G) and each individual channel ratio of each protein was log2-
transformed (columns H - K). 
Secondly, each channel MD1 was subtracted from log2-transformed ratio of each protein to get 
normalized ratios, which were then averaged to get a final MSS2/healthy ratio. Thirdly, a global 
median ratio (MDglobal) and standard deviation (SDglobal) were calculated by considering all 
corresponding protein ratios (MSS2/Healthy). Lastly, relative standard deviations (RSD) were 
calculated for each protein by using the normalized ratios of the four individual ratios (Fig. 3.3). 
 
Figure 3.3: The overall median (MD1) of the respective channel was subtracted from the log2-transformed ratio of each protein 
(columns L - O) such that the overall median of the log2-ratios per channel is now centered around zero. An average (AVG) ratio 
of MSS/Healthy was calculated using the normalized ratios across all channels for each protein (column Q). Next, MDglobal and 
SDglobal were calculated using MSS/Healthy over all proteins. To estimate the variation between the replicates, relative 
standard deviation (RSD) values (column V) were calculated using the back-transformed log-2 normalized ratios of each protein 
(columns R - U). 
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Only proteins with RSD values ≤ 20% and with log2-ratios ≥ 2*SDglobal away from the MDglobal 
were considered as regulated. 
MSS-LCs and mice tissues (skeletal muscle and brain): iTRAQ 8-plex data 
As the iTRAQ 8-plex data comprised 3 - 4 biological replicates per condition, instead of working 
with 7 ratios against one reference sample, as provided by PD, here ratios were transformed 
into normalized abundance values (NAVs). Thus, for statistical comparison e.g. Student’s T-Test, 
a hypothetical ratio (i.e. 113/113) was generated in order to have eight data points in an 
experiment. The individual channel ratios of each protein were log2-transformed and for each 
channel MD1 over all proteins was calculated (same as above). Next, a second median (MD2) 
was generated by taking the MD1s across all channels. MD2 was then subtracted from the 
individual MD1s to deduce the normalization factors (NFs) for each channel (Fig. 3.4). 
 
Figure 3.4: A hypothetical ratio i.e. 113/113 was created (column D). Four ratios were obtained from PD and each individual 
channel (columns D - K) of each protein was log2-transformed (columns L - S). 
These NFs were then used to normalize the respective log2-transformed ratios for each protein 
per channel to obtain normalized ratios (NR). Next, a third median (MD3 or scaling factor, Fig. 
3.5, column AB) was calculated by taking the NRs for each protein across all channels. This MD3 
was then subtracted from the NR of each protein to get NAVs that were then grouped 
accordingly (4 healthy or 4 MSS patients) for each protein. Next, the Student's T-Test p-values 
with a significance level of ≤ 0.05 (two-sample assuming unequal variance) and ratios (i.e. 
MSS/Healthy) were calculated. Finally, MDglobal and SDglobal were calculated by considering 
all corresponding protein ratios i.e. MSS/healthy. Only proteins with Student’s T-Test p-values ≤ 
0.05 and with log2-ratios ≥ 2*SDglobal away from the MDglobal were considered as potentially 
regulated. In case of mice skeletal muscle and brain tissue samples, the pooled sample of three 
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biological replicates of wild type or woozy was grouped with the respective condition to have 
four data points for each biological state (Fig. 3.5). 
 
Figure 3.5: The median subtracted log2-ratios (columns T - AA) of each protein across all channels were used to calculate a 
median or scaling factor (column AB) to zero-center the medians. After subtracting the scaling factor from each normalized 
ratio, the generated normalized abundance values (columns AC - AJ), were grouped accordingly and an average (AVG) ratio of 
MSS/Healthy was calculated for each protein (column AK). Next, MDglobal and SDglobal were calculated using MSS/Healthy 
ratios over all proteins. To estimate the significance between the conditions, Student’s T-Test p-values (with a significance level 
of 0.05) were generated (column AL). The final ratios (column AM) were calculated by back-transforming log-2 average ratio 
(AVG, column AK) of each protein. 
3.2.15.2 Label-free data 
3.2.15.2.1 Precursor area quantification 
Quantitative analysis of the acquired label-free MS data of SIL1-depleted HEK293 cells was 
performed using the Progenesis software. The triplicate measurements of both sample sets i.e. 
∆SIL1_1 and ∆SIL1_2, respectively, were compared to the corresponding control triplicates (Scr) 
separately. After importing the MS raw files, data processing including (i) feature/peptide 
extraction, (ii) selection of the reference LC-MS run, (iii) alignment, (iv) peak picking and (v) 
normalization was done automatically by Progenesis. A feature is defined as the sum of all the 
MS signals produced by the same peptide ion across all the samples analyzed and has specific 
characteristics such as retention time, m/z, charge and intensity 138. Next, the features within a 
set of defined parameters i.e. retention time and m/z windows with charge states from +2 to +4 
were considered for peptide statistics and ANOVA. Furthermore, given the nature of label-free 
quantification, where many samples are measured under the exact same conditions and 
therefore produce a considerable extent of redundant (or overlapping) MS/MS information for a 
single feature across multiple LC-MS runs, the number of redundant MS/MS spectra used for 
database search was reduced. Therefore, for a given feature, rank value was restricted to a 
maximum of 10 i.e. only the 10 potentially best MS/MS spectra per feature were considered for 
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NSAF = Normalized spectral abundance factor; k = protein; SpC = 
total number of MS/MS spectra identifying a protein (k); L = 
length of the protein (k); N = total number of proteins in an 
experiment. 
database search. Spectra were exported as peak lists and database searches were performed 
using Mascot, OMSSA, and X! Tandem. Next, the search results from different algorithms were 
combined and filtered at a FDR of 1% using PeptideShaker. Thus generated quality-controlled 
identification results were then directly re-imported into Progenesis to match quantified 
features to peptide and protein identifications. Then for each protein, the average of the NAVs 
(obtained from Progenesis) from the triplicate analyses was calculated to determine the ratios 
between the scrambled controls and SIL-1 depleted samples. Only proteins that were (i) 
commonly quantified in all the replicates, (ii) with at least two unique peptides, (iii) an ANOVA 
p-value of ≤ 0.05 (from Progenesis) and (iv) an average ratio (ΔSIL1/Scr) ≤ 0.667 or ≥ 1.6 
(corresponding to 1.6-fold regulation; log2 ratios of +/- 0.65) were considered as regulated. 
3.2.15.2.2 Normalized spectral abundance factor (NSAF) 
Human RCMH data 
In total 16 MS raw files were converted into peak lists (mgf files) using ProteoWizard and were 
searched separately using Mascot, MS-GF+, and X! Tandem. The identification results from the 
different search algorithms were imported into PeptideShaker for data interpretation and 
validation as described above. Next, the 1% FDR quality controlled data was exported and only 
proteins that were identified with ≥ 1 validated peptide were considered for calculating NSAF 
value 111a for each protein. Additionally, the abundance of each protein was normalized with the 
abundance of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) - well-known housekeeping 
protein. 
(NSAF)k =  (SpC L)k�
∑ (SpC L)i�Ni=1  
Human skeletal muscles 
A comparative proteomic analysis of human skeletal muscles was not feasible with iTRAQ or 
precursor area-based label-free quantification approaches due to (i) limited number of samples, 
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(ii) very low amount of sample material (~5 µg) and (ii) high biological variation between the 
samples i.e. one clinically very ill patient against two healthy controls. For this reason, NSAF 
values of the raw MS data were calculated (as described above) in each dataset and the 
resulting estimated protein abundances were compared between the index patient and two 
controls datasets to achieve relative quantification. As the data comparison was based on a 
single shot LC-MS analysis, stringent filtering criteria were applied to increase both quality and 
confidence of the quantification results. Firstly, only those proteins that were identified in all 
the three datasets with ≥ 2 validated peptides and spectra (1% FDR) were considered for 
calculating the NSAF values. Secondly, RSD values were calculated for each protein by taking the 
NSAF values of the two controls. Thirdly, a ratio (Index/Control) was calculated for each protein 
by taking the NSAF value of the index patient and an average NSAF value of the controls (see 
below). 
NSAF Index(NSAF Control1 + NSAF Control2)/2 
Next, for each protein, the ratio (Index/Control) was normalized by a correction factor obtained 
by the alignment of TICs of the three samples to compensate for the systematic errors. Lastly, 
the normalized ratios were log2-transformed and only proteins with a ratio of < 0.49 or > 2.03 
(corresponding to 2-fold regulation; log2 ratios of +/- 1.0) and RSD values ≤ 20% (only controls) 
were considered as regulated. 
3.2.15.3 Targeted - MS data 
PRM raw data analysis of SIL1-depleted HEK293 cells was performed using the Skyline software. 
For both sample sets, triplicate measurements of ∆SIL1_1 and ∆SIL1_2, respectively were 
compared to the corresponding control (Scr) triplicates as previously described (see Section 
3.2.15.2.1). The scheduled targeted MS/MS data of 9 samples was imported into Skyline for 
visualization and validation. For each peptide/precursor ion (total 74 corresponding to 26 UPR-
related proteins), manual validation of MS/MS signals was performed since the peaks generated 
from the co-eluting peptides with identical m/z values as that of targeted peptide ion could lead 
to false peak annotations.  Hence, an in house generated Q Exactive spectral library which 
contained the information (a blue print) of the experimental MS/MS spectra of the peptides 
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that were selected for this assay was used for peak selection and assignment. Furthermore, for 
a given targeted peptide the corresponding fragment ion peaks which were ambiguous and 
below the limit of quantification of the instrument (i.e. Q Exactive MS) were discarded. Only 
those fragment ion peak areas were used for integration (i) that were observed within the 
predicted retention time windows of the corresponding precursor ion, (ii) with product ion 
intensities corresponding to the spectral library information and (iii) detected within 10 ppm 
mass accuracy. Next, the corresponding peptide peak areas were exported to generate protein 
ratios (ΔSIL1/Scr) and Student's T-Test p-values (two-sample assuming unequal variance) were 
determined. Only proteins that at least had a reproducible ≥ 1.3-fold (up/down) regulation 
compared to control and had a Student’s T-Test p-values ≤ 0.05 were considered as regulated. 
However, three out of 26 proteins selected for the PRM-assay method showed inconsistencies 
in statistical evaluation and had to be removed. The details of the UPR-related proteins used for 
the PRM-based targeted assay are given in the Appendix 10.8. 
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4 Results 
 In vitro protein carbamylation 4.1
In aqueous solutions, urea dissociates upon heating and over time. One of its major degradation 
products is isocyanate, which in buffer solutions (pH between 7.0 - 9.0) containing proteins; 
covalently reacts mainly with N-termini and epsilon amino group of Lys residues 139 (Fig. 4.1). 
 
Figure 4.1: Urea-induced carbamylation reaction mechanism in presence of heat (> 37°C) or prolonged exposure 
with urea in aqueous buffers containing protein/peptides. 
In urea-based sample preparation protocols e.g. FASP 120,  a systematic study was conducted to 
evaluate the extent of carbamylation under conditions that are typically used during sample 
preparation and proteolytic digestion 122 (Table 4.1). For this purpose, a peptide mixture of five 
model proteins namely, serum albumin, β-casein, β-lactoglobulin, hemoglobin (all bovine) and 
myoglobin (horse) was generated as described in section 3.2.12.1. By using a stock on the 
peptide instead of the protein level enabled better inter-comparability and consequently 
quantification of the extent of carbamylation as this allowed to reduce the technical variability 
to level of carbamylation and exclude proteolytic digestion as a source of differences between 
samples. Moreover, this allowed for a more comprehensive study of N-terminal carbamylation 
compared to the presence of only five accessible N-termini on the protein level 122. 
As expected, when treated with harsh conditions (2), nearly all identified peptides were 
carbamylated (99% N-termini, 90% Lys) (Fig. 4.2 A). Under conditions often used for reduction 
(3), nearly 13% of peptides were carbamylated at their N-terminus whereas only 4% of Lys side 
chains were modified. This might be attributed to higher reactivity of primary amines towards 
isocyanate compared to the epsilon amino group on Lys at basic pH 140. In many protocols, after 
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lysis (and sometimes initial Lys-C digestion) urea concentration is lowered to 2.0 M to keep 
polypeptides in an unfolded state and solubilized during digest. Under these conditions, nearly 
the same number of carbamylated peptides were identified for both buffers tested i.e. (4) 
NH4HCO3 (21% N-termini, 2.2% Lys) and (5) Tris-HCl (23% N-termini, 1.2% Lys), suggesting that 
one fifth of N-termini and ~2% of Lys residues can be carbamylated during overnight incubation 
at 37°C in presence of 2.0 M urea. Upon lowering the urea concentration to 0.1 M in the 
digestion buffer (6), 2% of N-termini and 0% of Lys residues were modified (Fig. 4.2 A). 
Table 4.1: Summary of the different conditions used to assess the degree of carbamylation during common sample 
processing procedures (3-9) when compared to controls (1-2). 
Condition Buffers Incubation conditions Protease Purpose Adapted from 
1 No treatment (0.1% TFA (v/v)) - Trypsin Control - 
2 8.0 M urea, 100 mM Tris-HCl (pH 8.5) 61°C, 15 h Trypsin Harsh - 
3 8.0 M urea, 100 mM Tris-HCl (pH 8.5) 56°C, 30 min Trypsin Reduction 127 
4 2.0 M urea, 50 mM NH4HCO3 (pH 7.8) 37°C, 15 h Trypsin Digestion 
128 
5 2.0 M urea, 100 mM Tris-HCl (pH 8.5) 37°C, 15 h Trypsin Digestion 129 
6 0.1 M urea, 50 mM NH4HCO3 (pH 7.8) 37°C, 15 h Trypsin Digestion - 
7 0.2 M GuHCl, 50 mM NH4HCO3 (pH 7.8) 37°C, 15 h Trypsin Digestion - 
8 8.0 M urea, 100 mM Tris-HCl (pH 8.5) 20°C, 18 h Trypsin Digestion 120 
9 8.0 M urea, 100 mM Tris-HCl (pH 7.9) and 
2.0 M urea, 100 mM Tris-HCl (pH 7.9) 
20°C, 18 h and 
20°C, 4 h 
Lys-C 
Trypsin 
Digestion 
Digestion 
120
 
 
 
Figure 4.2: Share of carbamylated peptides (A) and PSMs (B) identified after treating the peptide mixture (5 proteins) with 
different incubation conditions as summarized in Table 4.1 122. 
In addition, a buffer with GuHCl was evaluated as an alternative chaotropic agent; as expected 
carbamylation could not be detected due to the absence of urea, albeit, primary amines are 
potentially prone to guanidinylation in presence of GuHCl. However, overnight incubation at 
37°C with GuHCl (7) did not result in detectable guanidinylation of N-termini and Lys side chains. 
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Next, (8) the conditions used for Lys-C digestion were evaluated by incubating the peptide 
mixture in 8.0 M urea for 18 h at 20°C, thus detecting 11% of N-termini and 2% of Lys residues 
carbamylated (Fig. 4.2 A). Notably, when prepared freshly, no differences could be detected 
between the 4-month and the 8-year old urea, suggesting that urea degradation occurs only in 
aqueous solutions. 
Because of the relatively high share of urea-induced carbamylation with Lys-C, the conditions 
often used during two-step digestion procedure (9) involving initial proteolysis in 8.0 M urea 
(similar to 8), followed by 4-fold dilution and digestion with trypsin at 20°C for 4 h were 
evaluated. For this, human fibroblasts were lysed with 0.1% Rapigest and a two-step digestion 
was performed with Lys-C and trypsin (see Section 3.2.12.2), once in the presence of urea (urea-
based) and once in Rapigest (urea-free). After the database searches of LC-MS data, the number 
of identified non-carbamylated PSMs was nearly identical in both cases i.e. 12,982 in urea-based 
and 12,321 in urea-free samples (Table 4.2). 
Table 4.2: Summary of two-step digest condition (9) performed with Lys-C and trypsin using fibroblast lysates. 
Condition number of proteins identified 
with ≥ 1 unique peptide 
number of 
peptides identified 
number of 
PSMs  
% of carbamylated peptides 
(N-termini, Lys and Arg) 
Urea-based 1578 ± 17 6465 ± 330 12982 ± 720 0.3% ± 0.1% 
Urea-free (Rapigest) 1547 ± 13 5806 ± 252 12321 ± 460 0.2% ± 0.1% 
 
Nevertheless, as an example for the potential severity of the problem, the occurrence of urea-
induced carbamylation was evaluated in a recently published study that aimed to investigate 
the N-terminal proteome of Escherichia coli (prepared using urea) in a single 6 h LC-MS run 128. 
For this, the MS raw data was re-searched using the same search parameters that were used for 
the carbamylation experiment in this work. Remarkably, the database searches revealed that at 
1% FDR, 27.4% of the identified peptides (2,597 out of 9,481) and 25.7% of the PSMs (4,103 out 
of 15,948) were indeed carbamylated preferentially on the N-termini (~24% compared to ~7% of 
Lys residues) 122. 
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 Investigation of clinically unaffected cell types - Human 4.2
4.2.1 MSS fibroblasts 
The selective vulnerability of SIL1-deficiency in certain tissues and organs of MSS patients has 
been confirmed by different research groups 5, 18, 41. However, ultra-structural investigations (i.e. 
TEM, Fig. 4.3) on MSS-patient derived fibroblasts revealed morphological alterations 141 
suggesting that loss of functional SIL1 also has an effect on tissues or cellular populations that 
are apparently not MSS-vulnerable. One of these findings include dilated ER lumen suggesting 
an increased burden on the ER due to the 
accumulation of most likely, unfolded or 
misfolded proteins. Furthermore, the 
presence of vacuoles filled with electron-
dense membranous coils (so called myelin-like 
material) adjacent to the ER indicates 
proteolytic degradation (Fig. 4.3). One of the 
major tasks of this work was to further 
investigate these findings and to see whether 
one can identify the molecular reasons for 
these changes on the proteome level and 
deduce what could be a partially 
compensating effect that renders these 
tissues unaffected in MSS patients. For this, 
iTRAQ-based (4-plex) proteomics analysis was performed with the cultured fibroblasts derived 
from two MSS-patients (family MSS2) and their respective healthy controls. The LC-MS analysis 
of the 24-OFFGEL fractions led to the quantification of 2,993 proteins (≥ 2 unique peptides, 1% 
FDR). Out of these, 136 proteins showed altered levels (set criteria: an average MSS/Healthy 
ratio of ≤ 0.5 or ≥ 2.0 for down-/upregulation and RSD ≤ 20%) and among which 57 proteins 
were down- and 79 proteins were upregulated when compared to healthy fibroblasts. Details of 
altered proteins are given in the Appendix 10.3. 
Figure 4.3: TEM findings in MSS2 fibroblasts showing 
dilated ER-lumen and ER membrane with a high 
density of ribosomes (white arrow) and abnormal 
membranous coils (black arrow). Scale 1 µm. 
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SIL1 - previously described as a low abundant ER-resident co-chaperone 142, was one of the 
downregulated proteins (Fig. 4.4). Moreover, this finding is in line with the mutation analysis of 
the MSS2 case. Genetic studies of MSS2 patient identified missense or nonsense type mutation 
in SIL1 leading to an expression of SIL1 transcripts (mRNA) lacking the complete exon 6 (so-
called exon skipping). Despite the absence of exon 6, the SIL1 protein is still translated, but with 
an in-frame deletion of 64 amino acids (position Ala152 to Gln215) and it is predicted to be 
present in low levels in MSS2 patients 40 (Fig. 4.5). Furthermore, one of the major interaction 
sites of SIL1 with BiP is composed of these 64 amino acids 41b. As a result, even if present in low 
amounts, the truncated SIL1 protein will not be able to bind the ADP-BiP-substrate complex and 
catalyze the release of ADP. 
 
Figure 4.4: Product ion (MS/MS) spectra acquired in the Orbitrap mass analyzer (R = 7,500 FWHM at m/z 400) of two iTRAQ 4-
plex labeled peptides that belong to SIL1. The amino acids marked in red indicate the sites of attachment of the isobaric tags. As 
shown, the relative intensities of the reporter ions of the two MSS2 patients’ replicates reflect the relatively reduced abundance 
of SIL1 with respect to healthy controls. Notably, the real downregulation of SIL1 might be higher than the here indicated ~3-
fold, as reporter ion based quantification generally tends to underestimate regulation levels. 
>sp|Q9H173|SIL1_HUMAN Nucleotide exchange factor SIL1 OS=Homo sapiens GN=SIL1 PE=1 SV=1 
MAPQSLPSSRMAPLGMLLGLLMAACFTFCLSHQNLKEFALTNPEKSSTKETERKETKAEE 
ELDAEVLEVFHPTHEWQALQPGQAVPAGSHVRLNLQTGEREAKLQYEDKFRNNLKGKRLD 
INTNTYTSQDLKSALAKFKEGAEMESSKEDKARQAEVKRLFRPIEELKKDFDELNVVIET 
DMQIMVRLINKFNSSSSSLEEKIAALFDLEYYVHQMDNAQDLLSFGGLQVVINGLNSTEP 
LVKEYAAFVLGAAFSSNPKVQVEAIEGGALQKLLVILATEQPLTAKKKVLFALCSLLRHF 
PYAQRQFLKLGGLQVLRTLVQEKGTEVLAVRVVTLLYDLVTEKMFAEEEAELTQEMSPEK 
LQQYRQVHLLPGLWEQGWCEITAHLLALPEHDAREKVLQTLGVLLTTCRDRYRQDPQLGR 
TLASLQAEYQVLASLELQDGEDEGYFQELLGSVNSLLKELR 
Figure 4.5: FASTA sequence of human SIL1 protein (http://www.uniprot.org/uniprot/Q9H173.fasta). The motif i.e. Ala152 to 
Gln215 (amino acids indicated in red), which is responsible for the interaction between SIL1 and BiP is absent in the MSS2 family 
patient due to the lack of exon 6 in SIL1 mRNA transcripts. The amino acid sequences highlighted in green were detected and 
quantified by iTRAQ-based LC-MS analysis (see Figure 4.4). 
 
The MSS2/Healthy ratios of BiP and GRP170 showed a marginal upregulation (both ~1.6) and 
thus these two candidates did not pass the strict criteria for differentially regulated proteins. 
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Notably, nine out of 136 altered proteins have been associated with various autosomal 
recessive disorders and MSS being one of them according to the information listed in UniProtKB 
(http://www.uniprot.org) as of December 2015. The following protein-related data which are 
not derived from UniProtKB are marked by their references. Among the upregulated proteins, 
alpha-crystallin B chain (CRYAB) has been related to cataracts and muscular dystrophy and 
mitochondrial superoxide dismutase [Mn] (SOD2) was reported to cause retinopathy (an eye 
disease). Furthermore, bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 1 (NDST1) 
is involved in mental retardation, whereas bifunctional 3'-phosphoadenosine 5'-phosphosulfate 
synthase 2 (PAPSS2) and basement membrane-specific heparan sulfate proteoglycan core 
protein (HSPG2) have been associated with skeletal muscle abnormalities. Interestingly, apart 
from retinopathy, the other phenotypes are similar to the prominent clinical findings in MSS 
patients 41a. Notably, heme oxygenase (HMOX1) and heat shock protein beta-6 (HSPB6) - both 
involved in the oxidative stress response pathway, showed increased abundances suggesting 
the ER-stress and subsequent activation of the UPR pathway 143. Furthermore, ubiquitin 
carboxyl-terminal hydrolase isozyme L1 (UCHL1), which is involved in processing of the ubiquitin 
precursors as well as ubiquitinated proteins showed increased levels in MSS2 fibroblasts, 
indicating a potential triggering of the ERAD leading to proteasome-mediated ubiquitin-
dependent protein catabolic process. Remarkably, UCHL1 has been related to two 
neurodegenerative disorders, one of them being the Parkinson’s disease 5 144 and the other one 
is childhood-onset neurodegeneration with optic atrophy (NDGOA). 
The imbalance between the rates of protein production and protein degradation could be one 
of the reasons for aggregate formation. Carboxypeptidase M (CPM) - a protein processing 
enzyme that is involved in the membrane-localized degradation of extracellular proteins was 
downregulated in the MSS2 fibroblasts. Similarly collectin-12 (COLEC12), which is presumed to 
play a role in clearance of amyloid β peptides in the Alzheimer’s disease also showed reduced 
abundance in MSS2. These results are in accordance with the TEM findings that detected dense 
membranous material in the vicinity of the ER and the nucleus (Fig. 4.3). 
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4.2.2 MSS lymphoblastoid cells 
Application of iTRAQ 8-plex technology, high-pH RP fractionation and LC-MS analysis led to the 
quantification of 4,858 proteins (≥ 2 unique peptides, 1% FDR) in the LCs obtained from four 
individual patients i.e. MSS24, MSS32, MSS33 and MSS94 along with four different healthy 
controls. The chemical labeling strategy revealed 112 proteins with significantly altered 
abundances (set criteria: Student's T-Test p-value ≤ 0.05, an average MSS/Healthy ratio of ≤ 0.75 
or ≥ 1.32 for down-/upregulation) in MSS-LCs of which 48 proteins were down- and 64 proteins 
were upregulated. Details of altered proteins are given in the Appendix 10.4. 
As already seen in MSS-derived fibroblasts, SIL1 was again among the downregulated proteins in 
MSS-derived LCs. Thereby, the genetic cause in all MSS patients (MSS24, MSS32, MSS33 and 
MSS94 41a) is in accordance with the detection of residual - most likely non-functional SIL1 
protein level in this sample set (Fig. 4.6 A) and furthermore, these results are in line with the WB 
analysis (Fig. 4.6 B).  
 
Figure 4.6: (A) Product ion (MS/MS) spectra acquired in the Orbitrap (R = 7,500 FWHM at m/z 400) of an iTRAQ 8-plex labeled 
SIL1 peptide. The amino acid marked in red indicates the site of attachment of the isobaric tag. (B) Western Blot analysis 
performed with five different MSS patients’ and two healthy controls using an anti-SIL1 antibody (top) and an anti-GAPDH 
antibody (as loading control, bottom). The image is adapted from 41a which shows that SIL1 mutations result in substantially 
decreased SIL1 levels depending on the type of mutation in patients MSS24, MSS32, MSS33, MSS64 and MSS94, respectively 
compared to the levels in controls. "The seemingly "milder" mutations [small in-frame deletion (MSS24.1), missense mutation 
(MSS32.1) and frameshift mutation in the last exon (MSS64.1)] have similar effects as truncating mutations that are expected to 
lead to nonsense mediated messenger RNA decay (MSS33.1 and MSS94.1)" 41a. 
However, the expression levels of both BiP and GRP170 were almost stable (MSS/Healthy ratio 
for both = 0.8). Nevertheless, similar to the MSS-fibroblasts, alterations in some of the 
subcellular compartments were detected in this clinically unaffected cellular population as well. 
It is known that mitochondrial dysfunction caused by accumulation of misfolded proteins is 
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linked to various neurodegenerative and neuromuscular disorders in man and mouse 35, 145. 
Proteomic profiling of MSS-LCs revealed increased abundances of mitochondrial proteins which 
promote apoptosis i.e. cytochrome C (CYCS) and apoptosis-inducing factor 2 (AIFM2). Besides, 
reduced abundances of mitochondria-associated carnitine O-palmitoyltransferase 1, liver 
isoform (CPT1A), peptide chain release factor 1-like (MTRF1L), TOM1-like protein 2 (TOM1L2) 
and thioredoxin reductase 2 (TXNRD2) indicate abnormal functioning of this subcellular 
organelle. Nevertheless, upregulation of mitochondrial short/branched chain specific acyl-CoA 
dehydrogenase (ACADSB), phospholipid hydroperoxide glutathione peroxidase (GPX4) and 
peroxiredoxin-5 (PRDX5) is in agreement with the activation of pro-survival/mitoprotective 
strategies in SIL1-deficient LCs to avoid cell death. In addition, downregulation of inhibitor of 
nuclear factor kappa-B kinase-interacting protein (IKBIP), which is a target of cellular tumor 
antigen (TP53) with pro-apoptotic function indicate negative regulation of apoptosis. 
Although the ER can form intracellular networks independently of cytoskeletal structures, 
integrity and distribution of this compartment in mammalian cells are influenced by cytoskeletal 
components 146. Remodeling of the cytoskeleton affecting both actin filaments and 
microtubules upon loss of functional SIL1 in LCs is shown by downregulation of myristoylated 
alanine-rich C-kinase substrate (MARCKS) and upregulation of tyrosine-protein kinase (HCK), 
fermitin family homolog 2 (FERMT2), kinesin-like protein (KIF21A), profilin-2 (PFN2), protein 
XRP2 (RP2) and septin-1 (SEPT1). 
Identical to the MSS-derived fibroblasts, proteins that are involved in the ubiquitin-proteasome 
pathway e.g. ankyrin repeat domain-containing protein 13A (ANKRD13A) and ubiquitin-
conjugating enzyme E2 variant 3 (UEVLD) were upregulated in the MSS-LCs indicating activation 
of the ERAD pathway. Furthermore, cathepsin B (CTSB) - a thiol protease, which participates in 
intracellular degradation and turnover of proteins showed increased abundance suggesting the 
role of CTSB in clearing misfolded proteins. This is in line with the TEM findings of electron-
dense autophagy material observed in the MSS-LCs (Fig. 4.7 C, D). 
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Figure 4.7: TEM findings in control LCs (A, B) and LCs derived from MSS patients (C - E). (A, B) Regular organelle 
structures in LC derived from healthy controls. Scale bars in A = 5 µm; in B = 2 µm. (C) Intense coloration of the 
nucleus and accumulation of electron-dense material (white arrow) in a LC derived from a MSS patient. Scale bar = 
7.5 µm. (D) Detailed magnification of (C) emphasizes widened rough ER (white arrow) and outfoldings of the lifted-
off nuclear envelope (asterisk) as well as accumulation of vesicular structures partially filled with electron-dense 
material. Scale bar = 1 µm. (E) TEM data pf another MSS-patient derived LC presenting with in nuclear and cytosolic 
alterations (white arrows). Scale bar = 7.5 µm. The TEM studies were performed at the Institute of Neuropathology, 
Aachen. 
SIL1 is ubiquitously expressed in the brain and its loss leads to cerebellar ataxia - a clinical 
hallmark of MSS. Notably, ataxin-10 (ATXN10) is necessary for the survival of cerebellar neurons 
and induces neuritogenesis by activating the Ras-MAP kinase pathway. Upregulation of ATXN10 
in MSS-LCs might indicate a compensatory strategy to antagonize Purkinje cell degeneration in 
SIL1-deficient cerebella 147. Moreover, ATXN10 plays a role in the maintenance of critical 
intracellular glycosylation levels and homeostasis. Similarly, galectin-1 (LGALS1), which belongs 
to the family of β-galactoside-binding proteins showed increased abundances in SIL1-deficient 
LCs. LGALS1 has been reported to be involved in various cell defense mechanisms including pro- 
survival and establishment of homeostasis 148. In addition, it was shown that galectin-1 has an 
indirect neuroprotective function in immune mediated inflammatory neurodegenerative 
disorders e.g. multiple sclerosis 149. 
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 Investigation of clinically affected tissues - Mouse 4.3
To gain insights into this pathological condition of SIL1-loss on the global level, proteomic 
profiling of Sil1-deficient affected tissues i.e. cerebellum and skeletal muscles derived from the 
woozy mice and the respective wild type littermates was performed. 
4.3.1 Woozy cerebellum 
The cerebellum also known as the "little/small brain" is located at the back of the mammalian 
brain and it constitutes ≥ 50% 150 of the total number of neurons - the basic working units of the 
brain. Its main functions are maintaining balance and posture, coordinating motor activities and 
learning new cognitive skills. Cerebellar damage is usually manifested in the form of ataxia i.e. 
loss of motor coordination, which is a prominent overlapping symptom between SIL1/Sil1-
mutant man and woozy mouse. 
Similar to MSS-LCs, iTRAQ 8-plex labeling in combination with RP pH 6.0 fractionation and LC-
MS/MS analysis were performed using three biological replicates of woozy and wild type (26-
weeks old, female) cerebella. This led to the quantification of 3,580 proteins (≥ 2 unique 
peptides, 1% FDR) wherein, ~3% (112) were found to be significantly altered (set criteria: 
Student's T-Test p-value ≤ 0.05, an average woozy/wild type ratio of ≤ 0.74 or ≥ 1.34 for down-
/upregulation). Among these 112 proteins, ~79% (88) were down- and ~21% (24) were 
upregulated. Details of altered proteins are given in the Appendix 10.5. 
Remarkably, BiP and its alternate NEF i.e. Grp170, showed relatively stable protein abundances 
(i.e. woozy/wild type ratios of 0.95 and 0.98, respectively) in the woozy with respect to wild type 
littermates, whereas Sil1 could not be quantified. This result however, is in contrast to the 
findings of Zhao et al., 47 who reported increased levels of BiP in the Purkinje cells of Sil1-mutant 
animals. The plausible reason for the discrepancy between the two datasets can be due to the 
fact that Zhao and colleagues performed their studies only on the Purkinje cell population. 
Whereas, the complete cerebellum of woozy was used for proteomics analysis, which comprises 
different cell types. Furthermore, one can speculate the presence of pro-survival mechanisms in 
other cell populations of the cerebellum that might compensate for Sil1-loss in the woozy. To 
support this presumption, upregulation of certain proteins that are known for their cell survival 
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(or cytoprotective) capabilities were found in the proteomics data of woozy mice. For instance, 
mast/stem cell growth factor receptor Kit (Kit) protein, which plays an essential role in the 
regulation of cell survival and proliferation, showed upregulation in woozy mice. It is well-known 
that oxidative stress is among the main factors in causing cellular damage. In this regard, 
upregulation of cytosolic proteins, such as nicotinate phosphoribosyl transferase (Naprt) and 
peroxiredoxin-6 (Pdrxn6), which play a protective role against oxidative injury, indicate an 
activation of defense mechanisms in Sil1-deficient cerebellar neuronal cells. Notably, increased 
abundance of caspase-3 (Casp3), which is involved in the execution of glial cell apoptosis, was 
found in the neuronal cells of the woozy. This finding consolidates the TEM findings (Fig. 4.8 A) 
that detected the presence of apoptotic material in the nerve cells and thus complementing 
morphological and proteomics analyses. In contrast, inositol 1,4,5-trisphosphate receptor type 1 
(Itpr1) - an ER-membrane bound intracellular ligand-gated calcium channel that plays a role in 
the ER-stress induced cell death showed decreased levels in the woozy indicating a negative 
regulation of apoptosis. 
Whereas increased levels of glial fibrillary acidic protein (Gfap) were found in the woozy. GFAP is 
one of the most widely used markers of neurologic damage in humans 151. Interestingly, 20 
proteins that are associated with intra-/extracellular calcium (Ca2+) regulation, Ca2+ storage and 
signaling were found to be downregulated in woozy. Despite the lack of evidence that supports 
the direct interaction between SIL1 and Ca2+, the altered levels of the latter can be attributed to 
the dysfunctional SIL1-BiP machinery leading to disturbed cellular homeostasis 34c. These include 
(i) Ca2+ binding proteins: calcium-dependent secretion activator 2 (Cadps2) and calbindin 
(Calb1), (ii) Ca2+ dependent ion channels: calcium/calmodulin-dependent protein kinase type IV 
(Camk4) and voltage-dependent calcium channel subunit alpha-2/delta-2 (Cacna2d2), (iii) 
proteins involved in Ca2+ homeostasis: regulator of microtubule dynamics protein 3 (Rmdn3). 
Remarkably, Calb1 - a Purkinje cell marker, was also downregulated in the Zhao et al., dataset.  
Cell-cell communication is mainly carried out by signaling pathways involving receptors and ion 
channels present in the plasma membrane 152. Notably, protein kinase C gamma type (Prkcg) is 
solely expressed in the brain and the spinal cord and it is the most abundant isozyme of the 
protein kinase C family in the cerebellum. Prkcg is activated by fatty acids and plays diverse 
roles in cellular signaling events of the neurons in a Ca2+-dependent manner 153 including 
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regulation of the neuronal receptors e.g. glutamate receptor 4 (Gria4) and cell survival after 
cerebellar ischemia 154. Owing to its important role in the regulation of neuronal signaling 
pathways, Prkcg-deficient mice manifest symptoms of mild deficits in spatial and contextual 
learning and impaired motor coordination due to disturbances in the development process of 
the Purkinje cells 153. The low abundance level of Prkcg therefore correlates with the observed 
neurodegeneration in woozy. Moreover, Ca2+ also plays an important role in the transmission of 
neurotransmitters at the neuromuscular junction - a chemical synapse formed by the contact 
between a motor neuron and a muscle fiber, by regulating the voltage-dependent ion channels 
155.  The relatively low abundances of voltage-dependent P/Q-type calcium channel subunit 
alpha-1A (Cacna1a) and sarco-/endoplasmic reticulum calcium ATPase 2 (Atp2a2) might indicate 
neuromuscular degeneration in the SIL1-mutant woozy mouse and MSS patients. 
The cytoskeleton of a nerve cell is typically elaborated due to the axon and the dendrite - parts 
of a neuron that specialize in exchange of information (or impulses) between neurons at the 
synapse. Notably, cytoskeletal abnormalities caused due to the altered intracellular Ca2+ levels 
have been associated with aging and certain neurodegenerative disorders 156. Besides Camk4, 
calcium/calmodulin-dependent protein kinase type II subunit beta (Camk2b), which plays an 
important role in the cytoskeletal reorganization of neuronal cells, was also downregulated in 
woozy suggesting a negative effect on the structural integrity of these cells. Additionally, SH3 
and multiple ankyrin repeat domains protein 1 (Shank1) and 2 (Shank2) that are involved in the 
structural and functional organization of the dendrites particularly at the synaptic junction, 
showed reduced abundances in woozy. Further, delphilin (Grid2ip), a postsynaptic scaffolding 
protein present at the Purkinje cell synapse was also downregulated, which clearly shows the 
degeneration of this neuronal cell population as a consequence of Sil1-loss. 
In addition, the TEM findings in the neocerebellum (Fig. 4.8 A-D) of woozy mouse (26-weeks old) 
revealed electron-dense material present in the neuronal cells indicative of protein aggregates. 
The presence of lysosomal autophagic material (Fig. 4.8 A) in the nuclear and perinuclear 
regions indicate activation of the ER-stress induced autophagy-lysosomal protein degradation. 
This finding is in accordance with the results from Zhao et al., suggesting that loss of the 
Purkinje cells causes early onset of ataxia in woozy animals. In addition to the above findings, 
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damaged mitochondria (which usually trigger apoptosis) were also detected in the nerve cells 
(4.8 D). 
 
Figure 4.8: TEM findings in neocerebellum of woozy mouse at the age of 26 weeks: (A) Accumulation of electron-
dense material and lysosomes in the vicinity of a nucleus (white arrows). (B) Proliferation of vesicular structures 
partially filled with electron-dense material within a glial cell (white arrows). (C) Degeneration of small myelinated 
axons (white arrows) in the proximity of a neuronal nucleus. (D) Mitochondrial degeneration (white arrow) in an 
apoptotic neuronal cell surrounded by small and large myelinated axons. Scale bar = 1 µm. The TEM studies were 
performed at the Institute of Neuropathology, Aachen. 
4.3.2 Woozy skeletal muscles 
The mammalian skeletal muscle consists of elongated, multinucleated, transversely striated 
fibers that are typically attached to bones and tendons. Its main function is contraction and 
relaxation, which provides stability and movement of the body. By employing an identical 
iTRAQ-based LC-MS methodology as above, a total 2,055 proteins (≥ 2 unique peptides, 1% FDR) 
were quantified of which 64 proteins were significantly differentially regulated (set criteria: 
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Student's T-Test p-value ≤ 0.05, an average woozy/wild type ratio of ≤ 0.70 or ≥ 1.43 for down-
/upregulation) in woozy mice. Details of altered proteins are given in the Appendix 10.6. 
Notably, ~83% (53) of the altered proteins were up- and the remaining 11 proteins were 
downregulated. This relatively lower number of the total quantified proteins compared to the 
primary cell lines data (i.e. MSS fibroblasts and LCs) can be attributed to (i) the complex nature 
of the skeletal muscle itself 157 and (ii) the presence of highly abundant cytoskeletal proteins i.e. 
actin and myosin. Not surprisingly, 46% of all quantified and validated (1% FDR) PSMs belong to 
these two candidates (including different types and their isoforms) in this iTRAQ dataset. Based 
on the NSAF value calculation, this corresponds to 34% of estimated relative protein abundance 
of various forms of actin and myosin. Nevertheless, some of the key UPR-related proteins i.e. 
BiP (Hspa5), calnexin (Canx) and protein disulfide isomerase-6 (Pdia6) (Fig. 4.9) could still be 
detected demonstrating the robust combination of iTRAQ technology, high-pH RP fractionation 
and sensitivity of the LC-MS analysis. These results are in agreement with the WB findings that 
showed elevated levels of the UPR pathway proteins (Fig. 4.10). Besides, increased levels of 
proteins that are involved in (i) the ERAD pathway: transitional endoplasmic reticulum ATPase 
(Vcp), dnaJ homolog subfamily B member 6 (Dnajb6) and (ii) proteolysis: beclin-1 (Becn1) and 
TAR DNA-binding protein 43 (Tdp43) could be detected in the WB analysis (Fig. 4.10). The 
woozy/wild type ratio of Grp170 also showed an upregulation in iTRAQ dataset (~1.4) however, 
it did not pass the strict criteria for differentially regulated proteins. Notably, Grp170 (Hyou1), 
the ER-resident chaperone/NEF for BiP, indeed showed moderately increased levels in Sil1-
mutant mice. In contrast, overexpression of Hyou1 in skeletal muscles was reported to cause 
severe myopathic changes in mice 158 and therefore its upregulation might be compromised to 
such levels as to avoid any negative effects causing further muscular damage 35. 
Moreover, upregulation of cytosolic ERAD-assisting chaperones i.e. heat shock protein beta-1 
(Hspb1) and beta-7 (Hspb7) was seen in the iTRAQ data of woozy. Interestingly, alpha-crystallin 
B chain (Cryab) (involvement in cataracts and muscular dystrophy), which showed increased 
abundance in the MSS2-fibroblasts was also among the upregulated candidates in the woozy 
mice. 
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Figure 4.9: Representative product ion (MS/MS) spectra acquired in the Orbitrap (R = 17,500 FWHM at m/z 200) of 
iTRAQ 8-plex labeled peptides which belong to BiP, calnexin and protein disulfide isomerase A6, respectively. The 
amino acid(s) marked in red indicates the site of attachment of the isobaric tag. Abbreviations: WT = wild type, WZ 
= woozy, WT Mix and WZ Mix = pooled samples of three biological replicates of each type, respectively. 
Proteins that are involved in the cytoskeletal organization showed increased abundances 
implying possible structural myopathic changes in the muscle fibers of woozy. These include: 
coronin-1A (Coro1a), tubulin beta-6 chain (Tubb6), profilin-1 (Pfn1), cofilin-1 (Cfl1) and xin actin-
binding repeat-containing protein 1 (Xirp1). Coro1a and Pfn1 are actin-binding proteins, and 
Tubb6 is a major part of microtubules, which are filamentous intracellular structures responsible 
for various kinds of movements in all eukaryotic cells. Moreover, Xirp1, which protects actin 
fibers from depolymerization, has been associated with the abnormal thickening of cardiac 
muscle in mice. 
It is well-known that Ca2+ plays a major role in muscle contraction - being the main signaling and 
regulatory molecule in the muscle fibers 159. Calsequestrin-2 (Casq2), a Ca2+-binding protein 
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(which also acts an internal calcium store in 
the sarcoplasmic reticulum of muscle cells) 
showed increased abundance in woozy. 
Casq2 regulates the release of lumenal Ca2+ 
through the calcium release channel 
ryanodine receptor 2 (Ryr2) and plays an 
important role in triggering muscle 
contraction as well as in excitation-
contraction coupling in cardiac muscles 160. 
Similarly, other Ca2+ binding protein proteins 
i.e. protein S100-A13 (S100a13), protein 
S100-A6 (S100a6), annexin A1 (Anxa1) and 
annexin A4 (Anxa4) showed high levels in 
woozy mice when compared to their wild 
type littermates. Upregulation of these Ca2+ associated proteins clearly indicate activation of the 
UPR pathway due to altered Sil1-BiP machinery or might reflect a cellular attempt to antagonize 
muscle fiber degeneration by forced contraction. 
Galectin-3 (Lgals3), which belongs to the same family of lectins as galectin-1 (upregulated in the 
MSS-LCs), plays an essential role in the regulation of cellular homeostasis. This protein was 
shown (i) to modulate cell growth, (ii) to control the cell cycle, and also (iii) involvement in the 
regulation of apoptosis 161. Owing to Lgals3 role in cell death inhibition, its upregulation in the 
woozy might indicate an activation of pro-survival mechanism in the Sil1-deficient woozy 
muscles. Besides, overexpression of elongation factor 1-alpha 1 (Eef1a1), which is involved in 
protein biosynthesis, has been reported to play a possible protective role under ER-stress 
caused due to aggregation of un-/misfolded proteins 162. Moreover, nestin (Nes), which is 
required for brain and eye development and survival 163 was also overexpressed in woozy, which 
is in accordance with the fact that apart from skeletal muscle, the brain and the eyes are 
severely affected by SIL1-loss in man. Similarly, mesencephalic astrocyte-derived neurotrophic 
factor (Manf), which has been reported to selectively promote the survival of dopaminergic 
neurons by inhibiting the ER-stress induced cell death, was also upregulated. 
Figure 4.10: Comparative WB analysis of skeletal muscles 
derived from woozy and wild type littermates (female, 3 
biological replicates each). Immunoblots indicate elevated 
levels of proteins that are associated with (i) the UPR 
pathway (Grp170, BiP, Pdi, peif2α), (ii) the ERAD pathway 
(Dnajb6, Vcp) and (iii) the proteolysis pathway (Beclin1, 
Tdp43) in woozy mice. Gapdh was used as loading control. 
The WB analysis was performed at the Institute of 
Neuropathology, Aachen.  
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 Proteomic profiling of an index patient - Human 4.4
Owing to the high sensitivity of MS and currently available quantification strategies, it was 
evaluated whether a comparative proteomics analysis can be conducted with a low amount of 
starting material (~5 µg of protein) obtained from a skeletal muscle biopsy of an index patient. 
After nano-LC-MS analysis, the NSAF values calculation and data normalization (see Section 
3.2.15.2.2), a total 95 proteins were relatively quantified (set criteria: an average index/control 
ratio ≤ 0.49 or ≥ 2.03 for down-
/upregulation, RSD ≤ 20%). 
Notably, ~93% (88) of the overall 
quantified proteins were up- and 
7 proteins were downregulated. 
Details of altered proteins are 
given in the Appendix 10.7. 
Based on the subcellular 
localization information; ~95% 
of total altered proteins belong 
to the vital cellular components 
i.e. the nucleus (19), the 
cytoplasm (47) and the 
mitochondria (20) indicating a 
high degree of physiological 
disturbances in skeletal muscle 
of the index patient. The main cytosolic proteins i.e. actin and myosin that play an important 
role in the proper function of muscle cells such as contraction/relaxation and cytoskeletal 
organization were found to be upregulated in the index patient. Some of the well-known 
examples include: actin cytoplasmic 1 and 2 (ACTB and ACTG1), actin, alpha skeletal muscle 
(ACTA1); myosins 1, 4, and 13 (MYH1, MYH4 and MYH13). Apart from these, other proteins 
which are involved in the movement e.g. tubulin beta chain (TUBB), tubulin alpha-4A chain 
(TUBA4A) and maintenance of the structural integrity of muscle fibers e.g. thymosin beta-4 and 
Figure 4.11: TEM findings on the muscle biopsy derived from the 
index patient. (A) Huge sub-sarcolemmal accumulation of vacuoles 
filled with electron-dense material most likely corresponding to 
protein aggregates (white arrows) and thus indicating a protein 
folding disorder as the cause of myopathy. (B) Sub-sarcolemmal build-
up of filamentous aggregates (white arrows) indicating further the 
impaired protein folding process as the major cause of the myopathic 
changes in this patient. Scale bar = 1 µm. The TEM studies were 
performed at the Institute of Neuropathology, Aachen. 
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beta10 (TMSB4X and TMSB10) also showed increased abundances in the index patient when 
compared to healthy controls, indicating a myopathic condition. These results are in accordance 
with the TEM findings (Fig. 4.11 A and B), which revealed electron-dense material and 
filamentous aggregates in the sarcoplasm (i.e. cytoplasm of muscle cells) of the muscle 
specimen of the index patient. Furthermore, increased levels of the cytoskeletal components 
indicate a possible formation of protein aggregates since upregulation of cytosolic molecular 
chaperones was found in the patient’s data which include heat shock protein HSP 90-alpha 
(HSP90AA1), heat shock-related   70 kDa protein 2 (HSPA2), heat shock cognate 71 kDa protein 
(HSPA8), heat shock 70 kDa protein 1A and 1B (HSPA1A and HSPA1B). These chaperones usually 
operate in a concerted manner to modulate protein aggregation in the cytoplasm. Besides, 
kelch-like protein 41 (KLHL41) - a cytosolic protein involved in development and differentiation 
of skeletal muscle fibers, was among upregulated proteins. Notably, KLHL41 has been 
associated with an autosomal recessive form of Nemaline myopathy (NEM9, OMIM: 615731) 
and one of its phenotypic manifestations is progressive distal muscle weakness starting at an 
early age, which was also observed in the index patient. In this regard, ryanodine receptor 1 
(RYR1), a sarcoplasmic reticulum (i.e. sER in muscle cells) membrane bound Ca2+ ion channel 
also showed increased abundance in the index patient. Strikingly, mutations in RYR1 have been 
linked to the central core disease (CCD, OMIM: 117000) - a skeletal muscle disorder. Moreover, 
both NEM9 and CCD are classified as congenital myopathies and the clinical hallmark of these 
disorders is the presence of rod-like structures in muscle cells 164. 
Furthermore, upregulation of the mitochondrial ATP synthase subunit beta (ATP5B) that 
participates in the ATP production suggest an energy demand due to the cellular burden caused 
due to protein aggregation. Additionally, cytochrome c oxidase subunit 2 (MT-CO2) is involved 
in the respiratory chain in the mitochondria showed increased levels in the index patient, which 
is indicative of apoptosis. Recently, a novel mutation was identified on the MT-CO2 that causes 
mitochondrial dysfunction leading to myopathy and neuromuscular disorders 165. Histones are 
the basic proteins which reside in the nucleus and play a major role in gene regulation. In total, 
9 different types of histones (out of 19 nucleus-residing proteins) were upregulated in the 
patient indicating an increased transcription regulation of proteins e.g. molecular chaperones, 
which might be involved in the ER quality control to cope with the cellular stress. Notably, 
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creatinine kinase m type (CKM), which is regarded as an indirect marker of muscle damage 166 
was upregulated in the patient and this correlates with the biochemical results that detected 
moderately increased levels of CKM. 
Among the downregulated proteins, decreased abundance of synaptopodin (SYNPO) - an actin 
binding protein, which is involved in the formation of telencephalic neurons, can be associated 
to the neuromuscular abnormalities presented by the index patient. FKBP3 - a member of the 
peptidyl prolyl cis/trans isomerases (PPIases) family, which catalyzes the cis-trans isomerization 
of proline peptide (Xaa-Pro) bonds in oligopeptides and also accelerates the protein folding 
process 167, was downregulated indicating protein aggregation. In addition, eukaryotic 
translation initiation factor 4B (EIF4B) - an mRNA binding protein, which is involved in the 
protein biosynthesis, showed low levels suggesting a possible translational attenuation as a 
consequence of the UPR pathway initiation. Further evidence of the UPR activation is revealed 
by the upregulation of ubiquitin-conjugating enzyme E2 N (UBE2N) and polyubiquitin-B (UBB), 
both involved in the ERAD-mediated protein ubiquitination pathway. 
 Proteomic profiling of SIL1-depleted HEK293 cell line  4.5
From the above results, it can be deduced that the loss of functional SIL1 may lead to cellular 
perturbations owing to dysfunctional BiP-controlled protein folding in the ER-lumen. However, 
due to the absence of appropriate in vitro cell models, the precise cellular pathophysiological 
mechanisms leading to neuromuscular degeneration in MSS are still unclear 168. For this, a 
comparative proteomics analysis was performed using SIL1-depleted human embryonic kidney 
293 (HEK293) cells to better understand the structural changes of the ER that closely mimic 
pathological alterations in MSS due to the absence of SIL1. The two SIL1-depleted cell clones 
(∆SIL1_1 and ∆SIL1_2) and one scrambled (Scr) transfected cell clone (as a negative control) 
were prepared using the FASP protocol (see Section 3.2.6). Next the samples were analyzed by 
label-free quantitative proteomics. Precursor ion area-based quantification (see Section 
3.2.15.2.1) led to the quantification of 2,819 proteins (≥ 2 unique peptides, 1% FDR) of which 
459 (16%) showed altered levels (set criteria: ANOVA p-value ≤ 0.05, an average ∆SIL1/Scr ratio 
≤ 0.667 or ≥ 1.6 for down-/upregulation). Of these, 141 (31%) were up- and 318 (69%) were 
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downregulated in HEK293-∆SIL1 cell line, respectively. Details of altered proteins are given in 
the Appendix 10.9. 
By using the gene ontology (GO) 169 analysis in conjunction with the STRING database 170, 
differentially regulated proteins (or genes) were enriched under the domain "biological process" 
term to better understand the effects due to SIL1-loss. The "GO term analysis" analyzes datasets 
for the overrepresentation of specific biological terms or functions by making use of the GO 
classification, in which genes are assigned to a set of predefined terms depending on their 
functional characteristics. The GO analysis results of the altered proteins revealed that they are 
involved in important cellular pathways and are described below in detail. However, due to a 
high number of differentially regulated proteins in this dataset, only their gene names are used 
as shown in the Fig. 4.12. 
Organization and proper function of cytoskeleton relies on the number and spatial arrangement 
of membrane proteins. They render binding sites e.g. to actin filaments and microtubules, and 
are possible substrates of SIL1-BiP machinery. In HEK293-∆SIL1 cell line, altered levels of the 
plasma membrane-associated proteins e.g. CKAP4, FERMT2, RDX, TLN1 and VCL were identified. 
In addition, increased levels of PFN1, CFL1, PDXP and DSTN (an actin-depolymerizing protein) 
and decreased abundance of GSN were found. GSN is Ca2+- regulated, actin-modulating protein 
that can promote assembly of monomers into filaments (nucleation) as well as repair filaments 
already formed. Downregulation of GSN could indicate an altered ER homeostasis or suggest an 
alternate mechanism to counteract cytoskeletal disturbance 168. Increased abundances of TBCA, 
TBCE and TBCB, which provide attachment of cytoskeletal filaments to plasma membrane 
proteins, indeed support the latter assumption. Besides, downregulation of cytoskeleton 
proteins such as, EPPK1, TUBGCP3, MYO1C, MYH10, MAP1B, NEFL, NEFM and VIM were also 
detected. Notably, VIM plays a role in the progression of cataracts [OMIM: 116300] - one of the 
clinical hallmarks of MSS 168. Drebrin-like protein (DBNL) interacts with Dynamin (DNM2), which 
plays an important role in vesicular trafficking processes and also involved in various 
neuromuscular disorders e.g. Charcot-Marie-Tooth disease [OMIM: 606482]. Increased 
abundances of these two candidates indicate an altered protein trafficking between the ER, the 
Golgi and the plasma membrane. 
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Figure 4.12: Graphical representation of different subcellular compartments and the respective resident proteins that showed 
significant regulation (set criteria: ΔSIL1/Scr ratio of ≥ 1.6-fold, log-2 scale; ANOVA p-value ≤ 0.05) determined by label-free 
quantitative MS data as described in detail in the section 3.2.15.2.1. The gene name color coding represents increased (blue) 
and decreased (red) protein abundances. Figure adapted from 168. 
Further evidence of disturbed protein transport system is shown by downregulation of RAB10, 
RHOB, RAP1A, EPT1, SURF4, STX16, TMED10 and VAPB, and upregulation of vesicular transport 
factors, such as USO1, PICALM, SNX3 and YKT6 (Fig. 4.12). Moreover, this data is in line with the 
TEM data that revealed proliferated Golgi and vesicular structures (Fig. 4.13 B). Together, 
altered levels of cytoskeletal and vesicular transport proteins might be due to dysfunctional 
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trafficking mechanism caused by SIL1-loss leading to an abnormal levels of the plasma 
membrane proteins including decreased levels of REEP5 (Fig. 4.12) 168. 
Mitochondrial damage is oftentimes represented by its aberrant shape as observed in the MSS-
LCs and woozy mice tissues. Despite SIL1 being an ER-resident protein, its association with the 
mitochondrial dysfunction could be explained by the following evidences: (i) mitochondria-ER 
associated membranes (MAMs) are specific domains that enable multiple adhesion sites 
between both organelles, (ii) mitochondria-ER interaction promotes mitochondrial fission, and 
(iii) actin polymerization, which is affected by SIL1-loss (see above) and this in turn modulates 
mitochondrial fission 168. Thus, cytoskeletal and mitochondrial disturbances can be ascribed to 
SIL1-depletion. The latter assumption is therefore supported by decreased abundances of 
several mitochondrial membrane and membrane binding proteins e.g. ACSL1, ACSL3, AGK, 
ATP5C1, ATP5J, ATP5J2, ATP5L, ATP5O, CISD1, HCCS, IMMT, MPC2, NNT, PPOX, SAMM50, 
SFXN1, SLC25A1, SLC25A3, SLC25A5, TOMM40, TSPO, VAT1, VDAC2 (Fig. 4.12). Furthermore, 
downregulation of CHCHD3, which plays crucial roles in the maintenance of different 
mitochondrial membranes including cristae, indicates the impact of SIL1-loss on this subcellular 
organelle. These findings correlate with mitochondrial alterations detected on the TEM level 
(Fig. 4.13 B, C) 168. In addition, HEK293 ∆SIL1 cells showed an increased abundance of a subset of 
mitochondrial matrix/luminal proteins that might counteract mitophagy (i.e. selective 
degradation of mitochondria by autophagy). These proteins take part in proper cytoplasmic 
mitochondrial distribution (CLUH), lipid (ECHS1, HADH) and ketone body (ACAT1) metabolism, 
tricarboxylic acid cycle (FH, MDH2), cell redox homeostasis (TXN2), amino acid metabolism 
(GOT2, IVD, OAT), nucleotide (AK2, AK4, DUT, TYMS) and protein biosynthesis (SARS2), protein 
folding (GRPEL1, HSPA9, LYRM7, TIMM8B and TIMM13) and proteolysis (PITRM1) (Fig. 4.12) 168. 
Notably, these results are in accordance with the observed mitochondrial alterations in MSS 35 
for which SIL1 was described as a modulator 45b to mitochondrial dysfunction 171. 
The alterations of nuclear envelope architecture are hallmarks of SIL1/Sil1 chaperonopathies in 
skeletal muscle fibers in man and mouse 35. The TEM studies on ∆SIL1 HEK293 cells showed 
abnormal nuclear morphology including the nuclear envelope and the nuclear membrane (Fig. 
4.13 B). The occurrence of these disturbances can be attributed to differential regulation of 
nuclear envelope related proteins and the nuclear pore complex proteins i.e. TPR, NUP210, 
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SUN1/2, NUTF2, and EMD including VAPB (Fig. 4.12). Other TEM findings include elongated ER 
particularly in the perinuclear region (Fig. 4.13 B, C), abnormal lysosomes and autophagic 
vacuoles (Fig. 4.13 D). To support this, the proteomics data revealed altered levels of ~28% ER-
membrane proteins, implying that these are potential targets of the SIL1-BiP protein folding 
complex 168. Whereas, increased levels of ubiquitin hydrolases e.g. UCHL3, USP5 and proteases 
e.g. LAP3, CTSD indicate activation of lysosome-associated autophagy. Notably, CTSD is involved 
in the pathogenesis of several disorders including the Alzheimer’s disease 168. 
 
Figure 4.13: TEM data in (A) scrambled transfected HEK293 cells showing normal organelle morphology. Scale 
bar=1.0 μm. Whereas, ∆SIL1 HEK293 cells showed (B) elongated ER structures, abnormal mitochondria (blue 
arrow), lysosomes (white arrows), and altered nuclear morphology (black arrow). Scale bar=0.25 μm. Further, (C) 
widened rER (large black arrow) and altered nuclear envelope (black arrow in inset) were also detected. 
Mitochondrion damage is indicated with an osmiophilic membrane (blue arrow in inset) and prominent Golgi-
cisterns (black arrowhead). Scale bar=1.0 μm. Lastly, (D) Lysosomal/autophagic material (white arrows) in the 
perinuclear cytoplasm and an osmiophilic inclusion in the nuclear envelope (black arrows) were found. Scale 
bar=0.5 μm. Figure adapted from 168. 
Based on these subcellular organelle perturbations, it was evident that the ER-stress induced 
UPR pathway has been triggered. Therefore, altered regulation of the UPR-related proteins was 
verified in the label-free analysis and further validated by the targeted PRM-based assay 116 (see 
Sections 3.2.13 and 3.2.15.3). These results suggest that the overall protein synthesis is reduced 
owing to (i) a decrease of transcription assisting factors: POU2F1, PURA, SNRPA, TRA2B, (ii) an 
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increase of the repressors: HRSP12 and PPP1R8, (iii) a decrease of IGF2BP1 and 2 that are 
involved in the transport and transient storage of mRNA and of the translational activator - 
GCN1L1 and (iv) reduced levels of the translocon proteins: SEC63, SSR1, SSR4 and MAP1B (Figs. 
4.12 and 4.14 A). Additionally, the eukaryotic translation initiation factor 3 (EIF3) complex is 
required for disassembly of ribosomes, upregulation of its subunits A, C, F, G, H, I, L and M (Fig. 
4.12) is consistent with the translational inhibition. Besides, increased abundances of certain 
transcription and translation factors, such as PAF1, TCEA1, EEF1G, and EEF1D (Fig. 4.12) are a 
hallmark of the UPR pathway and correspond to the induction of stress related factors 172. 
Further, targeted-PRM assay results showed increased levels of the UPR-pathway assisting 
factors i.e. BiP, GRP75, GRP94, GRP170, PDI and CALR (Figs. 4.14 A). This data is in good 
correlation with the WB analysis (4.14 B). 
 
Figure 4.14: Biochemical findings in scrambled transfected and SIL1-depleted HEK293 cells. (A) PRM-based 
targeted-MS analysis showed increase of UPR assisting factors including: GRP75 (~120%), BiP (~40%), GRP94 
(~50%), GRP170 (~100%), PDI (~60%), CALR (~80%), SEC31a (~80%), and SRP-α (~70%). Also in agreement with UPR 
activation, translocon proteins SEC61a (~40 %) and SEC62 (~20%) were decreased. Moreover, elevated levels of 
VCP (~100%) and DJ-1 (~250%) were indicative for ERAD activation. (B) The targeted-MS data was supported by the 
WB studies that reveal the activation of the UPR pathway due to the ER stress and protein clearance in SIL1-
depleted compared to scrambled transfected HEK293 cells. Figure adapted from 168. 
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 Characterization of human myoblastic cell line - RCMH 4.6
As myopathy is one of the clinical hallmarks of MSS and due to limited availability of the muscle 
biopsies from these patients; a human myoblastic cell line e.g. RCMH would be an ideal choice 
for (i) studying physiological processes, (ii) discovering pathological processes and (iii) 
developing novel cell-based therapies for muscular disorders 173. High-pH (6.0) RP fractionation 
of the tryptic peptides generated from the RCMH cells followed by LC-MS analysis and database 
searches of all 16 MS raw files led to the identification of 6,244 proteins with a FDR of ≤ 1% on 
the PSM, peptide, and protein level. Notably, the subsequent calculation of the NSAF values 
(see Section 3.2.15.2.2) of these proteins yielded a range of more than four orders of magnitude 
between the most abundant protein actin (ACTG1) and the ryanodine receptor 3 (RYR3). 
According to the UniProtKB: 2,132 proteins are localized in the cytoplasm (398 cytoskeletal), 
1,957 in the nucleus, 500 in mitochondria, 355 in the ER, 264 in the Golgi and 69 in lysosomes, 
whereas 169 proteins are secreted. The obtained NSAF values were then compared with two 
other cell types with well-characterized proteomes namely, HeLa and U2OS in order to identify 
an up-/downregulation of certain pathways and biological functions in RCMH cells and to 
deduce a more functional picture. For this, MS raw data from Guo et al., (HeLa) 174 and Beck et 
al., (U2OS) 175 were downloaded from PRIDE 176 repository and re-searched with the same 
software and settings as used for the RCMH data. This led to the identification of 6,304 proteins 
in HeLa and 7,158 proteins in U2OS compared to the 6,244 proteins in RCMH. Notably, these 
cell lines were selected owing to the still sparse availability of comprehensive high quality 
datasets for human cell lines. 
To classify the composition of these three apparently different proteomes, all the identified 
proteins in each dataset were analyzed for an enrichment of GO terms using the Ontologizer 
software 177 compared to the human UniProt database (downloaded on 11th of December 2013, 
containing 20,273 target sequences). Indeed, this analysis did not show major differences 
between RCMH and other cell types. This can be hypothesized as a possible consequence of the 
undifferentiated stage of the RCMH cell line in the culture conditions utilized, which favor 
proliferation rather than fusion and myotube formation in vitro 178. Moreover, this 
demonstrates a limitation of the general way the GO enrichment analyses are performed, as 
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these merely take into account the presence of proteins in lists rather than the actual 
expression levels, which are present in the used quantitative proteomics data. Consequently, as 
long as similar numbers of proteins for a given GO term are detected in two different cell types, 
they produce similar results, even if the respective proteins are considerably higher expressed in 
one of the two cell types. Therefore, only a subset of GO terms with respect to the origin of 
these cells that play a role in muscle function or are involved in myopathic disorders were 
considered and the NSAF values of the corresponding proteins were extracted in each sample 
set i.e. cytoskeleton (GO:0005856), proteasome complex (GO:0000502), striated muscle 
(combination of adaptation (GO:0014888), atrophy (GO:0014891), cell development 
(GO:0055002), nuclear part (GO:0044428), plasma membrane (GO:0005886), mitochondrion 
(GO:0005739), regulation of response to stress (GO:0080134), muscle cell development 
(GO:0055001), metabolic process (GO:0008152), endoplasmic reticulum (GO:0005783), Golgi 
apparatus (GO:0005794), neuromuscular process (GO:0050905), and autophagy (GO:0006914). 
Next, for each GO term and sample set, the number of corresponding proteins was determined 
and the sums of their NSAF values were calculated as well as the average NSAF (NSAF sum 
divided by number of proteins), which reflects the relative expression of the particular GO term 
for a representative comparison of the different proteomes. Thus, the differences in the 
expression patterns of RCMH, HeLa and U2OS became apparent for instance, proteins 
corresponding to striated muscle are clearly more abundant in RCMH than in U2OS and HeLa 
and the same holds true for proteins involved in muscle cell development. Furthermore, the 
expression levels of proteins related to the neuromuscular process are marginally higher in 
RCMH compared to HeLa, but remained nearly the same in U2OS (see Table 4.3).  
Identification of cytoskeletal components responsible for contraction can be considered as a 
rationale in the discovery of a suitable cell model for in vitro muscle investigations. The levels of 
actin and myosin - the chief structural proteins, were higher in RCMH cells compared to HeLa 
and U2OS. For instance, the NSAF value (normalized to GAPDH NSAF value) of actin, cytoplasmic 
1 (ACTB) was 3.6-fold and 2.1-fold higher in RCMH compared to HeLa and U2OS, respectively. 
Whereas, the abundances of different unconventional myosin light and heavy chains (including 
12 different unconventional myosins, 3 tropomyosins and myosin phosphatase Rho interacting 
protein) were more in RCMH compared to HeLa (~5-fold higher) and U2OS (~1.5-fold higher). 
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Table 4.3: Comparison of GO term expression levels between RCMH, HeLa and U2OS cells based on both NSAF sum 
and NSAF average. 
GO Term sum 
RCMH/HeLa 
average 
RCMH/HeLa 
sum 
RCMH/U2OS 
average 
RCMH/U2OS 
cytoskeleton 0.96 0.97 1.14 1.29 
proteasome complex 0.85 0.86 0.97 1.01 
striated muscle 1.54 1.21 1.47 1.54 
nuclear part 0.97 0.99 0.99 1.12 
plasma membrane 1.03 0.98 1.10 1.23 
mitochondrion 0.77 0.91 0.92 1.11 
regulation of response to stress 1.02 0.75 1.06 0.83 
muscle cell development 1.95 1.61 1.70 1.58 
metabolic process 0.91 0.92 0.98 1.10 
endoplasmic reticulum 0.98 1.00 1.14 1.29 
Golgi apparatus 1.07 1.05 1.04 1.06 
neuromuscular process 1.24 1.50 0.82 0.95 
autophagy 0.95 0.96 0.61 0.63 
 
Besides actin and myosin, expression of other cytoskeletal components e.g. desmin (DES) and 
titin (TTN) was also identified in in vitro muscle studies 179. In RCMH cell line, desmin is among 
the 100 most abundant proteins, which was not identified in other two cell lines. Furthermore, 
proteins that are involved in (i) maintaining stability of the cytoskeleton, such as α- and β-
spectrins (~4.4 and 6.4-fold higher than in HeLa, same in U2OS), (ii) anchoring of other cytosolic 
proteins e.g. filamins (actin-binding proteins) and the respective assembly promoting proteins 
i.e. α-, β- and γ-adducin (~9.2-fold higher than in HeLa, same in U2OS) including dystrophin 
(DMD) (~8-fold higher than in HeLa, same in U2OS) were detected in RCMH. These proteins are 
known to modulate mechanotransducer action - an important process that helps muscle fibers 
to cope with mechanical stress 180. In mammalian muscle cell, DMD connects cytoskeletal actin 
via the dystroglycan complex (DGC) to laminin (LAMB1) localized in the extracellular matrix. 
Apart from dystrophin, other components of DGC e.g. dystroglycan (DAG1; expression highest in 
RCMH), β-sarcoglycan (SGCB; ~9.2-fold higher than in HeLa, not detected in U2OS), Δ-
sarcoglycan (SGCD; only detected in RCMH), α-1-syntrophin (SNTA1; ~16-fold higher than in 
HeLa, not detected in U2OS), β-1-syntrophin (SNTB1; only detected in RCMH), β-2-syntrophin 
(SNTB2; highest expression in RCMH), and dystrobrevin beta (DTNB; 33-fold higher in RCMH 
than in HeLa, not detected in U2OS). Notably, some of these proteins have been reported to be 
involved in various types of myopathies e.g. mutations in DMD cause Duchenne muscular 
Results  101 
 
dystrophy [OMIM: 310200] - a muscle wasting disease mainly affecting young adult males 181. 
Additionally, RCMH proteome also includes NOS3 (not found in HeLa and U2OS), the endothelial 
isoform of the nitric oxide synthase as well as DGC assisting factors like ankyrin-3 (ANK3), which 
are required for costamere localization of dystrophin and DAG1 182. 
As seen in woozy mice and human index patient muscle datasets, the dysfunctional or damaged 
mitochondria can severely perturb metabolic processes leading to muscular disorders. 
Therefore, expression of the known mitochondrial proteins including succinate dehydrogenase 
subunits e.g. SDHA, SDHB, SDHC, and of SDHAF2 as well as of the cytochrome c oxidase subunits 
e.g. COA3, COX5A, COX6B1, COX6C, COX7A2L, COX17 and TACO1 in RCMH suggests that these 
cells are a suitable model for investigating metabolic processes in muscle. Interestingly, the 
expression levels of all succinate dehydrogenase subunits were higher in RCMH compared to 
HeLa, but remained the same in U2OS. The same trend was observed in the case of cytochrome 
c oxidase subunits. It is evident that the ER-stress caused due to the alterations in the protein 
folding machinery invariably triggers the cellular defense mechanisms, particularly the UPR and 
ERAD. Expression of proteins which belong to these pathways e.g. ATF6, HSPA5 (BiP), CALR, 
CANX, DNAJB6, EDEM2 and 3, EIF2AK3 (PERK), ERN1 (IRE1), HSPA1A, HYOU1 (GRP170), P4HB, 
SIL1 and UGGT (see Table 4.4) in RCMH suggests that this cell line can be used to investigate 
muscle-related pathophysiological processes.  
Table 4.4: NSAF value-based comparison of proteins that are part of the UPR, ERAD pathways and nuclear envelope 
integrity (NEI) between RCMH, HeLa and U2OS cells; (ND = not detected). 
Protein Gene NSAF 
RCMH/HeLa 
NSAF 
RCMH/U2OS 
Function 
Cyclic AMP-dependent transcription factor ATF-6 alpha  ATF6 ND ND UPR 
78 kDa glucose-regulated protein  HSPA5  1.4 1.8 UPR, ERAD, NEI 
Calreticulin  CALR 1.5 1.4 UPR 
Calnexin  CANX 1.3 1.5 UPR, NEI 
DnaJ homolog subfamily B member 6  DNAJB6 6.9 1.3 ERAD 
ER degradation-enhancing alpha-mannosidase-like protein 2  EDEM2 ND 1.3 UPR 
ER degradation-enhancing alpha-mannosidase-like protein 3  EDEM3 1.9 2.2 UPR 
Eukaryotic translation initiation factor 2-alpha kinase 3  EIF2AK3  24.5 ND UPR 
Serine/threonine-protein kinase/endoribonuclease IRE1  ERN1  ND 4.6 UPR 
Heat shock 70 kDa protein 1A/1B  HSPA1A 0.9 0.5 ERAD 
Hypoxia up-regulated protein 1  HYOU1  1.7 0.9 UPR 
Protein disulfide-isomerase  P4HB  1.1 1.6 UPR 
Nucleotide exchange factor SIL1  SIL1 4.1 2.6 UPR, ERAD, NEI 
UDP-glucose:glycoprotein glucosyltransferase 1  UGGT 1.7 0.5 UPR 
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Notably, all three major transducers of the UPR pathway i.e. ATF6, EIF2AK3 and ERN1 were 
identified in RCMH, but ATF6 was not detected in other two cell lines. Whereas, EIF2AK3 was 
not detected in U2OS and ERN1 was not identified in HeLa. Another aspect related to muscle 
physiology is the excitation-contraction-coupling (EC-coupling), whereby the electrical impulse 
(excitation) from the neuron is converted into a mechanical response (contraction) at the 
neuromuscular junction. In skeletal muscle, EC-coupling relies on a direct connection between 
the ryanodine receptor (RYR), a sarcoplasmic reticulum Ca2+ release channel and 
dihydropyridine receptors (DHPRs), acting as voltage-gated L-type Ca2+ channels 183. DHPRs are 
located on the sarcolemma (i.e. cell membrane of muscle cells), which also comprises the 
transverse tubules (i.e. invaginations of the sarcolemma). When an action potential (electrical 
impulse) is generated and propagated across the sarcolemma, it depolarizes the sarcolemma 
resulting in an increase of cytosolic Ca2+ concentration, which leads to muscle contraction in a 
Ca2+ dependent manner. In RCMH cells, expression of RYR and DHPR (QDPR) has been reported 
earlier 184. In line with these findings, expression of Ca2+ associated proteins, such as ATP2A2, 
ATP2B1, ATP2B4, CACNA1S, ESYT1, ESYT2, KCNMA1, CAMK2D, CAMK2G and CHERP were 
detected in RCMH. Besides, CALM1, CALU, and STIM1 were also identified.  Notably, 
accumulation of the latter proteins was linked with muscle fiber degeneration in neurogenic 
muscular atrophies, in which EC-coupling is altered due to neuronal dysfunction 185. Moreover, 
the identified α- and β- chains of spectrin (SPTAN1, SPTBN1) interact with CALM in a Ca2+ 
dependent manner and play an important for muscle contraction 186. 
Additionally, morphological studies on RCMH cells (cultured for 24 hours) were performed using 
scanning electron microscopy (SEM) and TEM (data not shown). The SEM studies revealed 
spread cells that exhibit cytoplasmic extensions. These microscopic protrusions of the plasma 
membrane not only increase the cell surface, but are also responsible for cellular 
communication and mechanotransduction. TEM studies confirmed the presence of cytoplasmic 
extensions and revealed prominent ribosome dense sarco-/endoplasmic reticulum networks. 
This morphological finding is in line with the expression of > 300 sarcoplasmic reticulum-
associated proteins identified by proteomics analysis 173. 
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5 Discussion and conclusions 
In this work, proteomic investigation of the Marinesco-Sjögren Syndrome (MSS) by MS-based 
quantitative approaches was performed to better understand the pathophysiology of this 
disorder. For this, unaffected (i.e. five different MSS cases; SIL1 non-vulnerable) and affected 
(i.e. woozy mouse; SIL1 vulnerable) tissues were studied (using iTRAQ) to gain insights into the 
role of SIL1 in BiP-mediated protein folding process in the ER. Additionally, characterization of in 
vitro models (i.e. HEK293-∆SIL1 and RCMH) was done to evaluate their suitability for studying 
neurodegenerative and neuromuscular disorders. Furthermore, sample preparation induced 
artificial modification (i.e. carbamylation of proteins/peptides) that might hinder labeling 
procedures (e.g. iTRAQ) and affect quantification accuracy, was studied in detail. 
 In vitro protein carbamylation - a potential unwanted artefact 5.1
Initially, urea was added to the digestion buffer (final concentration of 1.0 M, overnight 
incubation at 37°C) for processing the human fibroblasts (MSS2 study). Notably, the share of 
carbamylated PSMs identified (at 1% FDR) in the respective iTRAQ 4-plex dataset was found to 
be < 1% (data not shown). Although the number of carbamylated PSMs was relatively low, it 
gave a hint that there might be a possibility to introduce this artefact under certain conditions 
involving urea during sample preparation. Hence, as urea is the most frequently used organic 
compound in majority of the sample preparation protocols (e.g. FASP) for both qualitative and 
quantitative proteomics analyses, a systematic study was performed using a pool of peptide 
mixtures generated from five model proteins. The degree of carbamylation reaction at the N-
termini and epsilon amino group of Lys residues varied depending on the concentration of urea, 
exposure time with urea and heat. For instance, aqueous alkaline buffer solutions containing 
proteins or peptides together with urea at high concentrations (8.0 M) when heated at 
temperatures > 37°C for shorter time period (i.e. 30 min) resulted in ~13% of carbamylation. 
Whereas, at relatively low concentration i.e. 2.0 M, but longer incubation times at 37°C lead to 
almost 23% of carbamylation of N-termini. However, when a complex cell lysate (fibroblasts) 
was subjected to enzymatic proteolysis in presence of 2.0 M urea and 22 h of incubation at 37°C 
120, carbamylation of < 0.3% of the identified peptides was detected, which is indeed below the 
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applied FDR of ≤ 1% and thus not significant. Moreover, there were no differences detected 
between the urea-based and urea-free samples. While this is in contrast to the results above, it 
can be most likely attributed to two major reasons. Firstly, undersampling due to performing 
the MS analysis in a DDA mode of complex proteomes 187 will reduce the number of 
carbamylated peptides, since for each of the 100,000s of peptides in the complex digest, only a 
negligible number of the present copies are actually carbamylated. Secondly, since the N-
termini have a higher reactivity for carbamylation than Lys residues - this can cause an 
overestimation of carbamylated peptides in the already pre-digested reference sample in 
comparison to the fibroblast digest, in which new N-termini still have to be generated during 
the enzymatic digestion 122. 
Nevertheless, the peptide mixtures data demonstrate that the usage of urea results in in vitro 
carbamylation with N-termini being the most susceptible followed by Lys residues, whereas 
carbamylation of Arg residues is spared under commonly used sample processing conditions. 
Therefore, for the experiments following the MSS fibroblasts iTRAQ 4-plex study, urea-
containing buffers were freshly prepared and their usage was restricted only to eliminate the 
SDS from the samples using the FASP protocol (see Section 3.2.6). The remaining steps, such as 
carbamidomethylation (heating samples at 56°C for 30 min, see Section 3.2.5) and proteolytic 
digestion (overnight incubation at 37°C), were performed in the absence of urea. For the latter 
step, GuHCl was used as an alternate chaotrope to facilitate trypsin digestion. 
 Optimized sample preparation for quantification of SIL1 5.2
Despite its important role in the protein folding process, SIL1 is apparently present in relatively 
low abundance compared to GRP170 and BiP in different eukaryotic cell lines/types (Fig. 5.1). 
Therefore, in order to relatively quantify such a low-stoichiometric protein, robust sample 
preparation workflows must be employed that can provide reliable results. In recent years, 
several sample preparation techniques emerged with the advent of MS-based proteomics that 
primarily focused on removing chemicals that interfere with proteolysis and downstream LC-MS 
analysis. These mainly include in gel, in solution and filer-based (e.g. FASP) digestion protocols. 
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Figure 5.1: Comparison between the relative molar concentration of SIL1, GRP170 and BiP in different human (i) cell lines i.e. 
RCMH, fibroblasts, LCs, HEK293, glioblastoma (A-172), HeLa and (ii) cell types i.e. thrombocytes (platelets), megakaryocytes, B 
cells (B lymphocytes). The molar concentrations of SIL1 and BiP are normalized with respect with GRP170. The numbers are 
based on the NSAF values that were generated from the label-free MS data of each cell line/type.         
Among those, the FASP technique has grown rapid popularity owing to its effectiveness in 
removing strong detergents (e.g. SDS) and tolerant to high concentrations of chaotropic agents 
(e.g. 8.0 M urea), which are frequently used to solubilize mainly membrane proteins. Moreover, 
FASP allows ease in sample handling and yields better proteome sequence coverages 120. 
Furthermore, iTRAQ labeling (8-plex) indeed improved the sensitivity of the analysis (owing to 
multiplexing) and in conjunction with high pH-RP fractionation (Fig. 5.2) provided relative 
quantification of 4,858 proteins with ≥ 2 unique peptides in the MSS-LCs dataset. Compared to 
the detection and quantification rates of other proteomics studies using LCs, this is the most 
comprehensive proteome profile of human LCs achieved so far 188. Besides, chemical labeling (4- 
and 8-plex) and offline fractionation strategies (OFFGEL-IEF and RP at pH 6.0) followed by LC-MS 
analysis enabled relative quantification of the low-abundant SIL1 in MSS-fibroblasts and MSS-
LCs datasets (Figs. 4.4 and 4.6 A). However, as shown in the Figure 5.1, the relative molar ratio 
of other NEF to BiP i.e. GRP170 is nearly 10-fold higher, which in fact is also constant across all 
cell lines. Therefore, even if loss of SIL1 leads to increase in a NEF that is 10 times more 
abundant, the current accuracy of the quantitation strategies (e.g. iTRAQ) might be insufficient 
to verify this with high confidence. To achieve this, AQUA (absolute quantification) 189 strategy 
can be employed wherein, stable isotope labeled (SIL) peptides as internal standards are used 
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i.e. adding a known amount of SIL 
counterpart of an endogenous peptide 
prior to LC-MS analysis.   
Furthermore, AQUA can also be 
combined with targeted-MS methods 
e.g. PRM for sensitive and accurate 
quantification of proteins 100 including 
the low abundant ones such as SIL1. 
Whereas in woozy tissues i.e. 
cerebellum and skeletal muscles, Sil1 
could not be not detected. Despite 
using the same workflow, the total 
number of quantified proteins in these 
two datasets (3,580 and 2,055, 
respectively) was relatively low 
compared to the primary cell lines data 
(4,858 proteins in MSS-LCs). The 
obvious reason for this difference is that 
the tissues are typically composed of 
multiple cell types and tend to be more 
complex with wide dynamic range of 
protein concentrations as opposed to 
the cell lines that comprise 
predominantly a single cell population. 
Therefore, direct analysis of crude 
tissue samples is complicated by the 
presence of abundant proteins which 
usually mask the low abundant 
candidates. This holds true particularly in woozy skeletal muscle data in which actin and myosin 
and their isoforms account for nearly one-third (34%) of quantified proteins. In order to 
Figure 5.2: Bottom-up proteomics workflow involving FASP, 
iTRAQ 8-plex labeling, high-/low pH RP-RP chromatography 
and MS analysis. Fragment ion spectra of a SIL1 peptide 
depicting the reporter ions indicative of its relative 
abundances across eight different samples.  
Discussion  107 
 
minimize the tissue complexity, protocols that are based on the subcellular organelle 
fractionation were developed to isolate for instance: nuclear, cytosolic, mitochondrial, ER 
compartments 190. This approach in combination with chemical labeling (e.g. iTRAQ) has been 
reported to not only increase the proteome coverage of tissues, but also to quantify low 
abundant proteins that are located in specific organelles 191. 
 SIL1 loss - impact on unaffected cell types and compensatory mechanisms 5.3
Since SIL1/Sil1 was identified as the pathogenic factor for MSS and woozy mouse phenotype 34c, 
41b, 42, several studies showed that mutations of this gene cause neurodegeneration and 
myopathic changes in man and woozy mouse 41a, 47, 192. However, the TEM findings (Fig. 4.3) 
revealed morphological alterations due to loss of SIL1, suggesting subclinical vulnerability in 
clinically unaffected tissues. Therefore, proteomics was used as a tool to verify these changes in 
the SIL1 non-vulnerable cell types (i.e. fibroblasts and LCs) and to understand the unknown 
rescue mechanisms that might be responsible for their survival. An iTRAQ-based quantification 
strategy revealed differential regulation of ~4.5% and ~2.3% of the total quantified proteins (i.e. 
2,993 and 4,858) in MSS derived fibroblasts and LCs, respectively compared to their healthy 
controls. Notably, the share of altered proteins was little i.e. only seven candidates were found 
commonly regulated in both cell types (Fig. 5.3).  
 
Figure 5.3: On left, Venn-diagram depicting the overlap of differentially regulated proteins obtained from MSS fibroblasts and 
LCs iTRAQ datasets. Five out of seven commonly quantified proteins showed regulation in similar direction (on right). The Venn-
diagram was created with http://bioinformatics.psb.ugent.be/webtools/Venn/. 
Among these, five proteins including SIL1 showed regulation in the same direction. Besides SIL1, 
in both cell types, D-3-phosphoglycerate dehydrogenase (PHGDH) was also downregulated. 
PHGDH has been linked to cerebellar ataxia, cataracts and mild psychomotor retardation 193, 
Discussion  108 
 
which are the characteristic phenotypes of MSS (see Figure 1.3). The reasons for such a minimal 
overlap of proteins (i.e. seven) between the two cell types can (i) be partly explained by the 
assumption that distinct genes are expressed in different cell populations and (ii) due to the 
intra-/interpatient biological variability between different MSS cases i.e. MSS2 (fibroblasts), 
MSS24, MSS32, MSS33, and MSS94 (all LCs). However, the abundances of BiP and GRP170 in 
both datasets were not significantly higher (see Sections 4.2.1 and 4.2.2) as expected since 
increased levels of the latter has been suggested as one of the compensatory mechanisms for 
the absence of SIL1 in man and mouse. One plausible explanation is that GRP170 and SIL1 might 
have redundant functions in certain cell types and thus GRP170 may act as an alternative NEF of 
BiP in the protein folding process 47, 194. Recently, Ichhaporia et al., 195 reported that the role of 
SIL1/Sil1 as unnecessary in BiP-mediated antibody (immunoglobulin, Ig) production and their 
secretion in MSS patients (EBV-LCs) and woozy mice. Further, they even pointed out that 
overexpression of GRP170 was not seen in the SIL1-deficient mutants and the levels of 
antibodies remained unchanged when compared to their respective healthy controls. 
Surprisingly, in the MSS-LCs proteomics dataset, a negligible number of Ig-related proteins (i.e. 
only seven) were quantified and their relative abundances did not pass the criteria for 
differentially regulated proteins. The exact reason for such low identifications of 
immunoglobulins in the iTRAQ dataset is unclear, but the relatively stable level of GRP170 
(MSS/Healthy ratio of 0.8) is in line with the findings of Ichhaporia et al. 
Nevertheless, the loss of SIL1 indeed showed an effect on these apparently MSS non-vulnerable 
cell populations and this was observed in the proteomics data as well as in the morphological 
findings (Fig. 4.7 C-E), suggesting that functional SIL1 is important for maintaining overall cellular 
integrity. In case of MSS-fibroblasts study, upregulation of HMOX1, HSPB6 and UCHL1 indicate 
an activation of the UPR pathway induced by the ER stress most likely caused due to the 
aggregation of un-/misfolded proteins within the ER lumen. Furthermore, altered levels of 
proteins that belong to the major subcellular compartments including the ER, the mitochondria 
and the nucleus were detected in MSS-LCs. The ER and mitochondria form physical interactions 
involved in the regulation of mitochondrial energetics and apoptotic signaling cascades and it is 
becoming increasingly clear that the ER stress can also modulate mitochondrial protein 
homeostasis (or proteostasis) and function 196. 
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In MSS-LCs dataset, increased abundances of CYCS and AIFM2 - both mitochondrial apoptosis 
promoting proteins and decreased levels of CPT1A, MTRF1L, TOM1L2 and TXNRD2 indicate a 
mitochondrial vulnerability due to SIL1 loss, which was already described in phenotypically 
affected tissues thus demonstrating an important interdependence of cellular SIL1 level and 
mitochondrial function. Besides, disturbances in the cytoskeletal organization were also 
detected in the MSS-LCs and moreover, initiation of the UPR and/or apoptotic pathways (for the 
establishment of homeostasis/cell death) was evident by the upregulation of ANKRD13A, UEVLD 
and CTSB. However, upregulation of the pro-survival proteins, such as ACADSB, GPX4, PRDX5, 
ATXN10 and LGALS1 could be responsible for the survival of MSS-LCs, which can be attributed to 
the impaired SIL1-BiP protein folding process. 
 Woozy mouse - comparable to MSS patients 5.4
Slightly over a decade ago, Zhao and colleagues 34c described the animal model of MSS i.e. 
woozy mouse and since then it has been regarded as the broad phenocopy of human MSS 35. 
Recently, Roos and co-workers 35 performed longitudinal studies on skeletal muscles derived 
from woozy to investigate the pathophysiology of Sil1 loss. Their findings showed prominent 
myopathic changes that progressed from mild to severe alterations in an age-dependent 
manner indicating the critical role of Sil1 in maintaining the skeletal muscle integrity. 
On the proteome level, disturbances in different subcellular compartments most likely caused 
by the ER-stress were observed in both affected tissues i.e. cerebellum and skeletal muscles 
(see Sections 4.3.1 and 4.3.2). Remarkably, altered levels of several Ca2+-associated proteins 
that are involved in maintaining cellular Ca2+ homeostasis, and proteins involved in the 
cytoskeletal organization were detected suggesting the impact of Sil1-loss and subsequent 
accumulation of un-/misfolded proteins leading to tissue damage. 
In woozy cerebella, degeneration of the Purkinje cells accompanied by cerebral ataxia has been 
related with early onset of neurodegeneration in the mutant animals 34c. Low abundances of 
Calb1, Prkcg and Grid2ip, which are involved in the development and proper functioning of this 
neuronal cell population, suggest that the Purkinje cells seem to be particularly sensitive to 
fluxes in intracellular calcium levels that could result from reduction of chaperone activity and 
the ER stress 197. Nevertheless, upregulation of pro-survival protein i.e. Kit and proteins that are 
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involved in antagonizing oxidative damage including Naprt and Pdrxn6 indicate that the other 
cerebellar cell populations might counteract the prolonged ER stress and its associated 
problems, including loss of calcium homeostasis. In case of woozy skeletal muscle, the cellular 
perturbations due to the absence of Sil1 were more prominent, which was evident by the 
upregulation of nearly 83% of the differentially altered proteins. Activation of the UPR pathway, 
most likely as a consequence of Sil1 loss was seen by the increased abundances Hspa5, Canx 
and Pdia6. Notably, upregulation of Lgals3, Eef1a1 and Manf - proteins that are involved in the 
pro-survival and protective mechanisms, particularly in the ER-stress conditions suggest an 
activation of the rescue processes even in Sil1-vulnerable tissues of the woozy. 
 Preliminary insights into index patient muscle pathophysiology  5.5
Proteomics analysis of the muscle specimen derived from an index patient who manifested 
neurodegenerative and myopathic abnormalities revealed increased levels of several 
cytoskeletal proteins. There is a good amount of evidence that muscle weakness can be a 
consequence of gene mutations on certain cytoskeletal proteins that cause myofibrillar and 
myosin storage myopathies that disrupt the function of skeletal and cardiac muscles 198. In most 
cases, various muscle proteins form aggregates that prevent these proteins from functioning 
normally in the myofibrils of the affected individuals. Therefore, based on the proteomics data it 
can be assumed that the index patient might have suffered from an idiopathic myopathy. 
 In vitro cell lines - suitable to study neuromuscular disorders 5.6
In vitro models (immortalized and non-immortalized) are extremely helpful to study human 
diseases because they allow to analyze different cell types independently from each other and 
to perform dynamic studies e.g. test treatments on isolated cells. Here, the human immortalized 
embryonic kidney cell cultures i.e. HEK293 were selected for depleting SIL1 and to subsequently 
investigate more closely the overall cellular disturbances upon SIL1-loss. Further, the HEK293 
cells have been reported to exhibit a wide variety of differentiations including: neural crest cells, 
neurons and glia (of myelin sheath). In fact, HEK293 cells (i) show characteristics of immature 
neurons with expression of neuron-specific proteins 199, (ii) were classified as a highly efficient 
screening tool for the drug development in neurological diseases 200 and to study 
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neurodegenerative disorders 201. Therefore, HEK293 cells were deemed fit for the generation of 
an in vitro model for MSS. The proteomics data indeed showed marked cellular perturbations in 
various subcellular organelles and their functions caused due to the absence of SIL1 (Fig. 4.12). 
These observed changes were in accordance with the findings detected in the proteomic 
profiling of MSS-fibroblasts and LCs. Therefore, SIL1-depleted HEK293 cells provided a better 
understanding of the cellular role of SIL1 in ER-associated protein processing and in 
manifestation and progression of neurodegenerative disorders e.g. MSS 168. Furthermore, using 
the same cell line (i.e. HEK293-∆SIL1), a PRM-based targeted MS method was established for a 
subset of proteins that are involved in the UPR pathway. In general, this method can be used 
not only to assay, but also to relatively quantify the UPR-associated proteins in different 
biological (human) samples wherein the activation of this pathway needs to be monitored. 
Notably, the assay can be performed using a single shot LC-MS/MS analysis on a MS with SRM 
or PRM capability e.g. Q Exactive MS. 
Next, a detailed proteome characterization of the human immortal RCMH myoblastic cell line 
was performed to evaluate its suitability as an in vitro model for studying myopathies and 
neuromuscular related disorders since most research groups currently utilize an extensively 
characterized mouse myoblastic C2C12 cells for their investigations 173. Proteome profiling of 
RCMH cells confirm the known expression of proteins important for muscle function. Moreover, 
comparison of the estimated protein abundances with two different proteomes (i.e. HeLa and 
U2OS), revealed that proteins related to special properties of muscle function are considerably 
enriched in RCMH (Table 4.3). 
To conclude, this work demonstrates a detailed proteomic investigation of Marinesco-Sjögren 
Syndrome - a debilitating multi-system disorder caused by the impaired protein folding process. 
These findings highlight that the loss of functional SIL1 - even in clinically non-affected tissues of 
MSS patients, results in morphological perturbations that can be associated with altered protein 
folding machinery. Further, proteomics data revealed abnormal cytoskeletal and mitochondrial 
integrity, activation of antagonistic apoptotic and pro-survival mechanisms as well as altered 
expression of proteins necessary for function and maintenance of skeletal muscle fibers and 
neurons. Moreover, the quantitative proteomics data of the Sil1-deficient woozy mice tissues 
has (i) improved the knowledge about proteins that are involved in the altered pathways of the 
Discussion  112 
 
damaged/degenerated cells, (ii) enhanced the commonality of phenotypic manifestations 
between MSS and woozy mouse due to the absence of SIL1/Sil1 and (iii) also led to the 
identification of some interesting candidates, which might act as pro-survival factors due to loss 
of functional SIL1 that have not been previously reported. Lastly, proteomic profiling of the 
human in vitro cell lines i.e. (i) HEK293-∆SIL1 has provided deeper insights into the role of SIL1 in 
MSS pathophysiology and (ii) enabled to establish RCMH as a suitable model to investigate 
processes related to muscle function e.g. mechanical stress burden and mechanotransduction, 
EC-coupling and other ER-associated myopathic disorders. 
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10 Appendices 
 Instruments and LC-MS parameters used - CID fragmentation  10.1
Instrument/Setup Settings/Parameters 
Experiment name 
Protein carbamylation 
(Peptide mixtures) 
Protein carbamylation 
(2-step digest, Fibroblasts) 
Human myoblastic RCMH; 
label-free 
LC-MS   U3000 nRSLC-LTQ Orbitrap XL U3000 HPLC-LTQ Orbitrap Velos U3000 nRSLC-Orbitrap Elite 
HPLC 
Column type, length Commercial, 15 cm Commercial, 50 cm Commercial, 50 cm 
Gradient 5-50% B in 50 min 3-42% B in 120 min 3-42% B in 187 min 
MS 
Polarity Positive Positive Positive 
Data acquisition mode, Top N DDA, Top 5 DDA, Top 15 DDA, Top 15 
Scan range (m/z) 300 - 2,000 300 - 1,500 300 - 1,500 
Resolution (FWHM)       
Full MS scan (Orbitrap) 60,000 at m/z 400 60,000 at m/z 400 60,000 at m/z 400 
MS/MS scan (Ion trap) 0.7 u 0.45 u 0.45 u 
Automated gain control (AGC) target values       
Full MS  5 x 105 1 x 106 1 x 106 
MS/MS 1 x 104 1 x 104 1 x 104 
Maximum ion injection times (ms)       
Full MS  500 100 100 
MS/MS  200 100 100 
Fragmentation type CID CID CID 
Precursor isolation width (m/z) 2.0 2.0 2.0 
Dynamic exclusion duration (s) 10 30 30 
Normalized collision energy (%) 35 35 35 
Activation time (ms) 30 10 10 
Lock mass - polysiloxane ion (m/z) 371.101236 371.101236 371.101236 
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 Instruments and LC-MS parameters used - HCD fragmentation 10.2
 
 
 
 
Instrument/Setup Settings/Parameters 
Experiment name 
Human EBV-LCs and Mice cerebella; 
iTRAQ 8-plex 
Human skeletal muscles; 
label-free 
LC-MS   U3000 HPLC-LTQ Orbitrap Velos U3000 nRSLC-Q Exactive 
HPLC 
Column type, length Self-packed, 30 cm Commercial, 50 cm 
Gradient 3-45% B in 120 min 3-35% B in 187 min 
MS 
Polarity Positive Positive 
Data acquisition mode, Top N DDA, Top 5 DDA, Top 15 
Scan range (m/z) 300 - 2,000 300 - 1,500 
Resolution (FWHM)   
Full MS (Orbitrap) 30,000  at m/z 400 70,000  at m/z 200 
MS/MS (Orbitrap) 7,500  at m/z 400 17,500  at m/z 200 
Automated gain control (AGC) target values   
Full MS  1 x 106 2 x 105 
MS/MS  1 x 105 5 x 104 
Maximum ion injection times (ms)   
Full MS  100 120 
MS/MS  200 250 
Fragmentation type HCD HCD 
Precursor isolation width (m/z) 2.0 2.0 
Dynamic exclusion duration (s) 30 12 
Normalized collision energy (%)  47 27 
Activation time (ms) 0.2 Not applicable 
Underfill ratio Not applicable 5% 
Lock mass - polysiloxane ion (m/z) 371.101236 371.101236 
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 Significantly altered proteins in the MSS-fibroblasts study  10.3
UniProt accession Protein Gene Unique Peptides PSMs MSS/Healthy RSD% 
P05120 Plasminogen activator inhibitor 2  SERPINB2  21 308 12.1 4% 
Q8TF66 Leucine-rich repeat-containing protein 15  LRRC15  5 24 8.8 4% 
P07197 Neurofilament medium polypeptide  NEFM  3 162 7.7 5% 
Q6P179 Endoplasmic reticulum aminopeptidase 2  ERAP2  3 15 7.2 10% 
O00469 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2  PLOD2  23 209 7.0 5% 
P28300 Protein-lysine 6-oxidase  LOX  4 20 6.7 6% 
P08254 Stromelysin-1  MMP3  12 126 6.4 12% 
P03956 Interstitial collagenase  MMP1  15 166 5.9 5% 
P07996 Thrombospondin-1  THBS1  21 147 5.8 3% 
P05362 Intercellular adhesion molecule 1  ICAM1  5 24 5.8 3% 
P04179 Superoxide dismutase [Mn], mitochondrial  SOD2  9 193 5.1 4% 
P01584 Interleukin-1 beta  IL1B  4 25 4.8 3% 
P04439 HLA class I histocompatibility antigen, A-3 alpha chain  HLA-A  2 57 4.5 10% 
Q14627 Interleukin-13 receptor subunit alpha-2  IL13RA2  2 2 4.4 8% 
P07951 Tropomyosin beta chain  TPM2  5 203 4.2 14% 
P04004 Vitronectin  VTN  2 5 4.1 8% 
P05121 Plasminogen activator inhibitor 1  SERPINE1  12 119 4.1 6% 
Q06033 Inter-alpha-trypsin inhibitor heavy chain H3  ITIH3  7 29 4.0 3% 
P12277 Creatine kinase B-type  CKB  8 36 3.9 3% 
P20936 Ras GTPase-activating protein 1  RASA1  16 166 3.9 3% 
O14558 Heat shock protein beta-6  HSPB6  5 65 3.8 1% 
Q14624 Inter-alpha-trypsin inhibitor heavy chain H4  ITIH4  2 16 3.5 6% 
O43719 HIV Tat-specific factor 1  HTATSF1  3 8 3.4 9% 
P09493 Tropomyosin alpha-1 chain  TPM1  7 136 3.4 8% 
O15427 Monocarboxylate transporter 4  SLC16A3  6 27 3.3 2% 
Q01995 Transgelin  TAGLN  13 329 3.3 2% 
P07093 Glia-derived nexin  SERPINE2  10 130 3.2 4% 
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P01023 Alpha-2-macroglobulin  A2M  5 170 3.2 3% 
O15460 Prolyl 4-hydroxylase subunit alpha-2  P4HA2  13 74 3.1 5% 
P55290 Cadherin-13  CDH13  2 3 3.1 2% 
P09936 Ubiquitin carboxyl-terminal hydrolase isozyme L1  UCHL1  10 150 3.1 1% 
P24821 Tenascin  TNC  17 71 2.9 3% 
Q96D15 Reticulocalbin-3  RCN3  8 82 2.7 7% 
P50479 PDZ and LIM domain protein 4  PDLIM4  6 13 2.6 1% 
P09038 Fibroblast growth factor 2  FGF2  3 19 2.6 5% 
P09601 Heme oxygenase 1  HMOX1  10 56 2.6 8% 
P10253 Lysosomal alpha-glucosidase  GAA  4 15 2.5 3% 
Q15582 Transforming growth factor-beta-induced protein ig-h3  TGFBI  4 13 2.5 2% 
P98160 Basement membrane-specific heparan sulfate proteoglycan core protein  HSPG2  17 51 2.5 3% 
Q96S97 Myeloid-associated differentiation marker  MYADM  2 70 2.5 3% 
P09486 SPARC  SPARC  5 12 2.5 6% 
P07585 Decorin  DCN  3 14 2.4 18% 
Q32MZ4 Leucine-rich repeat flightless-interacting protein 1  LRRFIP1  6 10 2.4 5% 
Q99439 Calponin-2  CNN2  8 110 2.4 1% 
O95340 Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 2  PAPSS2  10 41 2.4 2% 
P84157 Matrix-remodeling-associated protein 7  MXRA7  2 21 2.4 2% 
P04114 Apolipoprotein B-100  APOB  8 29 2.3 4% 
Q96NE9 FERM domain-containing protein 6  FRMD6  2 6 2.3 8% 
P98082 Disabled homolog 2  DAB2  13 46 2.3 6% 
P20337 Ras-related protein Rab-3B  RAB3B  5 62 2.3 12% 
Q8NBZ7 UDP-glucuronic acid decarboxylase 1  UXS1  2 4 2.3 14% 
Q9UHB6 LIM domain and actin-binding protein 1  LIMA1  15 85 2.3 2% 
P19971 Thymidine phosphorylase  TYMP  3 26 2.3 5% 
P01033 Metalloproteinase inhibitor 1  TIMP1  2 5 2.3 6% 
Q07065 Cytoskeleton-associated protein 4  CKAP4  39 777 2.2 4% 
P11233 Ras-related protein Ral-A  RALA  2 15 2.2 12% 
P69905 Hemoglobin subunit alpha  HBA1  5 86 2.2 13% 
Q9UBG0 C-type mannose receptor 2  MRC2  11 80 2.2 2% 
P11166 Solute carrier family 2, facilitated glucose transporter member 1  SLC2A1  3 29 2.2 9% 
P02649 Apolipoprotein E  APOE  2 6 2.2 15% 
P52848 Bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 1  NDST1  2 4 2.2 4% 
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Q96PD2 Discoidin, CUB and LCCL domain-containing protein 2  DCBLD2  2 10 2.2 4% 
Q15274 Nicotinate-nucleotide pyrophosphorylase [carboxylating]  QPRT  4 19 2.2 6% 
P13674 Prolyl 4-hydroxylase subunit alpha-1  P4HA1  19 114 2.1 3% 
Q96D46 60S ribosomal export protein NMD3  NMD3  2 5 2.1 20% 
P05161 Ubiquitin-like protein ISG15  ISG15  3 45 2.1 5% 
P43490 Nicotinamide phosphoribosyltransferase  NAMPT  18 219 2.1 1% 
P02511 Alpha-crystallin B chain  CRYAB  6 37 2.1 3% 
Q9UJ70 N-acetyl-D-glucosamine kinase  NAGK  10 53 2.1 4% 
P02765 Alpha-2-HS-glycoprotein  AHSG  4 55 2.1 10% 
P35579 Myosin-9  MYH9  115 2114 2.1 3% 
Q9UBR2 Cathepsin Z  CTSZ  4 56 2.1 3% 
O60711 Leupaxin  LPXN  6 28 2.1 7% 
P17936 Insulin-like growth factor-binding protein 3  IGFBP3  2 8 2.1 7% 
P51805 Plexin-A3  PLXNA3  2 7 2.1 14% 
P04216 Thy-1 membrane glycoprotein  THY1  4 51 2.1 2% 
Q0ZGT2 Nexilin  NEXN  4 5 2.1 2% 
Q9NR12 PDZ and LIM domain protein 7  PDLIM7  7 25 2.1 7% 
P52789 Hexokinase-2  HK2  4 121 2.0 3% 
O43175 D-3-phosphoglycerate dehydrogenase  PHGDH  12 96 0.5 5% 
P30837 Aldehyde dehydrogenase X, mitochondrial  ALDH1B1  5 34 0.5 3% 
Q12791 Calcium-activated potassium channel subunit alpha-1  KCNMA1  2 6 0.5 2% 
P29372 DNA-3-methyladenine glycosylase  MPG  3 19 0.5 8% 
Q96PY5 Formin-like protein 2  FMNL2  6 46 0.5 3% 
Q5SSJ5 Heterochromatin protein 1-binding protein 3  HP1BP3  10 48 0.5 3% 
Q6ZMZ3 Nesprin-3  C14orf49  5 9 0.5 7% 
Q8NEY1 Neuron navigator 1  NAV1  5 14 0.5 7% 
O75828 Carbonyl reductase [NADPH] 3  CBR3  3 140 0.5 2% 
Q9BYC5 Alpha-(1,6)-fucosyltransferase  FUT8  2 3 0.5 8% 
P16401 Histone H1.5  HIST1H1B  7 145 0.5 12% 
Q9BTZ2 Dehydrogenase/reductase SDR family member 4  DHRS4  4 45 0.5 4% 
P57764 Gasdermin-D  GSDMD  3 8 0.5 13% 
Q8WWI5 Choline transporter-like protein 1  SLC44A1  5 35 0.5 4% 
Q92466 DNA damage-binding protein 2  DDB2  2 3 0.5 12% 
Q5KU26 Collectin-12  COLEC12  13 48 0.5 2% 
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P20700 Lamin-B1  LMNB1  23 164 0.5 5% 
Q14699 Raftlin  RFTN1  10 29 0.5 3% 
P11498 Pyruvate carboxylase, mitochondrial  PC  7 33 0.5 7% 
Q9BQ39 ATP-dependent RNA helicase DDX50  DDX50  2 6 0.5 8% 
Q5T9L3 Protein wntless homolog  WLS  5 27 0.5 5% 
P14384 Carboxypeptidase M  CPM  2 5 0.4 7% 
P62995 Transformer-2 protein homolog beta  TRA2B  2 6 0.4 5% 
Q16719 Kynureninase  KYNU  3 8 0.4 7% 
Q8N4T8 Carbonyl reductase family member 4  CBR4  2 12 0.4 0% 
Q7L5Y1 Mitochondrial enolase superfamily member 1  ENOSF1  2 3 0.4 14% 
P17096 High mobility group protein HMG-I/HMG-Y  HMGA1  2 11 0.4 3% 
Q16666 Gamma-interferon-inducible protein 16  IFI16  14 57 0.4 7% 
Q9UDY2 Tight junction protein ZO-2  TJP2  4 10 0.4 7% 
O14684 Prostaglandin E synthase  PTGES  3 18 0.4 8% 
Q8N2H3 Pyridine nucleotide-disulfide oxidoreductase domain-containing protein 2  PYROXD2  5 16 0.4 6% 
Q92506 Estradiol 17-beta-dehydrogenase 8  HSD17B8  4 24 0.4 6% 
P51648 Fatty aldehyde dehydrogenase  ALDH3A2  12 46 0.4 4% 
Q96CX2 BTB/POZ domain-containing protein KCTD12  KCTD12  12 228 0.4 5% 
Q9HA77 Probable cysteine--tRNA ligase, mitochondrial  CARS2  2 4 0.4 11% 
P47712 Cytosolic phospholipase A2  PLA2G4A  6 44 0.4 4% 
Q9H173 Nucleotide exchange factor SIL1  SIL1  2 2 0.4 10% 
Q53EL6 Programmed cell death protein 4  PDCD4  5 49 0.4 8% 
Q9Y3Z3 SAM domain and HD domain-containing protein 1  SAMHD1  4 7 0.3 12% 
P16402 Histone H1.3  HIST1H1D  2 188 0.3 13% 
P62805 Histone H4  HIST1H4A  9 600 0.3 5% 
P52895 Aldo-keto reductase family 1 member C2  AKR1C2  3 233 0.3 3% 
P21266 Glutathione S-transferase Mu 3  GSTM3  5 58 0.3 8% 
Q9Y4K1 Absent in melanoma 1 protein  AIM1  2 6 0.3 10% 
Q658P3 Metalloreductase STEAP3  STEAP3  7 77 0.3 9% 
Q16647 Prostacyclin synthase  PTGIS  5 13 0.3 9% 
Q13228 Selenium-binding protein 1  SELENBP1  10 84 0.3 6% 
P08294 Extracellular superoxide dismutase [Cu-Zn]  SOD3  3 19 0.3 10% 
Q9P2B2 Prostaglandin F2 receptor negative regulator  PTGFRN  3 7 0.3 13% 
Q05707 Collagen alpha-1(XIV) chain  COL14A1  2 15 0.2 17% 
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P00966 Argininosuccinate synthase  ASS1  19 261 0.2 4% 
Q5BJF2 Transmembrane protein 97  TMEM97  2 3 0.2 13% 
O00534 von Willebrand factor A domain-containing protein 5A  VWA5A  2 3 0.2 11% 
O95425 Supervillin  SVIL  14 58 0.2 5% 
O60437 Periplakin  PPL  31 122 0.2 10% 
O14495 Lipid phosphate phosphohydrolase 3  PPAP2B  5 58 0.2 13% 
P29762 Cellular retinoic acid-binding protein 1  CRABP1  3 62 0.1 17% 
 
 Significantly altered proteins in the MSS-LCs study 10.4
UniProt accession Protein Gene Unique Peptides PSMs MSS/Healthy T.TEST 
Q96AC1 Fermitin family homolog 2  FERMT2  4 10 3.7 0.00 
P08631 Tyrosine-protein kinase HCK  HCK  5 29 2.8 0.05 
P35080 Profilin-2  PFN2  4 7 2.6 0.03 
P04066 Tissue alpha-L-fucosidase  FUCA1  6 14 2.2 0.00 
Q8N584 Tetratricopeptide repeat protein 39C  TTC39C  3 5 2.0 0.04 
Q14108 Lysosome membrane protein 2  SCARB2  2 5 1.8 0.02 
P28068 HLA class II histocompatibility antigen, DM beta chain  HLA-DMB  4 9 1.8 0.01 
P06239 Tyrosine-protein kinase Lck  LCK  12 49 1.8 0.02 
P09917 Arachidonate 5-lipoxygenase  ALOX5  12 41 1.7 0.03 
P06340 HLA class II histocompatibility antigen, DO alpha chain  HLA-DOA  2 5 1.7 0.02 
Q7Z3E5 LisH domain-containing protein ARMC9  ARMC9  4 10 1.7 0.01 
Q7Z4S6 Kinesin-like protein KIF21A  KIF21A  9 27 1.7 0.04 
P07203 Glutathione peroxidase 1  GPX1  9 37 1.7 0.01 
P04114 Apolipoprotein B-100  APOB  7 18 1.7 0.01 
P28067 HLA class II histocompatibility antigen, DM alpha chain  HLA-DMA  2 5 1.6 0.00 
Q14005 Pro-interleukin-16  IL16  14 51 1.6 0.02 
O95671 N-acetylserotonin O-methyltransferase-like protein  ASMTL  19 79 1.5 0.03 
P02774 Vitamin D-binding protein  GC  4 6 1.5 0.01 
Q86W92 Liprin-beta-1  PPFIBP1  2 3 1.5 0.02 
P36969 Phospholipid hydroperoxide glutathione peroxidase, mitochondrial  GPX4  7 22 1.5 0.04 
O95571 Persulfide dioxygenase ETHE1, mitochondrial  ETHE1  9 31 1.5 0.02 
Q8IY21 Probable ATP-dependent RNA helicase DDX60  DDX60  15 41 1.5 0.01 
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Q6WKZ4 Rab11 family-interacting protein 1  RAB11FIP1  9 21 1.5 0.02 
Q9UBB4 Ataxin-10  ATXN10  19 69 1.5 0.01 
P19823 Inter-alpha-trypsin inhibitor heavy chain H2  ITIH2  4 12 1.5 0.04 
P07858 Cathepsin B  CTSB  2 5 1.5 0.00 
Q8IZQ5 Selenoprotein H  SELH  3 7 1.5 0.00 
Q8WYJ6 Septin-1  Sep 01 18 87 1.5 0.01 
P16219 Short-chain specific acyl-CoA dehydrogenase, mitochondrial  ACADS  9 30 1.5 0.02 
Q9BRQ8 Apoptosis-inducing factor 2  AIFM2  2 3 1.4 0.04 
P11310 Medium-chain specific acyl-CoA dehydrogenase, mitochondrial  ACADM  19 122 1.4 0.04 
P04062 Glucosylceramidase  GBA  2 3 1.4 0.00 
Q8IZ07 Ankyrin repeat domain-containing protein 13A  ANKRD13A  9 33 1.4 0.05 
P00395 Cytochrome c oxidase subunit 1  MT-CO1  3 21 1.4 0.01 
P13765 HLA class II histocompatibility antigen, DO beta chain  HLA-DOB  11 20 1.4 0.01 
Q5R372 Rab GTPase-activating protein 1-like  RABGAP1L  20 67 1.4 0.01 
Q9UPR0 Inactive phospholipase C-like protein 2  PLCL2  3 5 1.4 0.01 
Q9P1Z2 Calcium-binding and coiled-coil domain-containing protein 1  CALCOCO1  2 4 1.4 0.01 
P41218 Myeloid cell nuclear differentiation antigen  MNDA  20 44 1.4 0.04 
Q96LZ7 Regulator of microtubule dynamics protein 2  RMDN2  2 4 1.4 0.00 
Q8WZA0 Protein LZIC  LZIC  3 9 1.4 0.05 
Q14699 Raftlin  RFTN1  14 53 1.4 0.02 
P59768 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2  GNG2  4 7 1.4 0.04 
P19256 Lymphocyte function-associated antigen 3  CD58  3 8 1.4 0.00 
Q9BW62 Katanin p60 ATPase-containing subunit A-like 1  KATNAL1  2 5 1.4 0.02 
P02751 Fibronectin  FN1  6 11 1.4 0.00 
Q9BRX8 Redox-regulatory protein FAM213A  FAM213A  5 16 1.4 0.01 
Q12965 Unconventional myosin-Ie  MYO1E  27 100 1.4 0.02 
P30044 Peroxiredoxin-5, mitochondrial  PRDX5  10 82 1.4 0.01 
P99999 Cytochrome c  CYCS  7 50 1.4 0.01 
P09382 Galectin-1  LGALS1  13 108 1.4 0.04 
P45954 Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial  ACADSB  9 26 1.4 0.02 
P35625 Metalloproteinase inhibitor 3  TIMP3  3 6 1.3 0.00 
Q9NXH8 Torsin-4A  TOR4A  4 9 1.3 0.02 
O00750 Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta  PIK3C2B  3 5 1.3 0.01 
P49641 Alpha-mannosidase 2x  MAN2A2  4 13 1.3 0.01 
Q9UHG3 Prenylcysteine oxidase 1  PCYOX1  7 19 1.3 0.02 
O60711 Leupaxin  LPXN  14 45 1.3 0.04 
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O75695 Protein XRP2  RP2  5 7 1.3 0.04 
Q6P2P2 Putative protein arginine N-methyltransferase 10  PRMT10  3 8 1.3 0.00 
Q8IX04 Ubiquitin-conjugating enzyme E2 variant 3  UEVLD  3 7 1.3 0.01 
Q08722 Leukocyte surface antigen CD47  CD47  2 10 1.3 0.02 
Q05823 2-5A-dependent ribonuclease  RNASEL  2 4 1.3 0.01 
Q9HBL8 NmrA-like family domain-containing protein 1  NMRAL1  6 18 1.3 0.04 
Q96S94 Cyclin-L2  CCNL2  2 3 0.8 0.04 
Q9H9Y2 Ribosome production factor 1  RPF1  2 3 0.8 0.03 
P13674 Prolyl 4-hydroxylase subunit alpha-1  P4HA1  17 48 0.8 0.03 
Q9BVV7 Mitochondrial import inner membrane translocase subunit Tim21  TIMM21  2 2 0.8 0.01 
Q6ZVM7 TOM1-like protein 2  TOM1L2  2 2 0.8 0.03 
O00165 HCLS1-associated protein X-1  HAX1  4 4 0.8 0.01 
Q6N063 2-oxoglutarate and iron-dependent oxygenase domain-containing protein 2  OGFOD2  2 5 0.8 0.01 
O75794 Cell division cycle protein 123 homolog  CDC123  3 7 0.7 0.00 
Q13488 V-type proton ATPase 116 kDa subunit a isoform 3  TCIRG1  3 5 0.7 0.00 
Q8TBF2 Prostamide/prostaglandin F synthase  FAM213B  2 3 0.7 0.03 
Q00534 Cyclin-dependent kinase 6  CDK6  10 27 0.7 0.05 
Q15032 R3H domain-containing protein 1  R3HDM1  2 3 0.7 0.05 
Q9Y617 Phosphoserine aminotransferase  PSAT1  13 47 0.7 0.01 
Q9NNW7 Thioredoxin reductase 2, mitochondrial  TXNRD2  4 13 0.7 0.01 
Q4VC31 Coiled-coil domain-containing protein 58  CCDC58  2 6 0.7 0.01 
P18085 ADP-ribosylation factor 4  ARF4  7 75 0.7 0.01 
Q14213 Interleukin-27 subunit beta  EBI3  6 17 0.7 0.01 
Q9Y6E2 Basic leucine zipper and W2 domain-containing protein 2  BZW2  4 14 0.7 0.02 
Q7Z417 Nuclear fragile X mental retardation-interacting protein 2  NUFIP2  2 3 0.7 0.01 
P35610 Sterol O-acyltransferase 1  SOAT1  2 4 0.7 0.01 
Q96DU3 SLAM family member 6  SLAMF6  2 3 0.7 0.01 
Q8NFC6 Biorientation of chromosomes in cell division protein 1-like 1  BOD1L1  2 5 0.7 0.03 
Q15424 Scaffold attachment factor B1  SAFB  14 72 0.7 0.02 
P63218 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5  GNG5  2 8 0.7 0.03 
Q16222 UDP-N-acetylhexosamine pyrophosphorylase  UAP1  6 19 0.7 0.03 
Q9NYL4 Peptidyl-prolyl cis-trans isomerase FKBP11  FKBP11  4 10 0.7 0.03 
Q8WV28 B-cell linker protein  BLNK  9 15 0.7 0.02 
P29966 Myristoylated alanine-rich C-kinase substrate  MARCKS  3 8 0.7 0.01 
P84101 Small EDRK-rich factor 2  SERF2  3 11 0.7 0.01 
Q70UQ0 Inhibitor of nuclear factor kappa-B kinase-interacting protein  IKBIP  3 5 0.7 0.04 
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P62158 Calmodulin  CALM1  4 16 0.7 0.05 
Q86V48 Leucine zipper protein 1  LUZP1  3 4 0.7 0.03 
P51397 Death-associated protein 1  DAP  2 5 0.7 0.01 
Q9UGC7 Peptide chain release factor 1-like, mitochondrial  MTRF1L  2 4 0.6 0.01 
Q6UXH1 Cysteine-rich with EGF-like domain protein 2  CRELD2  2 7 0.6 0.05 
P06737 Glycogen phosphorylase, liver form  PYGL  4 18 0.6 0.00 
P02794 Ferritin heavy chain  FTH1  2 3 0.6 0.05 
P42331 Rho GTPase-activating protein 25  ARHGAP25  4 15 0.6 0.04 
P08236 Beta-glucuronidase  GUSB  2 3 0.6 0.00 
P28908 Tumor necrosis factor receptor superfamily member 8  TNFRSF8  3 6 0.6 0.00 
P50416 Carnitine O-palmitoyltransferase 1, liver isoform  CPT1A  13 30 0.6 0.01 
Q9BX59 Tapasin-related protein  TAPBPL  2 3 0.6 0.00 
P06454 Prothymosin alpha  PTMA  3 10 0.6 0.04 
O43175 D-3-phosphoglycerate dehydrogenase  PHGDH  17 64 0.5 0.03 
P02792 Ferritin light chain  FTL  4 5 0.4 0.01 
P04181 Ornithine aminotransferase, mitochondrial  OAT  3 7 0.4 0.03 
P21266 Glutathione S-transferase Mu 3  GSTM3  5 18 0.4 0.02 
Q9H173 Nucleotide exchange factor SIL1  SIL1  3 10 0.3 0.00 
 
 Significantly altered proteins in the woozy mice cerebella study 10.5
UniProt accession Protein Gene Unique Peptides PSMs woozy/wild type T.TEST 
P03995 Glial fibrillary acidic protein  Gfap  35 191 1.9 0.01 
P70677 Caspase-3  Casp3  2 4 1.7 0.00 
Q91XV3 Brain acid soluble protein 1  Basp1  8 24 1.6 0.05 
P23242 Gap junction alpha-1 protein  Gja1  8 29 1.5 0.04 
Q9WUC3 Lymphocyte antigen 6H  Ly6h  3 6 1.5 0.05 
Q8BWU8 Ethanolamine-phosphate phospho-lyase  Etnppl  9 29 1.5 0.01 
O88533 Aromatic-L-amino-acid decarboxylase  Ddc  4 10 1.5 0.04 
P61458 Pterin-4-alpha-carbinolamine dehydratase  Pcbd1  4 8 1.5 0.04 
Q99P58 Ras-related protein Rab-27B  Rab27b  4 9 1.5 0.03 
P11859 Angiotensinogen  Agt  2 5 1.5 0.00 
P55088 Aquaporin-4  Aqp4  4 11 1.4 0.00 
O88492 Perilipin-4  Plin4  4 7 1.4 0.01 
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P31650 Sodium- and chloride-dependent GABA transporter 3  Slc6a11  9 30 1.4 0.03 
P56528 ADP-ribosyl cyclase 1  Cd38  3 4 1.4 0.01 
Q8BZF8 Phosphoglucomutase-like protein 5  Pgm5  2 4 1.4 0.00 
O08709 Peroxiredoxin-6  Prdx6  20 143 1.4 0.03 
Q8BW75 Amine oxidase [flavin-containing] B  Maob  14 42 1.4 0.00 
P70689 Gap junction beta-6 protein  Gjb6  2 6 1.4 0.00 
P05532 Mast/stem cell growth factor receptor Kit  Kit  4 9 1.4 0.04 
Q3TVI8 Pre-B-cell leukemia transcription factor-interacting protein 1  Pbxip1  5 13 1.4 0.01 
Q3UNZ8 Quinone oxidoreductase-like protein 2  N/A 2 3 1.4 0.00 
P20152 Vimentin  Vim  31 145 1.4 0.01 
Q62421 Endophilin-A3  Sh3gl3  4 7 1.4 0.04 
Q8CC86 Nicotinate phosphoribosyltransferase  Naprt1  5 6 1.3 0.00 
Q80XD1 Beta-chimaerin  Chn2  2 6 0.7 0.02 
Q8VHC3 Selenoprotein M  Selm  4 17 0.7 0.00 
Q63959 Potassium voltage-gated channel subfamily C member 3  Kcnc3  9 36 0.7 0.00 
Q6NVG1 Lysophospholipid acyltransferase LPCAT4  Lpcat4  7 15 0.7 0.00 
P13707 Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic  Gpd1  22 134 0.7 0.01 
Q8C1B7 Septin-11  Sep 11 4 73 0.7 0.00 
Q3UUJ4 STE20-related kinase adapter protein alpha  Strada  2 2 0.7 0.04 
Q8BYR5 Calcium-dependent secretion activator 2  Cadps2  16 58 0.7 0.02 
P59644 Phosphatidylinositol 4,5-bisphosphate 5-phosphatase A  Inpp5j  4 10 0.7 0.02 
Q91Z69 SLIT-ROBO Rho GTPase-activating protein 1  Srgap1  2 6 0.7 0.02 
Q60598 Src substrate cortactin  Cttn  11 31 0.7 0.00 
Q9R0K7 Plasma membrane calcium-transporting ATPase 2  Atp2b2  53 193 0.7 0.00 
P28659 CUGBP Elav-like family member 1  Celf1  2 4 0.7 0.01 
Q80T41 Gamma-aminobutyric acid type B receptor subunit 2  Gabbr2  12 28 0.7 0.01 
A2ANU3 Synapse differentiation-inducing gene protein 1  Syndig1  2 3 0.7 0.00 
P97450 ATP synthase-coupling factor 6, mitochondrial  Atp5j  2 7 0.7 0.03 
Q91WG7 Diacylglycerol kinase gamma  Dgkg  5 9 0.7 0.02 
P28652 Calcium/calmodulin-dependent protein kinase type II subunit beta  Camk2b  11 75 0.7 0.02 
Q6PHS9 Voltage-dependent calcium channel subunit alpha-2/delta-2  Cacna2d2  16 42 0.7 0.00 
Q1RLL3 Copine-9  Cpne9  6 20 0.7 0.02 
P51880 Fatty acid-binding protein, brain  Fabp7  3 17 0.7 0.00 
Q8K0T7 Protein unc-13 homolog C  Unc13c  5 10 0.7 0.01 
P68510 14-3-3 protein eta  Ywhah  12 152 0.7 0.00 
Q9DB72 BTB/POZ domain-containing protein 17  Btbd17  8 21 0.7 0.01 
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P97434 Myosin phosphatase Rho-interacting protein  Mprip  4 8 0.7 0.00 
Q9ERG2 Striatin-3  Strn3  2 5 0.7 0.00 
P97445 Voltage-dependent P/Q-type calcium channel subunit alpha-1A  Cacna1a  8 23 0.7 0.01 
P62075 Mitochondrial import inner membrane translocase subunit Tim13  Timm13  3 15 0.7 0.02 
Q9EPW0 Type I inositol 3,4-bisphosphate 4-phosphatase  Inpp4a  12 41 0.7 0.00 
Q8K0T0 Reticulon-1  Rtn1  14 63 0.7 0.00 
P70302 Stromal interaction molecule 1  Stim1  6 11 0.7 0.00 
P16283 Anion exchange protein 3  Slc4a3  2 6 0.7 0.04 
Q4LDD4 Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 1  Arap1  2 5 0.7 0.00 
O55143 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2  Atp2a2  24 162 0.7 0.00 
P16305 Gamma-aminobutyric acid receptor subunit alpha-6  Gabra6  2 8 0.7 0.01 
Q6PB70 Anoctamin-8  Ano8  2 5 0.7 0.01 
Q6PA06 Atlastin-2  Atl2  7 22 0.7 0.00 
P08414 Calcium/calmodulin-dependent protein kinase type IV  Camk4  9 27 0.7 0.02 
Q5DTL9 Sodium-driven chloride bicarbonate exchanger  Slc4a10  12 40 0.6 0.00 
Q6WVG3 BTB/POZ domain-containing protein KCTD12  Kctd12  9 30 0.6 0.00 
P34884 Macrophage migration inhibitory factor  Mif  3 15 0.6 0.04 
Q3UJU9 Regulator of microtubule dynamics protein 3  Rmdn3  7 17 0.6 0.00 
O54931 A-kinase anchor protein 2  Akap2  2 3 0.6 0.00 
B9EJA2 Cortactin-binding protein 2  Cttnbp2  5 11 0.6 0.00 
P12660 Purkinje cell protein 2  Pcp2  3 16 0.6 0.00 
Q91YX5 Acyl-CoA:lysophosphatidylglycerol acyltransferase 1  Lpgat1  5 21 0.6 0.00 
Q69ZT1 Fanconi-associated nuclease 1  Fan1  2 2 0.6 0.00 
P57759 Endoplasmic reticulum resident protein 29  Erp29  9 28 0.6 0.00 
P0C605 cGMP-dependent protein kinase 1  Prkg1  2 3 0.6 0.00 
Q8K1S1 Leucine-rich repeat LGI family member 4  Lgi4  4 11 0.6 0.01 
O35143 ATPase inhibitor, mitochondrial  Atpif1  2 3 0.6 0.01 
P62748 Hippocalcin-like protein 1  Hpcal1  5 62 0.6 0.00 
Q68ED7 CREB-regulated transcription coactivator 1  Crtc1  3 7 0.6 0.01 
Q8C5W0 Calmin  Clmn  2 3 0.6 0.00 
Q8R1S4 Metastasis suppressor protein 1  Mtss1  3 9 0.6 0.00 
Q6ZQ82 Rho GTPase-activating protein 26  Arhgap26  9 26 0.6 0.00 
P84086 Complexin-2  Cplx2  3 33 0.6 0.00 
P56564 Excitatory amino acid transporter 1  Slc1a3  10 147 0.6 0.00 
B2RPU2 Pleckstrin homology domain-containing family D member 1  Plekhd1  3 4 0.5 0.00 
Q9JHG0 Cerebellin-3  Cbln3  2 5 0.5 0.01 
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P23818 Glutamate receptor 1  Gria1  11 39 0.5 0.00 
P25911 Tyrosine-protein kinase Lyn  Lyn  7 27 0.5 0.00 
Q9JM96 Cdc42 effector protein 4  Cdc42ep4  6 12 0.5 0.00 
Q8BXT1 Regulator of G-protein signaling 8  Rgs8  3 6 0.5 0.00 
Q80Z38 SH3 and multiple ankyrin repeat domains protein 2  Shank2  12 31 0.5 0.00 
Q80UP3 Diacylglycerol kinase zeta  Dgkz  10 18 0.5 0.00 
Q3UH99 Protein shisa-6 homolog  Shisa6  6 15 0.5 0.01 
Q9ERQ8 Carbonic anhydrase 7  Ca7  2 3 0.5 0.00 
D3YZU1 SH3 and multiple ankyrin repeat domains protein 1  Shank1  25 61 0.5 0.00 
Q80YX1 Tenascin  Tnc  6 13 0.5 0.00 
Q9JJZ2 Tubulin alpha-8 chain  Tuba8  4 460 0.5 0.00 
Q6WQJ1 Sn1-specific diacylglycerol lipase alpha  Dagla  9 20 0.4 0.00 
P97772 Metabotropic glutamate receptor 1  Grm1  14 35 0.4 0.00 
Q8R071 Inositol-trisphosphate 3-kinase A  Itpka  4 8 0.4 0.00 
O35544 Excitatory amino acid transporter 4  Slc1a6  5 69 0.4 0.00 
Q3TGF2 Protein FAM107B  Fam107b  3 3 0.4 0.00 
Q9JMF3 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-13  Gng13  4 9 0.4 0.00 
Q64518 Sarcoplasmic/endoplasmic reticulum calcium ATPase 3  Atp2a3  16 55 0.3 0.00 
Q61625 Glutamate receptor ionotropic, delta-2  Grid2  10 34 0.3 0.01 
Q8BW86 Rho guanine nucleotide exchange factor 33  Arhgef33  11 24 0.3 0.00 
P63318 Protein kinase C gamma type  Prkcg  19 57 0.3 0.00 
Q0VEJ0 Centrosomal protein of 76 kDa  Cep76  3 3 0.3 0.00 
Q0QWG9 Delphilin  Grid2ip  5 14 0.3 0.00 
P11881 Inositol 1,4,5-trisphosphate receptor type 1  Itpr1  73 294 0.3 0.00 
Q99JP6 Homer protein homolog 3  Homer3  14 45 0.3 0.00 
P12658 Calbindin  Calb1  15 145 0.2 0.00 
P28651 Carbonic anhydrase-related protein  Ca8  9 43 0.2 0.00 
Q9EQK7 Protein-S-isoprenylcysteine O-methyltransferase  Icmt  2 2 0.2 0.00 
 
 Significantly altered proteins in the woozy mice skeletal muscles study 10.6
UniProt accession Protein Gene Unique Peptides PSMs Woozy/Wild type T.TEST 
P16110 Galectin-3  Lgals3  3 7 3.2 0.02 
Q61878 Bone marrow proteoglycan  Prg2  2 4 2.7 0.00 
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P97352 Protein S100-A13  S100a13  5 18 2.3 0.04 
P50543 Protein S100-A11  S100a11  3 4 2.2 0.02 
P23927 Alpha-crystallin B chain  Cryab  8 86 2.0 0.01 
Q9R118 Serine protease HTRA1  Htra1  2 3 1.9 0.01 
P13595 Neural cell adhesion molecule 1  Ncam1  3 5 1.8 0.03 
P20029 78 kDa glucose-regulated protein  Hspa5  27 235 1.8 0.00 
P14602 Heat shock protein beta-1  Hspb1  10 84 1.8 0.00 
P35385 Heat shock protein beta-7  Hspb7  5 73 1.8 0.01 
P26350 Prothymosin alpha  Ptma  3 10 1.8 0.02 
P09541 Myosin light chain 4  Myl4  4 276 1.8 0.01 
P14069 Protein S100-A6  S100a6  3 15 1.7 0.02 
Q60854 Serpin B6  Serpinb6  18 173 1.7 0.05 
Q9CQI6 Coactosin-like protein  Cotl1  8 19 1.7 0.00 
P29391 Ferritin light chain 1  Ftl1  3 22 1.6 0.00 
O89053 Coronin-1A  Coro1a  8 20 1.6 0.01 
Q9CXI5 Mesencephalic astrocyte-derived neurotrophic factor  Manf  2 6 1.6 0.01 
O35367 Keratocan  Kera  9 40 1.6 0.00 
Q922F4 Tubulin beta-6 chain  Tubb6  3 127 1.6 0.04 
P62962 Profilin-1  Pfn1  7 67 1.6 0.03 
P48036 Annexin A5  Anxa5  13 69 1.6 0.01 
P10126 Elongation factor 1-alpha 1  Eef1a1  5 123 1.6 0.01 
Q3U5Q7 UMP-CMP kinase 2, mitochondrial  Cmpk2  2 4 1.6 0.01 
P50608 Fibromodulin  Fmod  8 62 1.6 0.00 
P28653 Biglycan  Bgn  7 50 1.6 0.01 
Q9EQK5 Major vault protein  Mvp  18 60 1.5 0.00 
P27661 Histone H2AX  H2afx  3 67 1.5 0.03 
P11352 Glutathione peroxidase 1  Gpx1  3 7 1.5 0.02 
P17710 Hexokinase-1  Hk1  9 40 1.5 0.00 
A2AMM0 Muscle-related coiled-coil protein  Murc  6 24 1.5 0.00 
Q61233 Plastin-2  Lcp1  4 15 1.5 0.01 
O70373 Xin actin-binding repeat-containing protein 1  Xirp1  21 57 1.5 0.00 
O08917 Flotillin-1  Flot1  3 5 1.5 0.01 
P18760 Cofilin-1  Cfl1  4 46 1.5 0.01 
P08226 Apolipoprotein E  Apoe  6 15 1.5 0.04 
P15864 Histone H1.2  Hist1h1c  3 64 1.5 0.01 
Q99KC8 von Willebrand factor A domain-containing protein 5A  Vwa5a  13 43 1.5 0.00 
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P54116 Erythrocyte band 7 integral membrane protein  Stom  3 7 1.5 0.00 
O09161 Calsequestrin-2  Casq2  5 18 1.5 0.03 
P10107 Annexin A1  Anxa1  8 29 1.5 0.03 
Q922R8 Protein disulfide-isomerase A6  Pdia6  7 33 1.5 0.00 
P97429 Annexin A4  Anxa4  13 59 1.5 0.02 
Q8R5J9 PRA1 family protein 3  Arl6ip5  4 16 1.5 0.03 
Q6P5H2 Nestin  Nes  8 17 1.5 0.02 
P35564 Calnexin  Canx  10 37 1.5 0.00 
Q3TW96 UDP-N-acetylhexosamine pyrophosphorylase-like protein 1  Uap1l1  6 16 1.5 0.01 
P43025 Tetranectin  Clec3b  3 9 1.5 0.00 
P21836 Acetylcholinesterase  Ache  2 4 1.5 0.00 
Q8C7E7 Starch-binding domain-containing protein 1  Stbd1  7 25 1.5 0.01 
Q8BMK4 Cytoskeleton-associated protein 4  Ckap4  5 7 1.4 0.02 
Q8BMD8 Calcium-binding mitochondrial carrier protein SCaMC-1  Slc25a24  2 4 1.4 0.02 
P09528 Ferritin heavy chain  Fth1  5 31 1.4 0.02 
P07934 Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform  Phkg1  10 57 0.7 0.01 
Q6PD26 GPI transamidase component PIG-S  Pigs  2 2 0.7 0.02 
Q9JL56 Glycerophosphodiester phosphodiesterase 1  Gde1  2 4 0.7 0.00 
P70266 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1  Pfkfb1  8 24 0.7 0.05 
Q9CXJ4 ATP-binding cassette sub-family B member 8, mitochondrial  Abcb8  9 18 0.7 0.01 
Q7TSH2 Phosphorylase b kinase regulatory subunit beta  Phkb  20 74 0.7 0.01 
Q7M729 Sodium channel subunit beta-4  Scn4b  3 7 0.7 0.00 
Q8C0L9 Glycerophosphocholine phosphodiesterase GPCPD1  Gpcpd1  5 10 0.6 0.00 
A3KFX0 Cytosolic 5'-nucleotidase 1A  Nt5c1a  5 12 0.6 0.00 
P56501 Mitochondrial uncoupling protein 3  Ucp3  2 5 0.6 0.00 
P31154 S-adenosylmethionine decarboxylase proenzyme 1  Amd1  3 6 0.4 0.01 
 
 Significantly altered proteins in the index patient skeletal muscle study 10.7
UniProt accession Protein Gene Peptides Spectra Index/Control RSD% 
P24043 Laminin subunit alpha-2  LAMA2 24 34 20.4 2% 
P07355 Annexin A2  ANXA2 26 61 12.2 14% 
P55084 Trifunctional enzyme subunit beta, mitochondrial  HADHB 21 43 7.4 5% 
P08572 Collagen alpha-2 COL4A2 7 13 6.7 18% 
P07437 Tubulin beta chain  TUBB 22 48 6.2 18% 
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P06576 ATP synthase subunit beta, mitochondrial  ATP5B 31 181 5.8 20% 
O75390 Citrate synthase, mitochondrial  CS 11 26 5.5 7% 
P49753 Acyl-coenzyme A thioesterase 2, mitochondrial  ACOT2 8 13 5.2 14% 
P07900 Heat shock protein HSP 90-alpha  HSP90AA1 7 10 5.2 18% 
P62937 Peptidyl-prolyl cis-trans isomerase A  PPIA 12 49 4.9 17% 
P68366 Tubulin alpha-4A chain  TUBA4A 16 46 4.9 10% 
O60814 Histone H2B type 1-K  HIST1H2BK 13 124 4.9 2% 
P12235 ADP/ATP translocase 1  SLC25A4 20 47 4.9 18% 
P33121 Long-chain-fatty-acid--CoA ligase 1  ACSL1 7 8 4.8 2% 
P00403 Cytochrome c oxidase subunit 2  MT-CO2 4 9 4.6 18% 
O00483 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4  NDUFA4 4 5 4.5 2% 
P09622 Dihydrolipoyl dehydrogenase, mitochondrial  DLD 9 17 4.4 18% 
Q9UKS6 Protein kinase C and casein kinase substrate in neurons protein 3  PACSIN3 10 18 4.3 8% 
P08133 Annexin A6  ANXA6 14 30 4.3 7% 
Q9P0L0 Vesicle-associated membrane protein-associated protein A  VAPA 4 7 4.2 2% 
Q9Y277 Voltage-dependent anion-selective channel protein 3  VDAC3 9 15 4.2 9% 
P22061 Protein-L-isoaspartate PCMT1 5 8 4.1 18% 
P63313 Thymosin beta-10  TMSB10 3 8 4.1 18% 
P06744 Glucose-6-phosphate isomerase  GPI 13 41 4.1 6% 
P21912 Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial  SDHB 7 17 3.8 16% 
Q05639 Elongation factor 1-alpha 2  EEF1A2 8 21 3.8 2% 
O60662 Kelch-like protein 41  KLHL41 26 64 3.8 5% 
P48735 Isocitrate dehydrogenase [NADP], mitochondrial  IDH2 22 76 3.8 8% 
P62805 Histone H4  HIST1H4A 13 63 3.7 4% 
P11217 Glycogen phosphorylase, muscle form  PYGM 69 249 3.6 14% 
P21817 Ryanodine receptor 1  RYR1 10 14 3.6 18% 
A0M8Q6 Ig lambda-7 chain C region  IGLC7 6 16 3.6 16% 
P68431 Histone H3.1  HIST1H3A 12 39 3.6 9% 
P07602 Prosaposin  PSAP 3 6 3.6 2% 
P36957 Dihydrolipoyllysine-residue succinyltransferase, mitochondrial  DLST 4 6 3.6 2% 
P40926 Malate dehydrogenase, mitochondrial  MDH2 21 85 3.6 5% 
Q9Y235 Probable C->U-editing enzyme APOBEC-2  APOBEC2 8 23 3.5 10% 
P04179 Superoxide dismutase [Mn], mitochondrial  SOD2 9 17 3.4 14% 
P13639 Elongation factor 2  EEF2 8 14 3.4 11% 
P04908 Histone H2A type 1-B/E  HIST1H2AB 11 55 3.3 8% 
P17174 Aspartate aminotransferase, cytoplasmic  GOT1 15 32 3.3 14% 
Appendices      147 
 
P28161 Glutathione S-transferase Mu 2  GSTM2 4 10 3.3 11% 
P15121 Aldose reductase  AKR1B1 6 10 3.3 15% 
P0C0S8 Histone H2A type 1  HIST1H2AG 9 55 3.3 5% 
O14983 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1  ATP2A1 46 150 3.2 18% 
P14618 Pyruvate kinase PKM  PKM 45 199 3.2 0% 
O75531 Barrier-to-autointegration factor  BANF1 7 14 3.2 19% 
P30041 Peroxiredoxin-6  PRDX6 13 32 3.1 2% 
P22695 Cytochrome b-c1 complex subunit 2, mitochondrial  UQCRC2 14 22 3.1 2% 
P48047 ATP synthase subunit O, mitochondrial  ATP5O 13 31 2.9 13% 
P62328 Thymosin beta-4  TMSB4X 13 35 2.9 15% 
Q6ZMU5 Tripartite motif-containing protein 72  TRIM72 15 28 2.9 18% 
P06733 Alpha-enolase  ENO1 27 99 2.8 12% 
P54652 Heat shock-related 70 kDa protein 2  HSPA2 17 44 2.7 18% 
Q9Y623 Myosin-4  MYH4 202 1907 2.7 13% 
P12882 Myosin-1  MYH1 352 3322 2.7 13% 
P61088 Ubiquitin-conjugating enzyme E2 N  UBE2N 2 3 2.7 2% 
Q9UKX3 Myosin-13  MYH13 85 750 2.6 1% 
P04406 Glyceraldehyde-3-phosphate dehydrogenase  GAPDH 55 444 2.6 9% 
P09651 Heterogeneous nuclear ribonucleoprotein A1  HNRNPA1 4 5 2.6 18% 
P16104 Histone H2AX  H2AFX 7 38 2.5 3% 
P19338 Nucleolin  NCL 11 14 2.5 12% 
P09104 Gamma-enolase  ENO2 14 86 2.5 19% 
P0C0S5 Histone H2A.Z  H2AFZ 3 18 2.5 13% 
P11142 Heat shock cognate 71 kDa protein  HSPA8 24 67 2.5 6% 
P13073 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial  COX4I1 7 15 2.5 15% 
Q9NTK5 Obg-like ATPase 1  OLA1 3 6 2.4 14% 
P0CG47 Polyubiquitin-B  UBB 3 10 2.4 8% 
P56134 ATP synthase subunit f, mitochondrial  ATP5J2 2 4 2.4 2% 
O95292 Vesicle-associated membrane protein-associated protein B/C  VAPB 3 4 2.4 2% 
P61981 14-3-3 protein gamma  YWHAG 5 12 2.4 17% 
P06732 Creatine kinase M-type  CKM 98 854 2.3 19% 
P40925 Malate dehydrogenase, cytoplasmic  MDH1 18 67 2.3 12% 
Q9UKX2 Myosin-2  MYH2 335 2762 2.2 18% 
P54296 Myomesin-2  MYOM2 41 102 2.2 11% 
Q06830 Peroxiredoxin-1  PRDX1 14 45 2.2 13% 
P0DMV8 Heat shock 70 kDa protein 1A  HSPA1A 21 48 2.2 16% 
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P0DMV9 Heat shock 70 kDa protein 1B  HSPA1B 21 48 2.2 16% 
P06748 Nucleophosmin  NPM1 6 12 2.2 2% 
P60709 Actin, cytoplasmic 1  ACTB 58 1002 2.1 5% 
P00558 Phosphoglycerate kinase 1  PGK1 32 116 2.1 8% 
P10412 Histone H1.4  HIST1H1E 16 34 2.1 16% 
P63261 Actin, cytoplasmic 2  ACTG1 59 985 2.1 5% 
P68133 Actin, alpha skeletal muscle  ACTA1 127 1899 2.1 3% 
Q86TC9 Myopalladin  MYPN 3 4 2.1 18% 
Q00872 Myosin-binding protein C, slow-type  MYBPC1 85 244 2.0 2% 
P20929 Nebulin  NEB 336 701 2.0 10% 
P17661 Desmin  DES 47 250 2.0 8% 
P23588 Eukaryotic translation initiation factor 4B  EIF4B 2 3 0.5 11% 
Q00688 Peptidyl-prolyl cis-trans isomerase FKBP3  FKBP3 10 15 0.5 13% 
P05413 Fatty acid-binding protein, heart  FABP3 15 33 0.5 3% 
Q9UBY9 Heat shock protein beta-7  HSPB7 10 26 0.4 2% 
P30049 ATP synthase subunit delta, mitochondrial  ATP5D 2 2 0.4 6% 
O15273 Telethonin  TCAP 3 7 0.2 11% 
Q8N3V7 Synaptopodin  SYNPO 2 2 0.1 2% 
 
 UPR pathway-associated proteins for the PRM-based targeted assay 10.8
UniProt Accession Protein  Gene Peptide Sequence Precursor m/z 
P11021 78 kDa glucose-regulated protein  GRP78 VEIIANDQGNR 614.8177 
P11021 78 kDa glucose-regulated protein  GRP78 TWNDPSVQQDIK 715.8492 
P11021 78 kDa glucose-regulated protein  GRP78 DNHLLGTFDLTGIPPAPR 645.3425 
P11021 78 kDa glucose-regulated protein  GRP78 LTPEEIER 493.7613 
P11021 78 kDa glucose-regulated protein  GRP78 IEWLESHQDADIEDFK 658.9742 
P14625 Endoplasmin  ENPL ELISNASDALDK 638.3250 
P14625 Endoplasmin  ENPL SILFVPTSAPR 594.3428 
P14625 Endoplasmin  ENPL GLFDEYGSK 508.2402 
P14625 Endoplasmin  ENPL LGVIEDHSNR 380.5316 
P14625 Endoplasmin  ENPL LSLNIDPDAK 543.2955 
Q9Y4L1 Hypoxia up-regulated protein 1  HYOU1 FPEHELTFDPQR 505.9124 
Q9Y4L1 Hypoxia up-regulated protein 1  HYOU1 LAGLFNEQR 524.2827 
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Q9Y4L1 Hypoxia up-regulated protein 1  HYOU1 DAVVYPILVEFTR 761.4192 
Q9Y4L1 Hypoxia up-regulated protein 1  HYOU1 EVEEEPGIHSLK 456.2331 
Q9Y4L1 Hypoxia up-regulated protein 1  HYOU1 AEAGPEGVAPAPEGEK 754.8650 
O94979 Protein transport protein Sec31A  SC31A TQPPEDISC[+57]IAWNR 843.8989 
O94979 Protein transport protein Sec31A  SC31A NPAVLSAASFDGR 652.8333 
O94979 Protein transport protein Sec31A  SC31A LVTFENVR 489.2744 
O94979 Protein transport protein Sec31A  SC31A AQDGSHPLSLQDLIEK 584.3039 
P02545 Prelamin-A/C  LMNA EGDLIAAQAR 522.2776 
P02545 Prelamin-A/C  LMNA EAALSTALSEK 560.2982 
P02545 Prelamin-A/C  LMNA TLEGELHDLR 591.8093 
P02545 Prelamin-A/C  LMNA LADALQELR 514.7904 
P05198 Eukaryotic translation initiation factor 2 subunit 1  IF2A VSPEEAIK 436.7398 
P05198 Eukaryotic translation initiation factor 2 subunit 1  IF2A ADIEVAC[+57]YGYEGIDAVK 936.9378 
P05198 Eukaryotic translation initiation factor 2 subunit 1  IF2A INLIAPPR 447.2820 
P05198 Eukaryotic translation initiation factor 2 subunit 1  IF2A VVTDTDETELAR 674.8332 
P27824 Calnexin  CALX APVPTGEVYFADSFDR 885.9203 
P27824 Calnexin  CALX GTLSGWILSK 531.3031 
P27824 Calnexin  CALX TPELNLDQFHDK 728.8570 
P27824 Calnexin  CALX AEEDEILNR 544.7646 
P38646 Stress-70 protein, mitochondrial  GRP75 DAGQISGLNVLR 621.8437 
P38646 Stress-70 protein, mitochondrial  GRP75 VINEPTAAALAYGLDK 823.4434 
P38646 Stress-70 protein, mitochondrial  GRP75 AQFEGIVTDLIR 681.3748 
P38646 Stress-70 protein, mitochondrial  GRP75 LLGQFTLIGIPPAPR 796.9798 
P55072 Transitional endoplasmic reticulum ATPase  TERA EVDIGIPDATGR 621.8199 
P55072 Transitional endoplasmic reticulum ATPase  TERA LEILQIHTK 547.8320 
P55072 Transitional endoplasmic reticulum ATPase  TERA WALSQSNPSALR 665.3491 
P55072 Transitional endoplasmic reticulum ATPase  TERA DVDLEFLAK 525.2793 
P04406 Glyceraldehyde-3-phosphate dehydrogenase  G3P IISNASC[+57]TTNC[+57]LAPLAK 611.9781 
P04406 Glyceraldehyde-3-phosphate dehydrogenase  G3P VPTANVSVVDLTC[+57]R 510.9363 
P04406 Glyceraldehyde-3-phosphate dehydrogenase  G3P LISWYDNEFGYSNR 588.6056 
P27797 Calreticulin  CALR FYALSASFEPFSNK 804.3907 
P27797 Calreticulin  CALR GQTLVVQFTVK 610.3559 
P27797 Calreticulin  CALR HEQNIDC[+57]GGGYVK 738.8304 
Q14554 Protein disulfide-isomerase A5  PDIA5 SEVAAENHLR 563.2860 
Q14554 Protein disulfide-isomerase A5  PDIA5 GPPLWEEDPGAK 648.3170 
Q14554 Protein disulfide-isomerase A5  PDIA5 GFPTIC[+57]YFEK 631.2997 
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O75190 DnaJ homolog subfamily B member 6  DNJB6 VEVEEDGQLK 573.2879 
O75190 DnaJ homolog subfamily B member 6  DNJB6 APGPWDPLASAAGLK 725.8881 
P04792 Heat shock protein beta-1  HB1 LFDQAFGLPR 388.5451 
P04792 Heat shock protein beta-1  HB1 LATQSNEITIPVTFESR 636.0021 
P07237 Protein disulfide-isomerase  PDIA1 ALAPEYAK 431.7371 
P07237 Protein disulfide-isomerase  PDIA1 VDATEESDLAQQYGVR 890.9210 
P49257 Protein ERGIC-53  LMAN1 GHPDLQGQPAEEIFESVGDR 1091.0140 
P49257 Protein ERGIC-53  LMAN1 DIDNLVQR 486.7591 
P61619 Protein transport protein Sec61 subunit alpha isoform 1  S61A1 IIEVGDTPK 486.2740 
P61619 Protein transport protein Sec61 subunit alpha isoform 1  S61A1 AFSPTTVNTGR 575.7962 
Q13217 DnaJ homolog subfamily C member 3  DNJC3 SQALNAFGSGDYTAAIAFLDK 720.6918 
Q13217 DnaJ homolog subfamily C member 3  DNJC3 LIESAEELIR 586.8297 
Q99442 Translocation protein SEC62  SEC62 VDYFIASK 471.7502 
Q99442 Translocation protein SEC62  SEC62 AVDC[+57]LLDSK 510.7551 
Q99497 Protein DJ-1  PARK7 DGLILTSR 437.7533 
Q99497 Protein DJ-1  PARK7 GPGTSFEFALAIVEALNGK 641.0070 
Q9H173 Nucleotide exchange factor SIL1  SIL1 EFALTNPEK 524.7691 
Q9H173 Nucleotide exchange factor SIL1  SIL1 LGGLQVLR 428.2742 
Q9NYU2 UDP-glucose:glycoprotein glucosyltransferase 1  UGGG1 LNIQPSEADYAVDIR 852.4336 
Q9NYU2 UDP-glucose:glycoprotein glucosyltransferase 1  UGGG1 IEYQFFEDR 623.7906 
Q9UBS4 DnaJ homolog subfamily B member 11  DJB11 FQDLGAAYEVLSDSEK 886.4229 
Q9UBS4 DnaJ homolog subfamily B member 11  DJB11 TLEVEIEPGVR 621.3404 
O75460 Serine/threonine-protein kinase/endoribonuclease IRE1  ERN1 LPFTIPELVQASPC[+57]R 864.4611 
P08240 Signal recognition particle receptor subunit alpha  SRPR NQGFDVVLVDTAGR 745.8835 
Q96RQ1 Endoplasmic reticulum-Golgi intermediate compartment protein 2  ERGI2 IDHLSFGELVPAIINPLDGTEK 793.4249 
Q9Y282 Endoplasmic reticulum-Golgi intermediate compartment protein 3  ERGI3 VEVTVFDPDSLDPDR 852.4098 
 
 Significantly altered proteins in the SIL1-depleted HEK293 cell line 10.9
UniProt Accession Protein Gene ∆SIL1/scr 
Q96FW1 Ubiquitin thioesterase OTUB1  OTUB1 4.9 
Q01581 Hydroxymethylglutaryl-CoA synthase, cytoplasmic  HMGCS1 4.6 
Q9NY33 Dipeptidyl peptidase 3  DPP3 4.6 
Q96C86 m7GpppX diphosphatase  DCPS 4.6 
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Q9H2J4 Phosducin-like protein 3  PDCL3 4.5 
P04818 Thymidylate synthase  TYMS 4.2 
Q96C90 Protein phosphatase 1 regulatory subunit 14B  PPP1R14B 4.2 
P02765 Alpha-2-HS-glycoprotein  AHSG 4.1 
Q08623 Pseudouridine-5'-monophosphatase  HDHD1 4.0 
P08397 Porphobilinogen deaminase  HMBS 3.9 
Q15102 Platelet-activating factor acetylhydrolase IB subunit gamma  PAFAH1B3 3.6 
Q99757 Thioredoxin, mitochondrial  TXN2 3.4 
O60701 UDP-glucose 6-dehydrogenase  UGDH 3.4 
P00374 Dihydrofolate reductase  DHFR 3.4 
P19623 Spermidine synthase  SRM 3.3 
O15294 UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit  OGT 3.2 
Q9UHY7 Enolase-phosphatase E1  ENOPH1 3.1 
P07339 Cathepsin D  CTSD 3.1 
P00338 L-lactate dehydrogenase A chain  LDHA 3.1 
Q9Y570 Protein phosphatase methylesterase 1  PPME1 3.1 
P29218 Inositol monophosphatase 1  IMPA1 3.1 
O75874 Isocitrate dehydrogenase [NADP] cytoplasmic  IDH1 3.1 
P68402 Platelet-activating factor acetylhydrolase IB subunit beta  PAFAH1B2 3.0 
Q4G0N4 NAD kinase 2, mitochondrial  NADK2 3.0 
Q9UHD1 Cysteine and histidine-rich domain-containing protein 1  CHORDC1 3.0 
P31350 Ribonucleoside-diphosphate reductase subunit M2  RRM2 2.9 
P15121 Aldose reductase  AKR1B1 2.9 
Q9UNZ2 NSFL1 cofactor p47  NSFL1C 2.9 
O00762 Ubiquitin-conjugating enzyme E2 C  UBE2C 2.9 
P20839 Inosine-5'-monophosphate dehydrogenase 1  IMPDH1 2.9 
Q96G03 Phosphoglucomutase-2  PGM2 2.9 
P30044 Peroxiredoxin-5, mitochondrial  PRDX5 2.9 
Q4VC31 Coiled-coil domain-containing protein 58 CCDC58 2.8 
Q9Y5J9 Mitochondrial import inner membrane translocase subunit Tim8 B  TIMM8B 2.8 
Q96GD0 Pyridoxal phosphate phosphatase  PDXP 2.8 
P52758 Ribonuclease UK114  HRSP12 2.8 
O00193 Small acidic protein SMAP 2.8 
P61916 Epididymal secretory protein E1  NPC2 2.8 
Q5U5X0 Complex III assembly factor LYRM7  LYRM7 2.8 
P54105 Methylosome subunit pICln  CLNS1A 2.7 
Appendices      152 
 
O75391 Sperm-associated antigen 7 SPAG7 2.7 
Q9NRX4 14 kDa phosphohistidine phosphatase  PHPT1 2.7 
P07741 Adenine phosphoribosyltransferase  APRT 2.7 
Q7Z4W1 L-xylulose reductase  DCXR 2.7 
Q15257 Serine/threonine-protein phosphatase 2A activator  PPP2R4 2.7 
Q96RP9 Elongation factor G, mitochondrial  GFM1 2.7 
P25787 Proteasome subunit alpha type-2  PSMA2 2.6 
P60174 Triosephosphate isomerase  TPI1 2.6 
Q9UL25 Ras-related protein Rab-21 RAB21 2.6 
Q9HC38 Glyoxalase domain-containing protein 4 GLOD4 2.6 
Q9BY32 Inosine triphosphate pyrophosphatase  ITPA 2.6 
Q16543 Hsp90 co-chaperone Cdc37  CDC37 2.6 
Q9NUQ9 Protein FAM49B  FAM49B 2.6 
P49773 Histidine triad nucleotide-binding protein 1  HINT1 2.6 
P13797 Plastin-3  PLS3 2.6 
P28072 Proteasome subunit beta type-6  PSMB6 2.6 
P27144 Adenylate kinase 4, mitochondrial  AK4 2.6 
P18669 Phosphoglycerate mutase 1  PGAM1 2.6 
O95336 6-phosphogluconolactonase  PGLS 2.6 
Q9NVS9 Pyridoxine-5'-phosphate oxidase  PNPO 2.6 
P52209 6-phosphogluconate dehydrogenase, decarboxylating  PGD 2.6 
O43768 Alpha-endosulfine  ENSA 2.6 
O94925 Glutaminase kidney isoform, mitochondrial  GLS 2.6 
Q5TDH0 Protein DDI1 homolog 2 DDI2 2.5 
P46108 Adapter molecule crk  CRK 2.5 
P31939 Bifunctional purine biosynthesis protein PURH  ATIC 2.5 
Q9HB07 UPF0160 protein MYG1, mitochondrial C12orf10 2.5 
P07195 L-lactate dehydrogenase B chain  LDHB 2.5 
P49720 Proteasome subunit beta type-3  PSMB3 2.5 
Q9BWD1 Acetyl-CoA acetyltransferase, cytosolic  ACAT2 2.5 
P17174 Aspartate aminotransferase, cytoplasmic  GOT1 2.5 
P09211 Glutathione S-transferase P  GSTP1 2.5 
Q99436 Proteasome subunit beta type-7  PSMB7 2.5 
Q96KP4 Cytosolic non-specific dipeptidase  CNDP2 2.5 
Q9UBQ7 Glyoxylate reductase/hydroxypyruvate reductase  GRHPR 2.5 
P06733 Alpha-enolase  ENO1 2.5 
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P06132 Uroporphyrinogen decarboxylase  UROD 2.5 
P51003 Poly PAPOLA 2.5 
Q13492 Phosphatidylinositol-binding clathrin assembly protein  PICALM 2.5 
P30046 D-dopachrome decarboxylase  DDT 2.5 
Q9NRN7 L-aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase  AASDHPPT 2.5 
P37837 Transaldolase  TALDO1 2.5 
P62136 Serine/threonine-protein phosphatase PP1-alpha catalytic subunit  PPP1CA 2.5 
Q99497 Protein DJ-1  PARK7 2.5 
Q5TFE4 5'-nucleotidase domain-containing protein 1  NT5DC1 2.5 
P23921 Ribonucleoside-diphosphate reductase large subunit  RRM1 2.4 
P16152 Carbonyl reductase [NADPH] 1  CBR1 2.4 
P15374 Ubiquitin carboxyl-terminal hydrolase isozyme L3  UCHL3 2.4 
Q9NZL9 Methionine adenosyltransferase 2 subunit beta  MAT2B 2.4 
P25789 Proteasome subunit alpha type-4  PSMA4 2.4 
Q9BTT0 Acidic leucine-rich nuclear phosphoprotein 32 family member E  ANP32E 2.4 
P24752 Acetyl-CoA acetyltransferase, mitochondrial  ACAT1 2.4 
P49189 4-trimethylaminobutyraldehyde dehydrogenase  ALDH9A1 2.4 
Q7KZ85 Transcription elongation factor SPT6  SUPT6H 2.4 
O43598 2'-deoxynucleoside 5'-phosphate N-hydrolase 1  DNPH1 2.4 
O15305 Phosphomannomutase 2  PMM2 2.4 
P48163 NADP-dependent malic enzyme  ME1 2.4 
O76003 Glutaredoxin-3  GLRX3 2.4 
P12277 Creatine kinase B-type  CKB 2.4 
P31153 S-adenosylmethionine synthase isoform type-2  MAT2A 2.4 
P06865 Beta-hexosaminidase subunit alpha  HEXA 2.4 
Q01518 Adenylyl cyclase-associated protein 1  CAP1 2.4 
P04075 Fructose-bisphosphate aldolase A  ALDOA 2.4 
Q01105 Protein SET  SET 2.4 
Q5TBB1 Ribonuclease H2 subunit B  RNASEH2B 2.4 
P10768 S-formylglutathione hydrolase  ESD 2.4 
Q8N7H5 RNA polymerase II-associated factor 1 homolog  PAF1 2.4 
P21283 V-type proton ATPase subunit C 1  ATP6V1C1 2.4 
P60983 Glia maturation factor beta  GMFB 2.4 
Q9H910 Hematological and neurological expressed 1-like protein  HN1L 2.4 
P18206 Vinculin  VCL 2.3 
P09972 Fructose-bisphosphate aldolase C  ALDOC 2.3 
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Q9NR45 Sialic acid synthase  NANS 2.3 
O75347 Tubulin-specific chaperone A  TBCA 2.3 
O00154 Cytosolic acyl coenzyme A thioester hydrolase  ACOT7 2.3 
Q8TDP1 Ribonuclease H2 subunit C  RNASEH2C 2.3 
P29401 Transketolase  TKT 2.3 
P31948 Stress-induced-phosphoprotein 1  STIP1 2.3 
Q9Y2Z0 Suppressor of G2 allele of SKP1 homolog  SUGT1 2.3 
P40926 Malate dehydrogenase, mitochondrial  MDH2 2.3 
P04406 Glyceraldehyde-3-phosphate dehydrogenase  GAPDH 2.3 
Q13526 Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1  PIN1 2.3 
Q9P287 BRCA2 and CDKN1A-interacting protein  BCCIP 2.3 
Q92688 Acidic leucine-rich nuclear phosphoprotein 32 family member B  ANP32B 2.3 
P25786 Proteasome subunit alpha type-1  PSMA1 2.3 
P23526 Adenosylhomocysteinase  AHCY 2.3 
Q15185 Prostaglandin E synthase 3  PTGES3 2.3 
P30086 Phosphatidylethanolamine-binding protein 1  PEBP1 2.3 
P62942 Peptidyl-prolyl cis-trans isomerase FKBP1A  FKBP1A 2.3 
P06744 Glucose-6-phosphate isomerase  GPI 2.3 
P58546 Myotrophin  MTPN 2.3 
O75792 Ribonuclease H2 subunit A  RNASEH2A 2.3 
Q13126 S-methyl-5'-thioadenosine phosphorylase  MTAP 2.3 
O43488 Aflatoxin B1 aldehyde reductase member 2  AKR7A2 2.3 
Q92530 Proteasome inhibitor PI31 subunit  PSMF1 2.3 
Q92820 Gamma-glutamyl hydrolase  GGH 2.3 
P55263 Adenosine kinase  ADK 2.3 
Q9BTE7 DCN1-like protein 5  DCUN1D5 2.3 
O75608 Acyl-protein thioesterase 1  LYPLA1 2.3 
Q04760 Lactoylglutathione lyase  GLO1 2.2 
O00584 Ribonuclease T2  RNASET2 2.2 
Q7Z4H3 HD domain-containing protein 2  HDDC2 2.2 
P60900 Proteasome subunit alpha type-6  PSMA6 2.2 
P22392 Nucleoside diphosphate kinase B  NME2 2.2 
P12955 Xaa-Pro dipeptidase  PEPD 2.2 
P78417 Glutathione S-transferase omega-1  GSTO1 2.2 
P14618 Pyruvate kinase PKM  PKM 2.2 
P40925 Malate dehydrogenase, cytoplasmic  MDH1 2.2 
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Q13867 Bleomycin hydrolase  BLMH 2.2 
P28074 Proteasome subunit beta type-5  PSMB5 2.2 
P14174 Macrophage migration inhibitory factor  MIF 2.2 
Q14166 Tubulin--tyrosine ligase-like protein 12 TTLL12 2.2 
P41240 Tyrosine-protein kinase CSK  CSK 2.2 
P22314 Ubiquitin-like modifier-activating enzyme 1  UBA1 2.2 
P24666 Low molecular weight phosphotyrosine protein phosphatase  ACP1 2.2 
O95861 3'(2'),5'-bisphosphate nucleotidase 1 BPNT1 2.2 
P00491 Purine nucleoside phosphorylase  PNP 2.2 
P14324 Farnesyl pyrophosphate synthase  FDPS 2.2 
P54725 UV excision repair protein RAD23 homolog A  RAD23A 2.2 
Q01469 Fatty acid-binding protein, epidermal  FABP5 2.2 
O00303 Eukaryotic translation initiation factor 3 subunit F  EIF3F 2.2 
Q7Z5L9 Interferon regulatory factor 2-binding protein 2  IRF2BP2 2.2 
Q9NQR4 Omega-amidase NIT2  NIT2 2.2 
P61604 10 kDa heat shock protein, mitochondrial  HSPE1 2.2 
Q9H993 UPF0364 protein C6orf211 C6orf211 2.2 
P28838 Cytosol aminopeptidase  LAP3 2.2 
Q16836 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial  HADH 2.2 
Q96CN7 Isochorismatase domain-containing protein 1 ISOC1 2.2 
O94903 Proline synthase co-transcribed bacterial homolog protein PROSC 2.2 
Q9NZL4 Hsp70-binding protein 1  HSPBP1 2.2 
Q12765 Secernin-1 SCRN1 2.2 
P42771 Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3  CDKN2A 2.2 
P63104 14-3-3 protein zeta/delta  YWHAZ 2.1 
P39687 Acidic leucine-rich nuclear phosphoprotein 32 family member A  ANP32A 2.1 
O00148 ATP-dependent RNA helicase DDX39A  DDX39A 2.1 
P28070 Proteasome subunit beta type-4  PSMB4 2.1 
P54819 Adenylate kinase 2, mitochondrial  AK2 2.1 
O14737 Programmed cell death protein 5  PDCD5 2.1 
P29692 Elongation factor 1-delta  EEF1D 2.1 
O00170 AH receptor-interacting protein  AIP 2.1 
P55786 Puromycin-sensitive aminopeptidase  NPEPPS 2.1 
O14745 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 SLC9A3R1 2.1 
O43719 HIV Tat-specific factor 1  HTATSF1 2.1 
P00505 Aspartate aminotransferase, mitochondrial  GOT2 2.1 
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O00299 Chloride intracellular channel protein 1  CLIC1 2.1 
P28066 Proteasome subunit alpha type-5  PSMA5 2.1 
O60493 Sorting nexin-3  SNX3 2.1 
P08243 Asparagine synthetase [glutamine-hydrolyzing]  ASNS 2.1 
Q5JRX3 Presequence protease, mitochondrial  PITRM1 2.1 
Q99613 Eukaryotic translation initiation factor 3 subunit C  EIF3C 2.1 
P43034 Platelet-activating factor acetylhydrolase IB subunit alpha  PAFAH1B1 2.1 
P07737 Profilin-1  PFN1 2.1 
Q9HAV7 GrpE protein homolog 1, mitochondrial  GRPEL1 2.1 
P04181 Ornithine aminotransferase, mitochondrial  OAT 2.1 
P48147 Prolyl endopeptidase  PREP 2.1 
O00273 DNA fragmentation factor subunit alpha  DFFA 2.1 
P30520 Adenylosuccinate synthetase isozyme 2  ADSS 2.1 
P08238 Heat shock protein HSP 90-beta  HSP90AB1 2.1 
Q15813 Tubulin-specific chaperone E  TBCE 2.1 
P00558 Phosphoglycerate kinase 1  PGK1 2.1 
O60763 General vesicular transport factor p115  USO1 2.1 
Q16763 Ubiquitin-conjugating enzyme E2 S  UBE2S 2.1 
Q13347 Eukaryotic translation initiation factor 3 subunit I  EIF3I 2.1 
Q8N8S7 Protein enabled homolog ENAH 2.1 
P12004 Proliferating cell nuclear antigen  PCNA 2.1 
P61970 Nuclear transport factor 2  NUTF2 2.0 
P48637 Glutathione synthetase  GSS 2.0 
Q12972 Nuclear inhibitor of protein phosphatase 1  PPP1R8 2.0 
P61106 Ras-related protein Rab-14 RAB14 2.0 
P07954 Fumarate hydratase, mitochondrial  FH 2.0 
P52788 Spermine synthase  SMS 2.0 
P61086 Ubiquitin-conjugating enzyme E2 K  UBE2K 2.0 
Q13564 NEDD8-activating enzyme E1 regulatory subunit  NAE1 2.0 
O60888 Protein CutA  CUTA 2.0 
Q14240 Eukaryotic initiation factor 4A-II  EIF4A2 2.0 
O43865 Putative adenosylhomocysteinase 2  AHCYL1 2.0 
Q92598 Heat shock protein 105 kDa  HSPH1 2.0 
P49419 Alpha-aminoadipic semialdehyde dehydrogenase  ALDH7A1 2.0 
Q9UJU6 Drebrin-like protein  DBNL 2.0 
O15067 Phosphoribosylformylglycinamidine synthase  PFAS 2.0 
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P49321 Nuclear autoantigenic sperm protein  NASP 2.0 
P49354 Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha  FNTA 2.0 
P34932 Heat shock 70 kDa protein 4  HSPA4 2.0 
P45974 Ubiquitin carboxyl-terminal hydrolase 5  USP5 2.0 
Q13177 Serine/threonine-protein kinase PAK 2  PAK2 2.0 
P54727 UV excision repair protein RAD23 homolog B  RAD23B 2.0 
P23381 Tryptophan--tRNA ligase, cytoplasmic  WARS 2.0 
P26639 Threonine--tRNA ligase, cytoplasmic  TARS 2.0 
P11766 Alcohol dehydrogenase class-3  ADH5 2.0 
O14818 Proteasome subunit alpha type-7  PSMA7 2.0 
P26641 Elongation factor 1-gamma  EEF1G 2.0 
P09960 Leukotriene A-4 hydrolase  LTA4H 2.0 
Q96PZ0 Pseudouridylate synthase 7 homolog  PUS7 2.0 
P54578 Ubiquitin carboxyl-terminal hydrolase 14  USP14 2.0 
Q08257 Quinone oxidoreductase  CRYZ 2.0 
Q9Y262 Eukaryotic translation initiation factor 3 subunit L  EIF3L 2.0 
Q13404 Ubiquitin-conjugating enzyme E2 variant 1  UBE2V1 2.0 
P50395 Rab GDP dissociation inhibitor beta  GDI2 1.9 
Q9NVA2 Septin-11 Sep 11 1.9 
P26440 Isovaleryl-CoA dehydrogenase, mitochondrial  IVD 1.9 
P68036 Ubiquitin-conjugating enzyme E2 L3  UBE2L3 1.9 
P35241 Radixin RDX 1.9 
Q99426 Tubulin-folding cofactor B  TBCB 1.9 
O75153 Clustered mitochondria protein homolog CLUH 1.9 
Q02790 Peptidyl-prolyl cis-trans isomerase FKBP4  FKBP4 1.9 
Q96EK6 Glucosamine 6-phosphate N-acetyltransferase  GNPNAT1 1.9 
Q9H4A4 Aminopeptidase B  RNPEP 1.9 
P18615 Negative elongation factor E  NELFE 1.9 
P23528 Cofilin-1  CFL1 1.9 
P15531 Nucleoside diphosphate kinase A  NME1 1.9 
Q9HC35 Echinoderm microtubule-associated protein-like 4  EML4 1.9 
O15498 Synaptobrevin homolog YKT6  YKT6 1.9 
Q9H773 dCTP pyrophosphatase 1  DCTPP1 1.9 
Q7L2H7 Eukaryotic translation initiation factor 3 subunit M  EIF3M 1.9 
P49366 Deoxyhypusine synthase  DHPS 1.9 
P49915 GMP synthase [glutamine-hydrolyzing]  GMPS 1.9 
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Q9NR33 DNA polymerase epsilon subunit 4  POLE4 1.9 
Q9GZT8 Putative GTP cyclohydrolase 1 type 2 NIF3L1  NIF3L1 1.9 
Q99733 Nucleosome assembly protein 1-like 4  NAP1L4 1.9 
Q15008 26S proteasome non-ATPase regulatory subunit 6  PSMD6 1.9 
O43765 Small glutamine-rich tetratricopeptide repeat-containing protein alpha  SGTA 1.9 
O75821 Eukaryotic translation initiation factor 3 subunit G  EIF3G 1.9 
P20618 Proteasome subunit beta type-1  PSMB1 1.9 
P32119 Peroxiredoxin-2  PRDX2 1.9 
Q5VW32 BRO1 domain-containing protein BROX  BROX 1.9 
Q96CX2 BTB/POZ domain-containing protein KCTD12  KCTD12 1.9 
P31946 14-3-3 protein beta/alpha  YWHAB 1.9 
P30084 Enoyl-CoA hydratase, mitochondrial  ECHS1 1.9 
P33316 Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial  DUT 1.9 
P23919 Thymidylate kinase  DTYMK 1.8 
Q9Y490 Talin-1 TLN1 1.8 
P00492 Hypoxanthine-guanine phosphoribosyltransferase  HPRT1 1.8 
O14929 Histone acetyltransferase type B catalytic subunit  HAT1 1.8 
Q15181 Inorganic pyrophosphatase  PPA1 1.8 
P60842 Eukaryotic initiation factor 4A-I  EIF4A1 1.8 
Q16851 UTP--glucose-1-phosphate uridylyltransferase  UGP2 1.8 
Q9NP81 Serine--tRNA ligase, mitochondrial  SARS2 1.8 
O00487 26S proteasome non-ATPase regulatory subunit 14  PSMD14 1.8 
Q9Y617 Phosphoserine aminotransferase  PSAT1 1.8 
Q9NTK5 Obg-like ATPase 1  OLA1 1.8 
Q9Y266 Nuclear migration protein nudC  NUDC 1.8 
Q99961 Endophilin-A2  SH3GL1 1.8 
P60981 Destrin  DSTN 1.8 
O15372 Eukaryotic translation initiation factor 3 subunit H  EIF3H 1.8 
P23193 Transcription elongation factor A protein 1  TCEA1 1.8 
P62937 Peptidyl-prolyl cis-trans isomerase A  PPIA 1.8 
O15212 Prefoldin subunit 6  PFDN6 1.8 
Q8TBC4 NEDD8-activating enzyme E1 catalytic subunit  UBA3 1.8 
Q14232 Translation initiation factor eIF-2B subunit alpha  EIF2B1 1.8 
Q14152 Eukaryotic translation initiation factor 3 subunit A  EIF3A 1.7 
Q2TAL8 Glutamine-rich protein 1 QRICH1 1.7 
Q9Y5L4 Mitochondrial import inner membrane translocase subunit Tim13 TIMM13 1.7 
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P51665 26S proteasome non-ATPase regulatory subunit 7  PSMD7 1.7 
P61758 Prefoldin subunit 3  VBP1 1.7 
P43487 Ran-specific GTPase-activating protein  RANBP1 1.7 
Q9C0C9 E2/E3 hybrid ubiquitin-protein ligase UBE2O  UBE2O 1.7 
P62258 14-3-3 protein epsilon  YWHAE 1.7 
P67870 Casein kinase II subunit beta  CSNK2B 1.7 
P11172 Uridine 5'-monophosphate synthase  UMPS 1.7 
P62993 Growth factor receptor-bound protein 2  GRB2 1.7 
Q15435 Protein phosphatase 1 regulatory subunit 7  PPP1R7 1.7 
Q9Y520 Protein PRRC2C  PRRC2C 1.7 
P61160 Actin-related protein 2  ACTR2 1.7 
Q9GZZ9 Ubiquitin-like modifier-activating enzyme 5  UBA5 1.7 
P50570 Dynamin-2  DNM2 1.7 
P11802 Cyclin-dependent kinase 4  CDK4 1.7 
P49327 Fatty acid synthase  FASN 1.7 
Q15691 Microtubule-associated protein RP/EB family member 1  MAPRE1 1.7 
P55036 26S proteasome non-ATPase regulatory subunit 4  PSMD4 1.6 
P12270 Nucleoprotein TPR  TPR 1.6 
Q5VT52 Regulation of nuclear pre-mRNA domain-containing protein 2 RPRD2 1.6 
Q96AC1 Fermitin family homolog 2  FERMT2 1.6 
O43242 26S proteasome non-ATPase regulatory subunit 3  PSMD3 1.6 
P38646 Stress-70 protein, mitochondrial  HSPA9 1.6 
Q9P289 Serine/threonine-protein kinase MST4  MST4 1.6 
P43686 26S protease regulatory subunit 6B  PSMC4 1.6 
Q13619 Cullin-4A  CUL4A 1.6 
Q6P1J9 Parafibromin  CDC73 1.6 
P09012 U1 small nuclear ribonucleoprotein A  SNRPA 0.6 
Q8IXT5 RNA-binding protein 12B  RBM12B 0.6 
P51570 Galactokinase  GALK1 0.6 
Q9NZI8 Insulin-like growth factor 2 mRNA-binding protein 1  IGF2BP1 0.6 
P50402 Emerin EMD 0.6 
P53582 Methionine aminopeptidase 1  METAP1 0.6 
P04843 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1  RPN1 0.6 
P61026 Ras-related protein Rab-10 RAB10 0.6 
P51571 Translocon-associated protein subunit delta  SSR4 0.6 
Q8NI36 WD repeat-containing protein 36  WDR36 0.6 
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Q96CW5 Gamma-tubulin complex component 3  TUBGCP3 0.6 
Q92616 Translational activator GCN1  GCN1L1 0.6 
P35613 Basigin  BSG 0.6 
Q14165 Malectin MLEC 0.6 
Q8IWA0 WD repeat-containing protein 75 WDR75 0.6 
O43795 Unconventional myosin-Ib  MYO1B 0.6 
O96008 Mitochondrial import receptor subunit TOM40 homolog  TOMM40 0.6 
Q9Y679 Ancient ubiquitous protein 1 AUP1 0.6 
P49207 60S ribosomal protein L34 RPL34 0.6 
O00264 Membrane-associated progesterone receptor component 1  PGRMC1 0.6 
P48047 ATP synthase subunit O, mitochondrial  ATP5O 0.6 
Q00577 Transcriptional activator protein Pur-alpha  PURA 0.6 
O95292 Vesicle-associated membrane protein-associated protein B/C  VAPB 0.6 
Q96QD9 UAP56-interacting factor  FYTTD1 0.6 
Q9Y512 Sorting and assembly machinery component 50 homolog  SAMM50 0.6 
P62995 Transformer-2 protein homolog beta  TRA2B 0.6 
Q9Y3B3 Transmembrane emp24 domain-containing protein 7  TMED7 0.6 
Q8WTT2 Nucleolar complex protein 3 homolog  NOC3L 0.6 
P07910 Heterogeneous nuclear ribonucleoproteins C1/C2  HNRNPC 0.6 
Q10471 Polypeptide N-acetylgalactosaminyltransferase 2  GALNT2 0.6 
Q16891 Mitochondrial inner membrane protein  IMMT 0.6 
P49755 Transmembrane emp24 domain-containing protein 10  TMED10 0.6 
P08670 Vimentin VIM 0.6 
P16615 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2  ATP2A2 0.6 
Q9UM00 Transmembrane and coiled-coil domain-containing protein 1  TMCO1 0.6 
O75964 ATP synthase subunit g, mitochondrial  ATP5L 0.6 
P14859 POU domain, class 2, transcription factor 1  POU2F1 0.6 
Q9Y3Y2 Chromatin target of PRMT1 protein  CHTOP 0.6 
Q53H12 Acylglycerol kinase, mitochondrial  AGK 0.5 
P35580 Myosin-10  MYH10 0.5 
P36542 ATP synthase subunit gamma, mitochondrial  ATP5C1 0.5 
P28288 ATP-binding cassette sub-family D member 3  ABCD3 0.5 
Q9HCU5 Prolactin regulatory element-binding protein  PREB 0.5 
O43920 NADH dehydrogenase [ubiquinone] iron-sulfur protein 5  NDUFS5 0.5 
Q9Y3A6 Transmembrane emp24 domain-containing protein 5  TMED5 0.5 
P08133 Annexin A6  ANXA6 0.5 
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P62805 Histone H4 HIST1H4A 0.5 
P11233 Ras-related protein Ral-A RALA 0.5 
A1L0T0 Acetolactate synthase-like protein  ILVBL 0.5 
Q9NX63 Coiled-coil-helix-coiled-coil-helix domain-containing protein 3, mitochondrial CHCHD3 0.5 
Q9Y276 Mitochondrial chaperone BCS1  BCS1L 0.5 
P60660 Myosin light polypeptide 6  MYL6 0.5 
Q96A26 Protein FAM162A  FAM162A 0.5 
Q8TC12 Retinol dehydrogenase 11  RDH11 0.5 
Q9Y2H6 Fibronectin type-III domain-containing protein 3A  FNDC3A 0.5 
P04637 Cellular tumor antigen p53  TP53 0.5 
Q9Y3E5 Peptidyl-tRNA hydrolase 2, mitochondrial  PTRH2 0.5 
Q9NPI6 mRNA-decapping enzyme 1A  DCP1A 0.5 
O43663 Protein regulator of cytokinesis 1 PRC1 0.5 
O00159 Unconventional myosin-Ic  MYO1C 0.5 
Q13724 Mannosyl-oligosaccharide glucosidase  MOGS 0.5 
P43307 Translocon-associated protein subunit alpha  SSR1 0.5 
Q00765 Receptor expression-enhancing protein 5  REEP5 0.5 
Q5JRA6 Melanoma inhibitory activity protein 3  MIA3 0.5 
Q9NTJ5 Phosphatidylinositide phosphatase SAC1  SACM1L 0.5 
P42858 Huntingtin  HTT 0.5 
Q07065 Cytoskeleton-associated protein 4  CKAP4 0.5 
Q13423 NAD(P) transhydrogenase, mitochondrial NNT 0.5 
O95573 Long-chain-fatty-acid--CoA ligase 3  ACSL3 0.5 
O95470 Sphingosine-1-phosphate lyase 1  SGPL1 0.5 
P18859 ATP synthase-coupling factor 6, mitochondrial  ATP5J 0.5 
Q7LGA3 Heparan sulfate 2-O-sulfotransferase 1  HS2ST1 0.5 
Q5HYI8 Rab-like protein 3 RABL3 0.5 
P45880 Voltage-dependent anion-selective channel protein 2  VDAC2 0.5 
Q9UH99 SUN domain-containing protein 2  SUN2 0.5 
Q6PL18 ATPase family AAA domain-containing protein 2  ATAD2 0.5 
Q9NXF1 Testis-expressed sequence 10 protein TEX10 0.5 
P21964 Catechol O-methyltransferase  COMT 0.5 
Q9C0D9 Ethanolaminephosphotransferase 1  EPT1 0.5 
Q8N5K1 CDGSH iron-sulfur domain-containing protein 2  CISD2 0.5 
P46821 Microtubule-associated protein 1B  MAP1B 0.5 
Q96G21 U3 small nucleolar ribonucleoprotein protein IMP4  IMP4 0.5 
Appendices      162 
 
Q8TEM1 Nuclear pore membrane glycoprotein 210  NUP210 0.5 
Q9NZ01 Very-long-chain enoyl-CoA reductase  TECR 0.5 
P78362 SRSF protein kinase 2  SRPK2 0.5 
Q9H9B4 Sideroflexin-1  SFXN1 0.5 
Q9P035 Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 3 PTPLAD1 0.5 
Q99536 Synaptic vesicle membrane protein VAT-1 homolog  VAT1 0.5 
P05141 ADP/ATP translocase 2  SLC25A5 0.5 
P07099 Epoxide hydrolase 1  EPHX1 0.5 
Q9P0M6 Core histone macro-H2A.2  H2AFY2 0.5 
P11388 DNA topoisomerase 2-alpha  TOP2A 0.5 
P07197 Neurofilament medium polypeptide  NEFM 0.5 
P14735 Insulin-degrading enzyme  IDE 0.5 
Q00325 Phosphate carrier protein, mitochondrial  SLC25A3 0.5 
P43304 Glycerol-3-phosphate dehydrogenase, mitochondrial  GPD2 0.5 
Q9Y6M1 Insulin-like growth factor 2 mRNA-binding protein 2  IGF2BP2 0.5 
Q9BZF1 Oxysterol-binding protein-related protein 8  OSBPL8 0.5 
P33121 Long-chain-fatty-acid--CoA ligase 1  ACSL1 0.5 
P51648 Fatty aldehyde dehydrogenase  ALDH3A2 0.5 
Q9P2B2 Prostaglandin F2 receptor negative regulator  PTGFRN 0.5 
Q9UGP8 Translocation protein SEC63 homolog SEC63 0.5 
Q9Y282 Endoplasmic reticulum-Golgi intermediate compartment protein 3  ERGIC3 0.5 
P50336 Protoporphyrinogen oxidase  PPOX 0.5 
Q9HCE1 Putative helicase MOV-10  MOV10 0.5 
P20645 Cation-dependent mannose-6-phosphate receptor  M6PR 0.5 
Q9BU23 Lipase maturation factor 2  LMF2 0.5 
P58107 Epiplakin  EPPK1 0.4 
Q8NF37 Lysophosphatidylcholine acyltransferase 1  LPCAT1 0.4 
P09525 Annexin A4  ANXA4 0.4 
Q9UHG3 Prenylcysteine oxidase 1  PCYOX1 0.4 
Q6ZXV5 Transmembrane and TPR repeat-containing protein 3  TMTC3 0.4 
Q9BXS6 Nucleolar and spindle-associated protein 1  NUSAP1 0.4 
Q9BUR5 Apolipoprotein O  APOO 0.4 
Q92522 Histone H1x H1FX 0.4 
P07196 Neurofilament light polypeptide  NEFL 0.4 
Q9NZ45 CDGSH iron-sulfur domain-containing protein 1  CISD1 0.4 
Q9ULX6 A-kinase anchor protein 8-like  AKAP8L 0.4 
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Q6NUQ4 Transmembrane protein 214 TMEM214 0.4 
Q709F0 Acyl-CoA dehydrogenase family member 11  ACAD11 0.4 
Q14254 Flotillin-2  FLOT2 0.4 
P06396 Gelsolin  GSN 0.4 
O94901 SUN domain-containing protein 1  SUN1 0.4 
P56134 ATP synthase subunit f, mitochondrial ATP5J2 0.4 
P62745 Rho-related GTP-binding protein RhoB  RHOB 0.4 
Q16822 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial  PCK2 0.4 
P53701 Cytochrome c-type heme lyase  HCCS 0.4 
O75955 Flotillin-1 FLOT1 0.4 
P04083 Annexin A1  ANXA1 0.4 
O75477 Erlin-1  ERLIN1 0.4 
P67812 Signal peptidase complex catalytic subunit SEC11A  SEC11A 0.4 
P53007 Tricarboxylate transport protein, mitochondrial  SLC25A1 0.4 
Q9Y394 Dehydrogenase/reductase SDR family member 7  DHRS7 0.4 
O95563 Mitochondrial pyruvate carrier 2  MPC2 0.4 
Q96N66 Lysophospholipid acyltransferase 7  MBOAT7 0.4 
O14662 Syntaxin-16  STX16 0.4 
Q7Z2K6 Endoplasmic reticulum metallopeptidase 1  ERMP1 0.3 
O15260 Surfeit locus protein 4 SURF4 0.3 
P30536 Translocator protein  TSPO 0.3 
P85298 Rho GTPase-activating protein 8  ARHGAP8 0.3 
P62834 Ras-related protein Rap-1A  RAP1A 0.3 
 
 
 
 
 
